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Autism spectrum disorders (ASDs) are childhood-onset developmental disorders 
which share core symptoms but show considerable variation in severity. The 
whole spectrum affects ~0.6-0.7% of children worldwide, inducing a substantial 
public health burden. Despite having a very high heritability, ASDs have shown 
exceptional genetic heterogeneity, which has complicated the identification of 
risk variants and left the etiology largely unknown. Recent studies suggest that 
rare, family-specific factors contribute significantly to the genetic basis of ASDs. 
In this study, we observed an association between DISC1 gene and ASDs with 
markers previously associated with psychiatric phenotypes. We identified a 
micro-RNA mediated regulatory mechanism, which might partially explain the 
wide-range neurobiological effects of DISC1. The results obtained from the study 
of extended Finnish ASD pedigrees show that even within single pedigrees from 
an isolated population, multiple distinct genetic variants are responsible for 
the phenotype. We conclude that sequencing of the shared haplotypes, linkage 
regions, and other identified susceptibility loci is essential to identify the causal 
variants in ASDs.
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ABSTRACT 
Helena Kilpinen, Genetic Mechanisms Underlying Autism Spectrum Disorders. 
National Institute for Health and Welfare (THL), Research 46/2010, 199 pages. 
Helsinki, Finland 2010.  
ISBN 978-952-245-376-1 (printed), ISBN 978-952-245-377-8 (pdf) 
 
Autism is a severe childhood-onset developmental disorder characterized by deficits 
in reciprocal social interaction, verbal and non-verbal communication, and 
dependence on routines and rituals. It belongs to a spectrum of disorders (autism 
spectrum disorders, ASDs) which share core symptoms but show considerable 
variation in severity. The whole spectrum affects approximately 0.6-0.7% of 
children worldwide, inducing a substantial public health burden and causing 
suffering to the affected families. Despite having a very high heritability, ASDs have 
shown exceptional genetic heterogeneity, which has complicated the identification 
of risk variants and left the etiology largely unknown. However, recent studies have 
identified an increasing number of rare genetic causes responsible for the phenotype 
in individual families, suggesting that rare, family-specific events contribute 
significantly to the genetic basis of ASDs. In this study, we have studied the genetic 
basis of autism spectrum disorders in Finnish families both genome-wide and from 
the perspective of a single candidate gene. 
 
First, we focused on the DISC1 (Disrupted-in-schizophrenia-1) gene on 
chromosome 1q42, which is one of the most studied candidate genes in 
neuropsychiatric genetics. It was originally described in a large Scottish pedigree 
with a balanced translocation disrupting the gene co-segregating with a variety of 
psychiatric conditions. Subsequent linkage, association, and functional studies have 
implicated DISC1 in the regulation of multiple aspects of embryonic and adult 
neurogenesis, and established its pathogenic role in multiple neuropsychiatric 
disorders across populations. We studied, for the first time, the role of DISC1 in 
ASDs, and identified association with markers and haplotypes previously associated 
with psychiatric phenotypes in the Finnish population. We identified four 
polymorphic micro-RNA target sites in the 3’UTR of DISC1, and showed that hsa-
miR-559 regulates DISC1 expression in vitro in an allele-specific manner. 
 
Second, we describe an extended autism pedigree with genealogical roots in Central 
Finland reaching back to the 17th century. To take advantage of the beneficial 
characteristics of population isolates to gene mapping and reduced genetic 
heterogeneity observed in distantly related individuals, we performed a 
microsatellite-based genome-wide screen for linkage and linkage disequilibrium in 
this pedigree. We identified a putative autism susceptibility locus on chromosome 
19p13.3 and obtained further support for previously reported loci at 1q23 and 
15q11-q13. Most promising candidates were two transducin-like enhancer of split 
(E(sp1) homolog, Drosophila) genes (TLE2 and TLE6), clustered on 19p13, and 
ATPase, Na+/K+ transporting, alpha 2 polypeptide (ATP1A2) on 1q23. 
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To follow-up this study, we extended our study sample from the same sub-isolate 
and initiated a genome-wide analysis of homozygosity and allelic sharing using 
high-density SNP markers. We also analyzed global gene expression in lymphocytes 
of these individuals, and performed pathway analysis of SNP and gene expression 
data to comprehensively investigate the genetic cause of ASDs in these individuals 
and to gain information of the underlying biological processes. We identified a small 
number of haplotypes shared by different subsets of the genealogically connected 
cases, along with convergent biological pathways from SNP and gene expression 
data, which highlighted axon guidance molecules in the pathogenesis of ASDs. 
 
In conclusion, the results obtained in this thesis show that multiple distinct genetic 
variants are responsible for the ASD phenotype even within single pedigrees from 
an isolated population. We suggest that targeted resequencing of shared haplotypes, 
linkage regions, and other susceptibility loci is essential to identify the causal 
variants and to understand the underlying mutational spectrum in autism spectrum 
disoders. We also report a possible micro-RNA mediated regulatory mechanism, 
which might partially explain the wide-range neurobiological effects of the DISC1 
gene. 
 
Keywords: Autism spectrum disorders, Asperger syndrome, isolated population, 
DISC1, miRNA, linkage analysis, gene expression, GWAS, pathway analysis 
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Autismi on vakava lapsuusiän kehityksellinen häiriö, jonka tyypillisiä oireita ovat 
ongelmat vastavuoroisessa sosiaalisessa vuorovaikutuksessa, sanallisessa ja sanatto-
massa kommunikaatiossa, sekä riippuvuus erilaisista rutiineista ja rituaaleista. Se 
kuuluu laajempaan autismikirjon häiriöiden ryhmään, jotka kaikki ovat perus-
oireiltaan samankaltaisia, mutta joiden vakavuusaste vaihtelee huomattavasti. 
Autismikirjon häiriöitä tavataan maailmanlaajuisesti noin 0,6-0,7 %:lla lapsista, ja 
ne aiheuttavat inhimillisen kärsimyksen lisäksi merkittäviä kuluja terveyden-
huollolle. Vaikka autismikirjon häiriöt ovat vahvasti perinnöllisiä, niiden geneet-
tinen tausta on osoittautunut erittäin heterogeeniseksi, mikä on vaikeuttanut 
altistavien geneettisten tekijöiden tunnistamista ja perimmäisten syiden selvittä-
mistä. Viimeaikaisissa tutkimuksissa on kuitenkin löydetty useita harvinaisia geneet-
tisiä tekijöitä, jotka riittävät aiheuttamaan häiriön yksittäisissä perheissä. Näiden 
löydösten perusteella on arvioitu, että harvinaiset, perhespesifiset geneettiset muu-
tokset selittävät merkittävän osan autismin periytyvyydestä. Tässä väitöskirjassa 
olemme tutkineet autismikirjon häiriöiden geneettistä taustaa suomalaisissa perheis-
sä sekä koko genomin laajuisesti, että yksittäisen ehdokasgeenin näkökulmasta. 
 
Ensimmäinen tutkimuskohteemme oli DISC1-geeni (Disrupted-in-schizophrenia-1), 
joka sijaitsee kromosomissa 1q42 ja joka on yksi tunnetuimmista geeneistä psykiat-
risen genetiikan alalla. Se kuvattiin alunperin suuressa skotlantilaisessa suvussa, jos-
sa balansoitu translokaatio periytyi yhdessä erilaisten psykiatristen sairauksien kans-
sa. Tätä seuranneet kytkentä-, assosiaatio-, sekä toiminnalliset tutkimukset ovat 
osoittaneet, että DISC1 säätelee lukuisia hermostokehityksellisiä tomintoja sekä 
alkionkehityksen aikana että aikuisiällä, ja useissa eri populaatioissa on havaittu, että 
muutokset DISC1:n toiminnassa voivat altistaa monille neuropsykiatrisille sairauk-
sille. Tässä väitöskirjassa tutkittiin ensimmäisen kerran DISC1-geenin merkitystä 
autismikirjon häiriöissä. Havaitsimme, että samat geenimerkit ja haplotyypit, joiden 
on aikaisemmin osoitettu assosioituvan muihin psykiatrisiin fenotyyppeihin suoma-
laisväestössä, assosioituivat myös autismikirjon häiriöihin. Havaitsimme lisäksi, että 
geenin 3’UTR aluella sijaitsee neljä polymorfista mikro-RNA:n (miRNA) sitoutu-
miskohtaa, ja osoitimme, että hsa-miR-559 säätelee DISC1:n ilmentymistä alleeli-
spesifisesti in vitro. Saamiemme tulosten perusteella DISC1:n geneettiset variantit 
altistavat autismikirjon häiriöille ja vaikuttavat geenin miRNA-välitteiseen sääte-
lyyn. 
 
Toiseksi, olemme kuvanneet yksittäisen suuren autismisuvun, jonka on havaittu pol-
veutuvan yhteisistä keskisuomalaisista esivanhemmista 1600-luvulla. Hyödyntääk-
semme populaatioisolaattien geenikartoitukselle tarjoamia mahdollisuuksia, teimme 
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genominlaajuisen kytkentä- ja kytkentäepätasapainoanalyysin mikrosatelliittimark-
kereilla tässä suvussa, jonka kaukaisen sukulaisuuden voidaan olettaa vähentävän 
geneettistä heterogeenisyyttä. Tunnistimme mahdollisen autismille altistavan lokuk-
sen kromosomissa 19p13.3, ja havaitsimme kaksi jo aiemmin autismiin yhdistettyä 
lokusta kromosomeissa 1q23 ja 15q11-q13. Lupaavimmat ehdokasgeenit olivat 
TLE2 ja TLE6 (transducin-like enhancer of split [E(sp1) homolog, Drosophila]), 
jotka sijaitsevat 19p13-lokuksessa, sekä ATP1A2 (ATPase, Na+/K+ transporting, 
alpha 2 polypeptide) kromosomissa 1q23. Tulokset osoittivat, että autismin geneet-
tinen tausta yksittäisessäkin suvussa on monitekijäinen, ja että altistavia geneettisiä 
muutoksia on tässä suvussa ainakin kolmella eri kromosomialueella. 
 
Selvittääksemme autismikirjon häiriöiden geneettistä ja biologista taustaa mahdolli-
simman kattavasti ja tutkiaksemme edellä saatuja tuloksia tarkemmin, laajensimme 
käyttämäämme keskisuomalaistaustaista aineistoa uusilla perheillä, joilla on saman-
kaltaiset genealogiset juuret. Teimme genominlaajuisen analyysin autismia sairasta-
vien henkilöiden homotsygoottisista genomisista alueista sekä alleelisesta jakami-
sesta käyttämällä tiheästi sijoittuvia SNP-markkereita. Analysoimme lisäksi geno-
minlaajuista geeniekspressiota saman aineiston henkilöiden valkosoluista, ja kartoi-
timme alustavasti mahdollisia altistavia biologisia reaktioreittejä käyttämällä sekä 
SNP- että geeniekspressiotuloksia. Tunnistimme pienen määrän haplotyyppejä, jotka 
osa sukupuun autismia sairastavista henkilöistä jakoi keskenään, sekä yhteneviä 
reaktioreittejä SNP- ja ekspressiodatasta, joiden perusteella aksoniohjaukseen osal-
listuvat molekyylit näyttäisivät liittyvän autismikirjon häiriöiden patogeneesiin. 
 
Yhteenvetona, tässä väitöskirjatyössä saadut tulokset osoittavat, että useat erilliset 
geneettiset muutokset johtavat autismikirjon häiriöihin, jopa populaatioisolaateissa 
ja yksittäisissä perheissä. Näiden tulosten perusteella voidaan sanoa, että kytkentä-
alueiden, jaettujen haplotyyppien, sekä muiden altistavien genomisten alueiden sek-
vensointi on välttämätöntä, jos halutaan tunnistaa varsinaiset mutaatiot ja variantit, 
jotka aiheuttavat autismikirjon häiriöitä. Tunnistimme myös mahdollisen mikro-
RNA-välitteisen säätelymekanismin, joka saattaa osittain selittää DISC1-geenin 
laaja-alaisia neurobiologisia vaikutuksia. 
 
Avainsanat: autismikirjon häiriöt, Aspergerin oireyhtymä, populaatioisolaatti, 
DISC1, miRNA, kytkentäanalyysi, geeniekspressio, GWAS, reaktioreittianalyysi 
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1 INTRODUCTION 
Childhood autism is the hallmark diagnosis of a spectrum of similar 
neurodevelopmental conditions, known as autism spectrum disorders (ASD). Autism 
was first described in 1943 by Leo Kanner, who reported children with intellectual 
disability and severe social isolation which was not explained by the developmental 
level of the children (Kanner 1943). It is characterized by various impairments in 
behavioral, communicational, and social skills, such as dependence on routines and 
rituals, and absence or delay of spoken language. Asperger syndrome (AS), part of 
the same spectrum, was described shortly after autism in 1944 by Hans Asperger, 
who described patients with "autistic psychopathy" but normal intellectual abilities 
(Asperger 1944). Altogether, ASDs affect 0.6-0.7 % worldwide and are amongst the 
most heritable of neuropsychiatric disorders. Autism has traditionally been 
considered a common complex disorder, and studies investigating its genetic 
component have been conducted since the 1980’s. 
 
Until recently, very little was known about the genetic basis of autism spectrum 
disorders, much like many other psychiatric and neurological disorders. Based on 
information from linkage analysis and candidate gene studies it was thought that 
most of the predisposing genetic variants would be common in the population, and 
an unspecified combination of both genetic and environmental factors would be 
required to cross the critical threshold of liability. However, the identification of 
genes and genetic variants predisposing to ASDs has been significantly complicated 
by their exceptional heterogeneity. Phenotypically, significant differences are seen 
across the core clinical features, and some individuals with ASDs have co-occurring 
medical conditions with known etiologies, such as mendelian genetic defects. 
Additionally, the extent of genetic heterogeneity in ASDs has only recently been 
fully revealed, suggesting that many of the predisposing genetic factors may be 
unique to specific families. Reflecting this, it has been suggested that instead of 
treating autism as a single diagnosis, it would be more appropriate to think about 
"the autisms" (Geschwind and Levitt 2007).  
 
It is interesting to note in this context that genetic findings that overlap among 
different neuropsychiatric disorders have been increasingly discovered. For 
example, association of genetic variants in the DISC1 gene (Disrupted-in-
schizophrenia-1, originally associated to schizophrenia) to a broad range of 
phenotypes, and the discovery of same, rare DNA copy number variants in 
schizophrenia and ASDs, has forced us to reconsider the usefulness of traditional 
diagnostic classifications. These observations also underscore the likelihood that the 
underlying biological processes among these distinct clinical phenotypes will be at 
1 Introduction 
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least partially convergent. The idea is further supported by this study, where we 
found that genetic variants of the DISC1 gene associate also to ASDs.  
 
This project was started during the early years of the "post-genomic" era and the 
ongoing refinement of the clinical (and genetic) relationship among "the autisms" 
and other neuropsychiatric traits. Whereas previously only targeted research 
questions about the genetic etiology of complex disease could be addressed, it is 
now possible to use approaches which query the entire genome of an individual. In 
this thesis, we have taken advantage of multiple layers of genome-wide data and the 
properties of the isolated Finnish population to explore the genetic and biological 
cause of ASDs in a set of genealogically connected individuals. As a result, a 
complex picture of multiple layers of genome biology has slowly started to emerge 
and provide cues of the mechanisms underlying various genetic traits and disorders. 
 
 
 
 
 
 
2 Review of the Literature 
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2 REVIEW OF THE LITERATURE 
2.1  Variation in the genome and complex diseases 
2.1.1  Genetic variation 
All human genomes are approximately 99.9% identical, and the remaining 0.1% of 
variation between individuals together with environmental factors is what makes 
people different from each other. Genetic variation comes in multiple forms, and the 
variable sites of the genome can be used as genetic markers to study phenotypic 
differences between individuals and populations. Of particular interest is the study 
of disease genetics, which aims to identify, or map, genetic differences in the 
genome, which determine whether an individual is susceptible to a disease or not. It 
has been known for long that certain phenotypic traits and diseases run in families, 
and can be transmitted from parents to offspring. Although familial is not a synonym 
for heritable, as shared environment alone can be sufficient to produce a shared 
phenotype, familial transmission of some traits was eventually found to be mediated 
by specific genetic differences which children inherited from their parents. 
 
Genetic variation among humans arises mainly through two distinct mechanisms. 
Mutations are introduced to the genome randomly, with an average frequency of ~ 
2.2 × 10−9 per base pair per year (Kumar and Subramanian 2002), although some 
regions of the genome are more vulnerable to mutations than others. Mutations are 
classified as point mutations, insertions, or deletions, based on their effect on the 
gene structure. They can also be classified as loss-of-function, gain-of-function, or 
neutral mutations, based on the effect they have on the function of the gene in 
question. Mutations are introduced to the genome either by external factors, such as 
mutagenic radiation or chemicals, or by internal factors such as occasional random 
errors in DNA replication during cell division. Another biological process that 
creates variation among humans is recombination. Recombination refers to the 
process in which a DNA molecule (or sometimes RNA) is broken and then joined to 
a different one. Homologous recombination occurs between similar molecules of 
DNA, usually during mitosis, whereas recombination during meiosis facilitates 
chromosomal crossover which creates novel, unique combinations of the parental 
genomes which are then transmitted to the offspring. 
 
Genetic variation in humans can roughly be divided into structural variation and 
sequence variation. While structural variation is a broad term encompassing many 
different types of rearrangements affecting the physical structure of the 
chromosome, such as deletions and duplications of regions of varying length, 
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sequence variation occurs only on the DNA sequence-level, i.e. on the level of 
single base pairs comprising the "genetic code". In the early days, available 
cytogenetic methods only allowed the detection of large structural variants, such as 
deletions of entire chromosome arms, whereas new technologies have made it 
possible to detect variation in DNA copy number (copy number variants, CNVs) at 
much higher resolution (Feuk et al. 2006). This has lead to studies showing that 
small deletions, duplications, and other types of structural variation are abundant in 
the human genome and their effect is often benign (Iafrate et al. 2004, Sebat et al. 
2004, Conrad et al. 2006, Redon et al. 2006, Conrad et al. 2010). Similarly, when 
DNA sequencing became common practice, it became clear that different kinds of 
sequence polymorphisms, such as single nucleotide polymorphisms (SNPs), are 
common in the genome, and contribute to the normal variation between individuals. 
2.1.2 Genetic mapping 
To determine whether a trait has a genetic component, the degree of its heritability 
needs to be determined. Heritability is defined as the proportion of the phenotypic 
variance which is explained by genetic factors. Estimates are by rule produced using 
family, twin, and adoption studies, for example by comparing concordance rates in 
monozygotic (MZ) and dizygotic (DZ) twins which share 100% or 50% of their 
genome, respectively. Once the genetic basis of a trait has been established, genetic 
mapping can be applied to identify genomic regions, genes, and specific genetic 
variants in the genome that cause or contribute to the phenotype. Genetic mapping 
takes use of naturally occurring genetic markers and does not require prior 
knowledge of the pathogenesis of the disease or other trait in question. Instead, the 
aim is to look for regions in the genome that are genetically or statistically linked 
with the phenotype. Genetic mapping is facilitated by strong linkage disequilibrium 
(LD) (see Section 2.1.4) between the marker allele and the causative variant, as well 
as high penetrance and large effect size of the causal variant. If a heritable disorder 
is caused by defects in a single gene, they are referred to as monogenic, or 
mendelian, disorders, and their inheritance follows the general laws of inheritance, 
first discovered by Gregor Mendel in the 19th century. If instead the disorder is 
caused by the combined effect of multiple different genes or other genetic factors, it 
is referred to as a polygenic, or a complex disorder. Different methods for genetic 
mapping are described in Section 2.1.5. 
 
A genetic marker is a variable, or polymorphic, segment of DNA with an 
identifiable physical location on a chromosome whose inheritance in pedigrees can 
be traced. To be suitable for genetic mapping studies a marker has to be sufficiently 
polymorphic. The most commonly used markers include SNPs and microsatellite 
markers (also called short tandem repeats). SNPs are mostly di-allelic and the most 
abundant type of variation in the genome. Based on the Phase II of the International 
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fr Project (see Section 2.1.4), the total number of common SNPs in the human 
genome is at lest ~9-10 million (Frazer et al. 2007). Microsatellies are multiallelic 
markers consisting of tens of copies of di-, tri- or tetranucleotide repeats, and 
therefore generally more informative for mapping. However, they are less abundant 
in the genome and suffer from a relatively high mutation rate of ~10-3 to 10-4 per 
locus per generation (Levinson and Gutman 1987, Weber and Wong 1993, Ellegren 
2000). 
2.1.3 Complex disease genetics 
The methodology used in complex disease genetics was originally developed for the 
mapping of monogenic disorders. The traditional way to identify a causative variant 
or a mutation was to start with a genome-wide linkage analysis in a small set of 
affected families, fine-map the identified linkage region to narrow down the region 
of interest, and eventually identify the gene or variant at the locus by physical 
mapping or direct sequencing. As linkage analysis is best suited for the 
identification of rare, relatively high-penetrant variants, new methods recently 
evolved to analyze the common variation in the genome. An example of such 
methods is a genome-wide association study (GWAS) where allele frequencies of 
thousands of common SNPs are compared between cases and controls (see Section 
2.1.5). 
 
Two main hypotheses exist regarding the genetic background of common complex 
diseases. The first is that a small number of rare genetic variants (< 1% frequency in 
the general population), each with a large effect, cause the disease (Reich and 
Lander 2001). The second is that common traits are caused by a relatively large 
number of common genetic variants, each with a small effect on the phenotype 
(Lander 1996, Chakravarti 1999). This is called the "common disease common 
variant" (CDCV) hypothesis, an example of which is Alzheimer’s disease, where a 
specific allele of the apolipoprotein E gene appears to be responsible for over 50% 
of cases (Corder et al. 1993). In reality, both types of variants are likely to contribute 
to the disease risk, as GWA studies have shown that common variation alone 
explains only a relatively small fraction of the overall genetic risk, and single 
common variants associated with a disease have at best modest effect sizes. In a 
recent study, the mean odds ratios were calculated for most rare and common alleles 
identified in complex diseases to date (Bodmer and Bonilla 2008). The mean odds 
ratio for rare alleles was 3.74 and for common alleles 1.36. As GWA studies tackle 
only common alleles (population frequency > 1%), the next wave of studies has 
already started to analyze rare variation, which will probably explains at least a part 
of the "missing heritability". 
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Overall, GWA studies in common complex diseases have been most successful in 
autoimmune diseases such as Crohn’s disease, for which over 30 loci accounting for 
~20% of the total heritability have been robustly identified (Barrett et al. 2008). This 
is a high percentage, since for most other common traits, such as height and serum 
lipid levels, the identified variants account for only ~5-10% of the heritability 
(Visscher 2008, Aulchenko et al. 2009). One of the most extensive GWAS efforts 
was the study by the Wellcome Trust Case Control Consortium (WTCCC), which 
analyzed 14 000 patient samples representing seven different common disorders and 
a set of 3000 shared controls (2007). The phenotypes included were Type I and 
Type II diabetes, Crohn’s disease, rheumatoid arthritis, hypertension, coronary 
artery disease, and bipolar disorder. Genome-wide significant loci were identified 
for all diseases, except hypertension. The total number of GWA studies published to 
date is approaching 800 (www.genome.gov/GWAStudies). GWAS in 
neuropsychiatric phenotypes have been less successful, potentially because the 
overall complexity in brain-related phenotypes is much higher or because common 
variation plays a much smaller role in these phenotypes. Yet, GWA studies have 
completely transformed genetic mapping studies, and substantially increased, and 
altered, our understanding of the genetic background of complex disorders. 
2.1.4 Extent of linkage disequilibrium 
Linkage disequilibrium (LD) is defined as the non-random association of alleles at 
separate but linked loci on the same chromosome. In the genome, LD exists as 
haplotype blocks which vary in length and consist of regions with low 
recombination separated by regions of high recombination rates (referred to as 
recombination hotspots). As a general rule, the further apart two loci are on a 
chromosome the weaker is the LD between them, with different chromosomes 
showing complete independence of each other, that is, linkage equilibrium. 
However, the exact extent of LD at different loci is not predictable and thus, the LD 
structure of the human genome in different populations has been intensively studied, 
mostly because the extent and distribution of LD determines the number of markers 
required for a GWA study (Service et al. 2006). LD is normally a result of ancestral 
haplotypes being common in the population, and the blocks typically contain only a 
few common haplotypes (Daly et al. 2001, Reich et al. 2001, Gabriel et al. 2002, 
Phillips et al. 2003). LD is the basis of genetic association studies where genetic 
variants predisposing to the phenotype-of-interest can be identified by genotyping 
other markers which are in LD with the predisposing variant (see Section 2.1.5, 
Association-based methods).   
 
A key effort in characterizing variation and LD in the human genome was 
undertaken by the International HapMap Project (www.hapmap.org) (2003, 2005), 
which set out to create a haplotype map of the entire genome. A haplotype map 
2 Review of the Literature 
THL – Research 46|2010 22 Genetic Mechanisms Underlying 
Autism Spectrum Disorders 
illustrates the LD structure across all chromosomes and predicts which markers are 
inherited together. The HapMap project identified, validated, and genotyped 
common SNPs in different global populations, and provided a publicly available 
resource of SNPs to the scientific community. In the Phase I of the project, ~one 
million SNPs were genotyped in four populations (CEU – Central Europeans in 
Utah, representing a Caucasian population, CHB – Han Chinese from Bejing, JPT – 
Japanese from Tokyo, YRI – Yorubans from Nigeria) (The International HapMap 
Consortium 2005), whereas in Phase II, the number of SNPs was extended to 3.1 
million (Frazer et al. 2007). In the currently ongoing Phase III, the number of 
analyzed individuals has been increased and an additional seven populations have 
been included. 
 
The extent of LD in a population is determined by the effective population size and 
the time since founding, which affect the number of different haplotypes present in 
the population and thus, the number of recombinations between markers. LD is also 
strongly influenced by the number of founders and the expansion rate of the 
population (Service et al. 2006). In a study by Service and colleagues (2006), the 
magnitude and distribution of LD was compared in 11 isolated populations (see 
Section 2.1.6) and an outbred European-derived sample. The authors discovered that 
although the profiles of the LD maps were very similar in all of the populations 
studied, as discovered before (Tapper et al. 2003, De La Vega et al. 2005), the 
overall length of the maps, i.e. the extent of LD, varied. Interestingly, the most 
extensive LD was observed in a sub-isolate of Finland (named Kuusamo), and the 
authors suggested that GWA studies with Finnish samples could require as much as 
~30% fewer markers than with samples from more outbred populations. However, 
this is merely a theoretical suggestion, since current GWA studies are mostly 
conducted using predesigned SNP platforms. Nevertheless, this observation proved 
that population isolates are beneficial for complex disease mapping. 
2.1.5 Methods for genetic mapping in disease genetics 
An overview of the most essential methods is given, with the emphasis on the 
methods used in this thesis. 
 
L i n k a g e  a n a l y s i s  
Linkage is a genetic phenomenon in which different characters, such as a phenotype 
and a marker allele, co-segregate in a pedigree because their determinants lie close 
together on a particular chromosome and are not separated by recombination. The 
probability of linkage correlates with the genetic distance of two loci. The closer the 
loci are the smaller is the probability of meiotic recombination occurring between 
them. This recombination fraction (θ) ranges from 0.5 (complete linkage) to 0 (no 
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linkage), and the relationship between the recombination fraction and actual genetic 
distance is defined by a specific mathematical mapping function. The logarithm of 
odds (LOD) score represents the probability that two loci are inherited together 
because of linkage instead of chance (Morton 1955). However, recombination is not 
random and its rate is known to vary depending on for example sex and genomic 
location (Broman et al. 1998, Yu et al. 2001). 
 
Linkage analysis is a family-based genetic analysis method to study whether two 
loci in the genome, i.e. the "disease locus" and the marker locus, are genetically 
linked together. The objective is to find a locus that is inherited together with the 
trait in question more often than it should by chance (Terwilliger and Ott 1994). 
Linkage analysis was one of the first methods developed for genetic mapping and it 
has traditionally been carried out using microsatellite markers, since these were 
among the first genetic markers to be discovered and, based on their properties, were 
well suited for genome-wide mapping. In a single-gene disease, linkage analysis is 
an extremely efficient way to pinpoint the risk locus, and further the gene, since the 
locus usually shows complete segregation with the trait. However, in genetically 
more complex diseases, multiple loci contribute to the disease risk and therefore, 
multiple linkage peaks are typically identified. Linkage analysis identifies only 
relatively large genomic regions, which is why a denser marker set needs to be 
subsequently genotyped at the regions in order to narrow down the region of 
interest. 
 
A s s o c i a t i o n - b a s e d  m e t h o d s  
A .  C a n d i d a t e  g e n e  s t u d i e s  
While linkage is a relationship between genetic loci, association is simply a 
statistical observation that might have various non-genetic causes (see also B. 
Genome-wide association studies). Association studies operate on the population 
level, and can be regarded as very large linkage studies of unobserved, hypothetical 
pedigrees (Cardon and Bell 2001). A candidate gene association study has 
traditionally been the next step after a genome-wide linkage scan. Once a number of 
genomic regions have been identified by linkage, candidate genes are chosen from 
the linked region, finemapped typically with SNP markers, and analyzed for a 
correlation, i.e. a statistical association with the phenotype. The aim is to increase 
the density of markers in a targeted locus, and identify common variants that would 
associate to the phenotype and explain the observed linkage signal. If the finding is 
real, the associating marker allele presumably is in LD with the actual disease 
predisposing variant and the variant is flanked with a detectable haplotype (Figure 
1). In rare cases, the associating allele might directly influence the risk of disease. 
Since linkage regions are typically large and contain tens or even hundreds of genes, 
it is usually not possible to analyze all of the genes. Thus, candidate genes are often 
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prioritized by prior biological information, picking the genes that seem most 
relevant to the phenotype in question. This is of course a biased approach, since the 
choice of genes is entirely dependent on existing data and the extent of knowledge 
of the person who picks the genes, and genes whose function is unknown or less 
well characterized, are often left out. Candidate gene association studies can also be 
performed on the basis of a specific biological hypothesis, instead of a positional 
hypothesis, i.e. a linkage analysis. In this case, a gene or a group of related genes is 
studied for association with the phenotype, because previous research information 
strongly supports the hypothesis that it would be involved in a particular disease 
based on its function. An example of this is an association study between 155 ion 
transport genes and migrane (Nyholt et al. 2008). 
 
 
 
 
Figure 1. Illustration of linkage disequilibrium (LD) as the basis of genetic 
association studies. A SNP or a mutation predisposing to a given phenotype (red) can be 
identified by genotyping other genetic markers (blue) which are in LD with the marker-
of-interest (denoted by arrows). However, the degree of LD at a given locus is not 
always predictable or consistent with distance (denoted by SNP3 which is not in LD with 
the predisposing SNP despite its close proximity). 
 
B .  G e n o m e - w i d e  a s s o c i a t i o n  s t u d i e s  
Genome-wide association studies (GWAS) were spurred by decreasing genotype 
costs, which enabled the genotyping of hundreds of thousands of SNP markers 
across the genome in very large patient cohorts. Like linkage studies, GWAS is a 
hypothesis-free approach, but instead of looking for a truly genetic phenomenon like 
linkage, it is merely a statistical comparison of allele frequencies between two 
groups. The overall aim of a GWAS is to analyze as much of the common genetic 
variation in the genome as possible. Typically carried out in a case-control setting, 
GWA studies are designed to search for association of common genetic variants 
(minor allele frequency > 1%), since the SNP content of most of the commercial 
genotyping platforms reflect that of the International HapMap project, which has 
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identified and catalogued common SNPs and the LD structure across the genome in 
different populations. As the number of SNPs in HapMap has increased, so has the 
content of SNP chips, with the current platforms profiling around one million SNPs 
at a time. A method called imputation can additionally be used to increase the 
number of analyzed SNPs and to fill in missing genotypes. In imputation, allele 
frequency and LD information from other comparable genotyping studies can be 
used to estimate the most probable genotype at any given locus. 
 
Due to the massive number of SNPs analyzed, the number of statistical tests in a 
GWAS is huge, which increases the burden of multiple testing. Thus, sufficient 
statistical power has become a key issue in GWA studies, leading to gigantic study 
samples which have already exceeded 100 000 in some phenotypes (Teslovich et al. 
2010). Larger study samples are also achieved through meta-analysis, which is 
statistical technique to combine results from multiple different studies. The 
statistical power issue goes hand-in-hand with the effect size of the genetic variants, 
since it has now become clear that individual variants cause only a small increase to 
the risk in most phenotypes, and the smaller the effect, the more statistical power 
(i.e. larger study sample) is needed to detect it on a reliable, genome-wide 
significant level. A case-control analysis is the most common strategy, because 
individual affected cases are easier to obtain in large numbers than complete 
families, but some family-based studies have also been seen (for e.g. Weiss et al. 
2009). The interest towards them and SNP-based linkage analyses has lately 
increased again, with the realization that common variants are not sufficient to 
explain the entire genetic component of common diseases. 
 
Analyzing huge study samples can easily introduce bias into a GWA analysis. The 
most common sources of bias include confounding factors such as population 
stratification (see also Section 2.1.6), insufficient quality control of raw genotype 
data, or genotyping errors. Also, as mentioned, underpowered study samples can 
introduce spurious false-positive associations, which is why independent replication 
of results is an essential confirmatory step. The signal intensity data from genome-
wide SNP genotyping platforms can also be used to analyze DNA copy number 
variation (CNV), i.e. a type of sub-microscopic structural variation of the genome.  
 
G e n e  e x p r e s s i o n  p r o f i l i n g  a n d  e Q T L s  
The process of cellular differentiation and development is primarily driven by the 
differential expression of genes. The relative abundance of specific transcripts in a 
cell at a given time is the key determinant for the function and developmental fate of 
the cell, and further, the whole organism. Differences in gene expression levels have 
been extensively studied to address the question of normal versus abnormal cellular 
state, and to characterize cellular differentiation processes by monitoring changes in 
gene expression profiles. In disease genetics, the aim of genome-wide, or global, 
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gene expression profiling is to determine the response of the studied tissue to the 
disease state and to identify those genes that are differentially expressed in the 
profiled tissue between disease cases and matched, healthy controls. However, one 
of the major challenges in gene expression studies has been the identification of an 
appropriate tissue or cell type for analysis, especially when studying phenotypes 
such as autism or other neuropsychiatric disorders, where the affected tissues are 
mostly unknown (Cole et al. 1999). 
 
Especially in brain-related phenotypes, Epstein-Barr virus transformed B-
lymphocytes (i.e. lymphoblastoid cell lines, LCLs) are the most common tissue used 
in gene expression profiling, although their use has often been criticized as being 
inappropriate. It has been argued that the immortalization of the cell line drastically 
changes the expression profile, introduces artifacts, and masks the possible true 
effects (Plagnol et al. 2008, Min et al. 2010). Also, blood-cell derived LCLs do not 
seem like the tissue-of-choice when looking for expression differences relevant to 
brain-related processes. However, there are also beneficial aspects of using LCLs. 
Firstly, and most importantly, they are easily accessible. Blood samples are 
relatively easy to obtain, as compared with other tissues, which enables larger 
sample sizes and better statistical power. Secondly, it has been argued that the 
transformation of the cells actually increases their comparability by removing effects 
of many environmental factors, such as smoking, which often affect the expression 
profile of native cells such as lymphocytes (Charlesworth et al. 2010). Thirdly, in 
many diseases, it is not at all clear which tissue would be more relevant to study. For 
example, expression profiling from brain tissue would require a very precise and 
informed hypothesis of the brain region most likely to be affected. This is especially 
true in autism, where the etiology remains poorly understood, and the causes and 
consequences of neurological and behavioral symptoms cannot be properly 
differentiated. 
 
Recently, large scale studies have begun to address the effects of genetic variation 
on gene expression levels on a genome-wide level. By quantifying the transcript 
levels in a given tissue and correlating this information for example with SNP or 
microsatellite genotypes using linkage (Goring et al. 2007) or association analysis 
(Dixon et al. 2007, Stranger et al. 2007a, Stranger et al. 2007b, Kwan et al. 2008), 
quantitative trait loci (QTL) contributing to gene expression differences among 
populations, individuals, and tissues have been identified and are generally referred 
to as expression-QTLs (eQTL). This approach is especially useful in trying to 
determine how the variants identified in GWA studies might mediate disease 
susceptibility, most of which fall into gene deserts or lack apparent functionality. 
Accordingly, a recent study showed that current signals obtained from GWA studies 
are enriched for these regulatory variants (Nica et al. 2010). 
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P a t h w a y  a n a l y s i s  
A biological pathway is traditionally defined as a series of interconnected enzymatic 
steps linked by the production of intermediates that are then used in the following 
enzymatic step to produce a specific product. However, a biological pathway can 
also refer to various cellular signaling pathways where a single input signal, such a 
mechanical or a chemical stimulus, is converted into distinct cellular responses (i.e. 
signal transduction). 
 
As the amount of various genome-wide datasets has quickly increased, biological 
pathway analysis has become a popular tool to address whether the most significant 
results are enriched for a particular group of genes with similar functions (i.e. 
belonging to a same pathway) more than would be expected by chance. To date, 
pathway analysis has mostly been applied to global gene expression datasets, but the 
last few years have seen an increasing number of studies, where similar 
methodology has been developed also for genome-wide association datasets (for e.g. 
Wang et al. 2007, Baranzini et al. 2009, Holmans et al. 2009, O'Dushlaine et al. 
2009). In contrast to gene expression data where a single transcript can generally be 
used to represent a single protein product (i.e. a single component of a pathway), 
GWAS data is less straightforward in terms of pathway analysis. With multiple 
SNPs per gene, variable gene size, and complex LD structures across the genome, 
defining how signals from individual SNPs represent genes and further, components 
of pathways, has proved challenging. 
 
Generally, two analysis strategies can be taken. One is to investigate a single, or a 
few, predefined candidate pathways for enrichment of significant p-values compared 
with all genes (Wang et al. 2009b). This can however introduce bias, both in gene 
selection and in assessing the significance of the finding compared with the untested 
pathways. The other is to use a hypothesis free approach and test all suggestively 
associated or differentially expressed genes, similar to the approach taken for 
example by Wang et al. (2007). This approach is biased by the data itself, i.e. it is 
dependent on the quality and properties of the initial GWAS or differential 
expression analyses, and should be interpreted within this context. However, 
focusing the analysis only on the most significant association hits is likely to ignore 
a significant number of false negative hits, especially in phenotypes such as autism, 
where large effect size variants are not present. 
 
Currently, pathway analysis is greatly restricted by our limited knowledge of cellular 
processes and the far-from-complete functional annotation of genes. Yet, especially 
in the case of GWAS datasets, pathway analysis can in part help to overcome the 
problem of replication with small effect size associations, in particular in datasets 
with limited statistical power, in which single-locus genome-wide significance 
cannot be reached. Instead of focusing on individual genes with strongest evidence 
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of differential expression or association with the phenotype, pathway-based 
approaches typically rank all genes based on their significance and search for 
enrichment among the top end of the gene list (including the borderline significant 
results often ignored by GWA studies) thereby assessing whether seemingly 
scattered findings converge on the level of pathways. 
 
Most of the pathway analysis methods for gene expression data are modifications of 
the original Gene Set Enrichment Analysis (GSEA) method, which determines 
whether an a priori defined set of genes shows statistically significant, concordant 
differences between two biological states such as phenotypes (Mootha et al. 2003, 
Subramanian et al. 2005). The GSEA was used as the basis for one of the first 
pathway analysis algorithms developed for GWAS as well (Wang et al. 2007), 
which has been applied in many later studies (for e.g. Menashe et al., Wang et al. 
2009a). 
 
S e q u e n c i n g - b a s e d  m e t h o d s  
Direct sequencing of DNA, i.e. traditional Sanger sequencing (Sanger and Coulson 
1975), has typically been applied in candidate gene-based studies to screen for 
genetic changes in individual genes in limited numbers of samples. Due to the 
laborious and relatively expensive nature of sequencing, it is usually applied only to 
the coding, or exonic, parts of a gene. The increasing demand for low-cost and 
efficient sequencing lead to the recent development of high-throughput sequencing 
methods, usually referred to as next-generation sequencing. This technology, based 
on the parallel production of millions of sequence reads at once, has made it possible 
to sequence substantially larger regions of the genome faster and cheaper, although 
the storage, handling, and analysis of the data still imposes a substantial 
computational challenge. 
 
With costs rapidly decreasing, it will soon be possible to sequence entire genomes of 
individuals for the purpose of research, as first initiated by the 1000Genomes project 
(www.1000genomes.org). The project aims to sequence the full genomes of ~1000 
individuals from different global populations and provide a comprehensive resource 
on human genetic variation. As sequencing is a superior method to identify rare 
genetic variants, which are currently gaining increased attention within the disease 
genetics field, an intermediate approach of sequencing the coding regions of the 
genome ("exomes") has been taken whilst waiting for costs to plummet. Examples 
of studies where whole-exome sequencing has been successfully used to identify 
recessive mutations have already started to emerge (Bilguvar et al. 2010, Ng et al. 
2010). In addition to DNA sequencing, next-generation sequencing can also been 
used for other applications. For example, RNA sequencing ("RNA-Seq") is used as a 
more comprehensive, probe-independent alternative to microarray-based gene 
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expression profiling, whereas "ChIP-Seq" is used to sequence immunoprecipitated 
DNA fragments in various epigenetic approaches. 
2.1.6 Isolated populations 
Isolated populations, also known as founder populations, are populations which have 
originated from a small number of original founders and subsequently rapidly 
expanded through normal population growth instead of immigration. Often these 
populations have experienced long periods of geographical or cultural isolation, 
which has further enhanced the isolation and lack of immigration. In such 
circumstances, genetic drift can have drastic effects on the gene pool by driving 
some alleles to fixation and others to extinction, thus reducing overall genetic 
heterogeneity. Since a low degree of genetic heterogeneity is ideal for all genetic 
mapping studies, the advantages of using isolated populations in disease genetics are 
well-recognized.  
 
Finland is a well-known isolated population which has originated from a small 
number of original settlers. Compared with the rest of Europe, samples from the 
Finnish population tend to exhibit a decrease in genetic diversity (Sajantila et al. 
1996) and increased degree of linkage disequilibrium (Varilo et al. 2003, Service et 
al. 2006) (see also Section 2.1.4), which has proved useful in mapping genetic 
diseases. Heterogeneity of the Finns is decreased also by various non-genetic 
factors, such as fairly uniform culture, lifestyle (such as diet), and standardized 
healthcare. Additionally, good genealogical records and reliable medical information 
make it easier to identify shared ancestry, construct pedigrees, and obtain correct 
diagnoses for the purpose of genetic studies. However, the distinct population 
history of Finland, characterized by multiple genetic bottlenecks followed by rapid 
growth without immigration, has left the population internally highly stratified, but 
also extremely homogenous within certain sub-isolates (Jakkula et al. 2008). Other 
isolated populations commonly used in genetic mapping studies include for example 
Iceland, Sardinia, Azores, and Newfoundland. 
 
Due to its population history and strong founder effect, the Finnish population has a 
unique collection of enriched recessive disease alleles. These ~30 monogenic 
diseases are referred to as the Finnish disease heritage, and to date, at least one 
causative mutation has been successfully identified in all but one of them (Peltonen 
et al. 1999). On the contrary, some monogenic diseases which are common in 
Europe, for example cystic fibrosis and phenylketonuria, are very rare in Finland. In 
founder populations, these recessive diseases are often characterized by the presence 
of a single founder mutation, whereas numerous mutations in the same genes are 
identified in the global population. For example, in an autosomal recessive 
congenital nephrotic syndrome (CNS), 94 % of the Finnish cases carry one of two 
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mutations of the NPHS1 gene, named FinMajor and FinMinor (Kestilä et al. 1998). 
Outside Finland, more than 119 different mutations in this gene have been described 
in CNS (Schoeb et al. 2010). 
 
The processes behind the enrichment of recessive alleles have been postulated to 
affect risk alleles in common complex diseases as well, and the use of population 
isolates in complex disease genetic has quickly become popular. The tendency of the 
affected individuals to share ancestral haplotypes derived from a small number of 
founders can be expected to reduce overall noise in the analysis and increase 
detection power in genetic mapping studies (Peltonen et al. 2000). For example, 
large Finnish pedigrees were used successfully in a study of familial combined 
hyperlipidemia that identified the USF1 gene (upstream transcription factor 1) as a 
risk factor for this complex disease (Pajukanta et al. 2004). Also, a gene conferring 
susceptibility to asthma (NPSR1, neuropeptide S receptor 1) was initially discovered 
by analyzing two  regional subpopulations of Finland (Laitinen et al. 2004). More 
recently, common alleles affecting susceptibility for multiple sclerosis were 
identified in a high-risk Finnish sub-isolate (Kallio et al. 2009, Jakkula et al. 2010). 
An important observation from these studies is that even if genetic variants 
predisposing to complex traits are originally identified from an isolated population 
or exceptional large families, they are often replicated in large-scale population 
samples elsewhere (Kristiansson et al. 2008). 
 
The era of genome-wide association studies has greatly increased the general 
awareness of population stratification, i.e. genetic differences among populations. 
With up to few million analyzed markers and study samples reaching tens of 
thousands, even slight effects of stratification can introduce huge bias to the results. 
The International HapMap Project (2005) was among the first to assess allele 
frequency differences of common variants among the Caucasian, African, Chinese, 
and Japanese populations , and subsequently, the genetic variation among many 
global populations has been extensively characterized (for e.g. Abdulla et al. 2009, 
Tishkoff et al. 2009, Xu et al. 2009, Behar et al. 2010). It is now known that 
significant population substructure can be present also within populations, such as in 
Europe (Novembre et al. 2008, Salmela et al. 2008). Strikingly, even in isolated 
populations such as Finland, substantial genetic substructure has been detected 
(Jakkula et al. 2008). 
2.1.7 Micro-RNAs 
Although GWA studies and other genetic mapping approaches have robustly 
identified a large number of loci and specific variants which contribute to the risk of 
many common diseases, the relationship between these variants and the actual 
disease mechanisms remains mostly unknown, despite a few exceptions (for e.g. 
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Moffatt et al. 2007). The detection and genome-wide mapping of eQTLs in different 
human tissues (Stranger et al. 2007a, Dimas et al. 2009) has greatly promoted the 
conception of what such mechanisms could be like, and further emphasized the 
importance of characterizing different types of regulatory elements in the genome. 
Transcription factors (TF) have traditionally been the key players in regulatory 
network studies, but the discovery of micro-RNAs (miRNA) in 2001 added another 
layer of complexity to these studies. Since both TF and miRNA binding sites can be 
disrupted by SNPs or CNVs, they have quickly become the target for intensive 
research in human genetics. For the purpose of Study I of this thesis, some of the 
central concepts of miRNAs will be covered in this review. 
 
B i o g e n e s i s  
Micro-RNAs (miRNAs) are short, ~22 nucleotide-long non-coding RNA-molecules, 
which occur naturally in cells and are capable of silencing protein coding genes 
post-transcriptionally by specifically binding the messenger RNA (mRNA). Micro-
RNAs are processed from longer transcripts which are initially either transcribed 
from independent miRNA genes by RNA polymerase II (pri-miRNAs), or processed 
from introns of protein-coding genes ("mirtrons") (Kim et al. 2009). Thus, a mature 
miRNA can occur from multiple distinct genomic loci, i.e. multiple different 
primary transcripts. An overview of the miRNA biogenesis is presented in Figure 2. 
The pri-miRNAs fold into hairpin structures, which are cleaved by an RNase-
enzyme, Drosha, into ~70-nucleotide pre-miRNAs. These pre-miRNAs are then 
exported from the nucleus into the cytoplasm where they are further cleaved by 
another RNase, Dicer, into ~20bp RNA duplex. One strand of this duplex represents 
the mature miRNA, which is subsequently loaded into a miRNA-induced silencing 
complex (miRISC). The other strand is called the "passenger" strand and is often, 
but not always, degraded. If both strands remain, the less abundant form (the 
"passenger") is denoted with an asterisk (*) in miRNA nomenclature. If 
predominance cannot be determined, the two forms are denoted with "3p" and "5p", 
referring to the 5’ and 3’ arms of the stem-loop precursor. The actual silencing 
process is carried out by the miRISC complex, together with associated molecules 
such as argonaute proteins, when the mature miRNA base-pairs with the target 
mRNA (Krol et al. 2010). 
 
S i l e n c i n g  m e c h a n i s m  
The miRNA-mediated silencing effect is achieved by either suppressing the 
translation or initiating the degradation of the target mRNA. Whilst the mechanism 
of mRNA deadenylation followed by its decay is fairly well characterized, the 
process of translational repression remains poorly understood (for e.g. Fabian et al. 
2010). The relative contributions of these two outcomes have been largely unknown, 
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particularly for endogenous targets which are expressed at relatively low levels and 
are hard to measure accurately. However, a recent study demonstrated that lowered 
mRNA levels account for 84% of the decreased protein production, and changes in 
mRNA levels closely reflect the impact of miRNAs on gene expression (Guo et al. 
2010). The authors also suggest that destabilization of target mRNAs is the 
predominant reason for reduced protein output. Mature miRNAs recognize their 
targets through specific basepairing between 5’ nucleotides 2 – 8 of the miRNA 
(which is referred to as the "seed" region) and complementary nucleotides in the 3’ 
untranslated region (3’UTR) of the target mRNA (Lewis et al. 2005). It is known 
that transcripts with multiple, non-overlapping miRNA binding sites are more 
responsive to miRNA-induced repression than those with a single binding site 
(Doench et al. 2003, Zeng et al. 2003). Interestingly, recent findings have also 
shown that under certain conditions, or in specific cells for example, miRNA-
mediated repression can be reversed or prevented. Further, interaction of the 
silencing complex and the mRNA 3’UTR can lead to upregulation rather than 
downregulation of translation (Vasudevan and Steitz 2007), which adds a whole new 
dimension to the regulatory capabilities of miRNAs. 
 
M i c r o - R N A  t a r g e t  p r e d i c t i o n  a n d  r e l e v a n c e  t o  
d i s e a s e  
Micro-RNA genes are abundant in the genome and it has been estimated that they 
regulate at least 50% of all human genes (Krol et al. 2010). The central miRNA 
database, miRBase (http://www.mirbase.org) (Griffiths-Jones et al. 2006), currently 
contains 940 annotated human miRNAs (release 15). The recognition that the 
specificity of the miRNA - target mRNA recognition arises from base-pairing 
between the seed region and the 3’UTR had direct implications for disease genetics. 
Since the target sites are subject to disruption by SNPs or mutations as any other 
genomic sequence leading to abnormal miRNA regulation of the gene or transcript 
in question, they can mediate disease susceptibility through variation among 
individuals. A multitude of miRNA target prediction algorithms subsequently 
followed and have been widely applied since. However, accurate prediction has 
proved challenging due to the extremely short length of the seed sequence, and the 
number of false-positive predictions is huge, which is why functional validation of 
targets is constantly increasing. 
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Figure 2. Outline of the micro-RNA biogenesis. 
 
Most of the prediction algorithms are based on a few major criteria. First, the 
predictions are currently limited to the 3’UTR sequences, although it is possible that 
target sites are present also elsewhere. Second, the exact base-pairing between the 
mRNA and the 5’ region of the miRNA is most crucial with seed nucleotides 2 – 7, 
but prediction specificity increases, when an 8-nucleotide match is required. It is 
also known that the length of the complementary region correlates with the 
efficiency of silencing (Grimson et al. 2007, Bartel 2009). Third, evolutionarily 
conserved sites are more likely to be true sites, and highly conserved miRNAs have 
many conserved targets (Lewis et al. 2005, Xie et al. 2005), even though 3’UTR 
sequences are typically poorly conserved. Some of the most commonly used 
prediction algorithms include TargetScan (www.targetscan.org), miRanda 
(www.microrna.org), and PicTar (www.pictar.org). Additional tools, such as 
RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid) and RNA22 
(http://cbcsrv.watson.ibm.com/rna22_targets.html), can take into account the 
thermodynamical properties of the binding between the miRNA and the target 
mRNA n their predictions. Common practice is to use multiple algorithms to do a 
prediction and then rank the obtained results based on convergent evidence from 
different methods. Target prediction methodology is additionally covered in Section 
4.3.2. 
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There is an increasing amount of evidence of the involvement of miRNAs in 
disease. The most common approach is a genome-wide analysis of differential 
miRNA expression in cases and controls, but targeted functional studies of 
individual miRNAs are also emerging (for e.g. Sethupathy et al. 2007, Tan et al. 
2007, Hollander et al. 2010). Although most studies have been performed in cancer 
(for e.g. Lu et al. 2005), there is also evidence of miRNA involvement in 
neuropsychiatric and neurodegenerative phenotypes, such as schizophrenia (Kim et 
al. 2010) and Alzheimer’s disease (Wang et al. 2008). 
 
One of the first and well-known examples of miRNA involvement in disease was 
from Tourette syndrome (TS), a condition phenotypically related to ASDs (Abelson 
et al. 2005). In this study, a frameshift mutation and two independent occurrences of 
the same non-coding sequence variant were identified in the 3’UTR of the SLITRK1 
gene in 174 unrelated TS probands. The variants were located in a conserved 
binding site for hsa-miR-189, and the authors showed that in the presence of hsa-
miR-189, the variants reduced the expression of SLITRK1 compared with the wild-
type gene. The variant was absent from 4296 controls, leading to a statistically 
significant association with TS. The authors further demonstrated that the expression 
patterns of SLITRK1 and hsa-miR-189 were overlapping and developmentally 
regulated in both mouse and human brain regions previously implicated in TS, and 
that the normal function of SLITRK1 in dendritic growth in primary neuronal 
cultures was affected by the mutation. Although this example only applies to rare 
cases of TS, it created a lot of excitement, because it was able to demonstrate a 
mechanism in humans, through which miRNAs can affect a disease phenotype. 
However, as with all mechanisms regulating gene expression, tissue-specificity of 
miRNAs remains an important question. Especially in disease-oriented miRNA 
studies like this one, addressing tissue specificity will be challenging since most 
miRNAs are likely have spatially and temporally narrow regulatory effects. 
2.2 Autism Spectrum Disorders 
2.2.1 Clinical features 
Autism spectrum disorders (MIM#209850), also known as pervasive developmental 
disorders (PDDs) (F84), include childhood autism (or autistic disorder, AD) (F84.0), 
Asperger syndrome (AS) (F84.5), atypical autism (F84.1), childhood disintegrative 
disorder (F84.3), and Rett syndrome (F84.2) according to the current International 
Classification of Diseases (ICD-10, World Health Organization 1993). An 
additional, commonly used term is PDD-NOS (pervasive developmental disorder 
not otherwise specified) (F84.9), which refers to an "autism-like" phenotype similar 
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to childhood autism, but falling short of the strict diagnostic criteria. ASDs have 
traditionally been conceptualized by most researchers as a continuum of the same 
disorder with varying degrees of severity, and in fact, it has been suggested that in 
the upcoming new edition of the ICD-classification, the disorders would be treated 
as a continuum of phenotypes. It is also likely that Rett syndrome, a close-to-
monogenic form of ASDs affecting predominantly girls (Amir et al. 1999), will be 
excluded from the group. 
 
Childhood autism is characterized by qualitative impairment or delayed 
development in verbal and non-verbal communication, reciprocal social interaction, 
and behavioural skills before the age of three years. The extent and quality of 
symptoms can vary significantly, and the impairments can be expressed in different 
ways. For example, although delay or absence of spoken language is fundamental in 
autism, it is not present in all affected individuals (Alarcon et al. 2002). Similarly, 
some affected individuals clearly avoid all forms of social interactions, whereas 
others seek actively for personal interactions, even if in that would be in a socially 
odd manner (Wing and Gould 1979, Volkmar et al. 1989). Asperger syndrome is a 
milder disorder of the spectrum, which shares the core clinical features of childhood 
autism, but does not present any major cognitive deficiencies. Individuals with AS 
typically have a fairly normal language development and average basic verbal skills 
for communication, and the disorder is usually recognized much later than childhood 
autism (Volkmar and Klin 2000). Typical features of AS include difficulties in 
socialization, one-sided way of communication, unusual patterns of interest, formal 
and pedantic speech and dependence of routines and rituals (Nieminen-Von Wendt 
2004). All diagnoses of ASDs are based on structured interviews and behavioral 
observation, in the absence of any molecular or physiological markers. The most 
commonly used diagnostic tool is the Autism Diagnostic Interview –Revised (ADI-
R) (Lord et al. 1994) accompanied by the Autism Diagnostic Observational 
Schedule (ADOS) (Lord et al. 1989), which have quickly become the gold standard 
tools in most autism research. The diagnostic criteria of childhood autism and AS, 
the two central phenotypes in this study are presented in Tables 1 and 2. 
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Table 1. ICD-10 diagnostic criteria for childhood autism (F84.0) (World Health 
Organization). 
_______________________________________________________________________ 
 
A. Presence of abnormal or impaired development before the age of three years, in at least one out 
of the following areas: 
(1) receptive or expressive language as used in social communication; 
(2) the development of selective social attachments or of reciprocal social interaction; 
(3) functional or symbolic play. 
 
B. Qualitative abnormalities in reciprocal social interaction, manifest in at least one of the 
following areas: 
(1) failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture to 
regulate social interaction; 
(2) failure to develop (in a manner appropriate to mental age, and despite ample opportunities) 
peer relationships that involve a mutual sharing of interests, activities and emotions; 
(3) A lack of socio-emotional reciprocity as shown by an impaired or deviant response to other 
people's emotions; or lack of modulation of behaviour according to social context, or a weak 
integration of social, emotional and communicative behaviours. 
 
C. Qualitative abnormalities in communication, manifest in at least two of the following areas: 
(1) a delay in, or total lack of development of spoken language that is not accompanied by an 
attempt to compensate through the use of gesture or mime as alternative modes of communication 
(often preceded by a lack of communicative babbling); 
(2) relative failure to initiate or sustain conversational interchange (at whatever level of language 
skills are present) in which there is reciprocal to and from responsiveness to the communications 
of the other person; (3) stereotyped and repetitive use of language or idiosyncratic use of words or 
phrases; 
(4) abnormalities in pitch, stress, rate, rhythm and intonation of speech; 
 
D. Restricted, repetitive, and stereotyped patterns of behaviour, interests and activities, manifest in 
at least two of the following areas: 
(1) an encompassing preoccupation with one or more stereotyped and restricted patterns of interest 
that are abnormal in content or focus; or one or more interests that are abnormal in their intensity 
and circumscribed nature although not abnormal in their content or focus. 
(2) apparently compulsive adherence to specific, non-functional, routines or rituals; 
(3) stereotyped and repetitive motor mannerisms that involve either hand or finger flapping or 
twisting, or complex whole body movements; 
(4) preoccupations with part-objects or non-functional elements of play materials (such as their 
odour, the feel of their surface, or the noise or vibration that they generate); 
(5) distress over changes in small, non-functional, details of the environment. 
 
E. The clinical picture is not attributable to the other varieties of pervasive developmental 
disorder; specific developmental disorder of receptive language (F80.2) with secondary socio-
emotional problems; reactive attachment disorder (F94.1) or disinhibited attachment disorder 
(F94.2); mental retardation (F70-F72) with some associated emotional or behavioural disorder; 
schizophrenia (F20) of unusually early onset; and Rett's syndrome (F84.2). 
_______________________________________________________________________________ 
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Table 2. ICD-10 diagnostic criteria for Asperger Syndrome (F84.5) (World Health 
Organization). 
_______________________________________________________________________________ 
 
A. A lack of any clinically significant general delay in spoken or receptive language or cognitive 
development. Diagnosis requires that single words should have developed by two years of age or 
earlier and that communicative phrases be used by three years of age or earlier. Self-help skills, 
adaptive behaviour and curiosity about the environment during the first three years should be at a 
level consistent with normal intellectual development. However, motor milestones may be 
somewhat delayed and motor clumsiness is usual (although not a necessary diagnostic feature). 
Isolated special skills, often related to abnormal preoccupations, are common, but are not required 
for diagnosis. 
 
B. Qualitative abnormalities in reciprocal social interaction (criteria as for autism). 
 
C. An unusually intense circumscribed interest or restricted, repetitive, and stereotyped patterns of 
behaviour, interests and activities (criteria as for autism; however it would be less usual for these 
to include either motor mannerisms or preoccupations with part- objects or non-functional 
elements of play materials). 
 
D. The disorder is not attributable to the other varieties of pervasive developmental disorder; 
schizotypal disorder (F21); simple schizophrenia (F20.6); reactive and disinhibited attachment 
disorder of childhood (F94.1 and .2); obsessional personality disorder (F60.5); obsessive-
compulsive disorder (F42). 
_______________________________________________________________________________ 
 
Intellectual disability (ID), also referred to as mental retardation, and epilepsy are 
the most commonly occurring associated medical conditions in ASDs. ID occurs in 
75-80% and seizures in 25-30% of autistic children (Bailey et al. 1996, Fombonne 
1999, Gillberg and Billstedt 2000), although a more recent study estimated the 
prevalence of cognitive defects to be lower than 50% (Chakrabarti and Fombonne 
2005). Information regarding AS is less well documented. About 10–15% of 
individuals with childhood autism have co-occurring medical conditions with known 
etiologies (Folstein and Rosen-Sheidley 2001), which are usually specific 
cytogenetic or single gene disorders. The most common associated Mendelian 
disorders are Fragile X syndrome (MIM#300624) (in 1-2% of ASD cases), tuberous 
sclerosis (TSC; MIM#191100) (in ~1% of ASD cases), and chromosome 15q11-13 
duplication syndrome (in 1-2% of ASD cases), which are reviewed for example by 
Gillberg and Billstedt (2000) or Freitag (2007) along with other coexisting disorders. 
The wide range of associated medical conditions in ASDs further adds to its clinical 
heterogeneity, and highlights the importance of accurate phenotyping for genetic 
studies, since the underlying genetic background is likely to reflect this 
heterogeneity, even in the idiopathic forms of the disorder. Also, as suggested, it is 
probably more appropriate to think about "the autisms" instead of arbitrarily 
grouping all existing cases under a single diagnostic class  (Geschwind and Levitt 
2007) (Figure 3). 
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Figure 3. Illustration of the concept of “The Autisms”, emphasizing some of the many 
etiological features and the clinical heterogeneity within ASDs. The central box lists 
some of the neurodevelopmental processes that might be disrupted in ASDs. Figure 
adapted from Geschwind and Levitt (2007). 
2.2.2 Prevalence 
Based on the most recent epidemiological review on ASDs (Fombonne 2009), the 
overall prevalence of all ASDs is 60-70/10 000 (0.6-0.7% of children), making it 
one of the most frequent childhood neurodevelopmental disorders. This study 
reviewed the results of altogether 43 studies published since 1966, and provides very 
good estimates of the current figures. The prevalence of strictly defined childhood 
autism is ~20/10 000, whereas for AS, the review gives an estimate of ~6/10 000 
which should be treated with caution, since only a few small epidemiological 
surveys specific for AS have been conducted (Ehlers and Gillberg 1993, Kadesjo et 
al. 1999, Mattila et al. 2007). Thus, this estimate is mostly based on more recent 
autism surveys, in which AS has been additionally studied. Though AS was first 
described already in 1944 (Asperger 1944), it remained widely unrecognized until 
the 1980’s, and was added to the ICD-10 as an independent diagnosis as late as 
1993, which explains the small number of surveys thus far. However, overall, the 
prevalence of AS seems much lower than that of childhood autism. The prevalence 
of PDD-NOS was estimated to be around 30/10 000 (Fombonne 2009).  
 
All ASDs are generally more common in males than in females (ratio ~4:1), but this 
difference is much smaller when only severe forms of childhood autism with 
intellectual disability are considered. On the contrary, in high-functioning children 
with childhood autism, the male-to-female ratio can be as high as 8:1 (Fombonne 
2005). The sex bias has not been explained to date, but it seems that it is not driven 
by X-chromosomal loci (Abrahams and Geschwind 2008) (see also Section 2.2.8). 
An exception to this is Rett syndrome, which occurs almost exclusively in females 
and is caused by mutations in Methyl-CpG-binding protein 2 (MeCP2) at 
chromosome Xq28 in ~80% of cases (Amir et al. 1999). 
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The prevalence of all ASDs has notably increased in the last decades, and older 
studies systematically obtain lower prevalence estimates than the more recent ones. 
Various environmental reasons for this have been proposed (reviewed for e.g. in 
Landrigan 2010), such as maternal exposure to rubella virus, but the majority of the 
field attributes the increase mainly to increased awareness of the disorders and 
broader diagnostic criteria rather than actual increased incidence. In particular, 
awareness of AS and milder phenotypes of the spectrum, such as PDD-NOS, has 
greatly increased and diagnostic accuracy has improved. Also, advances in health 
services worldwide have probably brought more affected individuals into surveys.  
2.2.3 Mode of inheritance 
In the 1940’s, both Kanner and Asperger noticed ASD-like personality traits in the 
parents of affected children in their original studies, and made a preliminary 
suggestion of a heritable component in the disorders they described. Still, it took a 
long time before the genetic and biological basis of autism was widely recognized 
and accepted. In the 1960’s it was thought that autism was caused by poor parenting, 
in particular mothers withholding their affection. Even though Kanner himself said 
in the early years that parental coldness might contribute to autism (Kanner 1949), 
he later renounced this theory. Yet, his statement was misused for a long time, and 
the concept of "refridgerator mothers" prevailed until the biological basis of autism 
was eventually established (Rutter 1968). The importance of genetic factors became 
clear when the co-occurrence of autism with chromosomal aberration syndromes, 
such as Fragile-X, was noticed (Blomquist et al. 1985). 
 
According to twin studies, childhood autism is clearly heritable. Concordance rates 
vary from 69-98% among MZ twins to 0-30% in DZ twins (Folstein and Rutter 
1977, Steffenburg et al. 1989, Bailey et al. 1995). However, most of the twin studies 
have been small, looking at tens of twin pairs only. In family studies, 2-6% of 
siblings of individuals with autism were found to have an ASD (Bailey et al. 1998). 
The heritability estimate, calculated from the MZ:DZ concordance ratio and sibling 
recurrence risk, is ~90%, which is one of the highest among complex disorders, 
(Szatmari et al. 1998, Folstein and Rosen-Sheidley 2001). 
 
For AS, no systematic twin studies have been performed, and the estimation of 
familial aggregation has been challenging due to the availability of case reports 
only. However, as noticed already by Asperger himself, family members of 
individuals with AS often have problems with social interaction as well, suggesting 
the involvement of genetic factors (Asperger 1944, Bowman 1988, Gillberg 1989, 
Volkmar et al. 1998). Also, it should be noted that even though AS is often seen in 
siblings of individuals with autism, large families exist where AS is transmitted 
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through the pedigree, in the absence of childhood autism, in a manner resembling 
dominant mode of inheritance (Ylisaukko-oja et al. 2004, Rehnström et al. 2006). 
 
The genetic basis of autism has traditionally been thought to resemble that of other 
common, complex disorders, with multiple common susceptibility variants 
comprising the majority of the risk. Earlier, it was estimated that the number of 
interacting loci contributing to autism susceptibility ranged between two and 15 
genes of varying effect (Pickles et al. 1995, Risch et al. 1999), but in the light of the 
knowledge gained from for example genome-wide association studies, the true 
number of involved loci is likely to be in hundreds. Also, recent GWA studies have 
shown that effect sizes for common variants in ASDs are exceptionally low (see 
Section 2.2.6), suggesting that rare genetic events are more likely to play a 
significant role in ASDs. Concurrent reports of rare, de novo CNVs, and rare, high 
penetrant mutations identified in individual ASD families (Section 2.2.7 and 2.2.9) 
have further strengthened this view, and underscored the substantial genetic 
heterogeneity in ASDs. Given that not all variants are fully penetrant and their 
expressivity can vary, the interaction between rare and common genetic variants 
needs to be fully characterized in order to understand the underlying genetic 
model(s) in ASDs. Also, it should be remembered that the autistic phenotype is not 
only a product of interactions between different combinations of susceptibility 
variants, but also of CNVs and other chromosomal aberrations, epistatic 
mechanisms, and epigenetic and environmental factors. 
2.2.4 Biological basis 
As with genetic findings, the underlying neurobiology of ASDs is likely to be 
heterogeneous and no single hypothesis has gained more support than others. ASDs 
are considered "developmental" disorders because symptoms appear soon after birth 
in early infancy, and they affect many aspects of cognition and behaviour, leaving 
them poorly developed. Still, it is completely unknown at which point the primary 
lesion (whatever that is) occurs, and why the affected processes specifically relate to 
language and social functions. 
 
The neuropathological findings in autism are greatly complicated by frequent co-
morbid features (see Section 2.2.1). Numerous small abnormalities have been 
reported, such as enlargement of the hippocampus and the amygdala (Schumann et 
al. 2004), but these have mostly been inconsistent. Postmortem and structural 
magnetic resonance imaging studies have highlighted the frontal lobes, amygdala 
and cerebellum as pathological (Amaral et al. 2008), and a number of functional 
neuroimaging studies have suggested that impairments in cortical connectivity are 
present in individuals with autism (Just et al. 2004, Koshino et al. 2008). In one of 
these studies, the brain activation of a group of high-functioning autistic participants 
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and intelligence quotient (IQ) matched controls was measured using functional 
magnetic resonance imaging (fMRI) during sentence comprehension. The authors 
report that the functional connectivity, meaning the degree of synchronization of the 
time series of the activation between the various participating cortical areas, was 
consistently lower for the autistic than the control participants (Just et al. 2004). 
 
One of the main biological themes in ASDs that has emerged is synaptic 
dysfunction. This was initially suggested by rare, high-penetrance mutations 
associated with autism which have recently been identified in multiple genes 
encoding for synaptic cell adhesion molecules, such as neuroligins, neurexins, and 
contactin-associated protein-like 2 (CNTNAP2) (see Section 2.2.9). These 
molecules connect pre- and post-synaptic neurons at the synaptic cleft, mediate 
synaptic signalling, and are suggested to shape neural networks by specifying 
synaptic functions (Sudhof 2008). Another suggested theme is neuronal excitability, 
i.e. the ratio of excitation and inhibition, which seems to be influenced by a number 
of autism-associated genes (Rubenstein and Merzenich 2003) such as neuroligins, 
whose mutations appear to affect the balance between excitatory and inhibitory 
synaptic transmission (Tabuchi et al. 2007). As suggested by Walsh and colleagues 
(2008), a unifying hypothesis might be that genes involved in autism would encode 
proteins which mediate activity-dependent changes of neuronal function (Hong et al. 
2005). Thus, autism would reflect abnormal regulation of gene expression under 
specific, neuronal activity-dependent processes, such as learning. This hypothesis is 
supported by a recent study, where homozygosity mapping in consanguineous 
autism families revealed homozygous deletions affecting genes whose level of 
expression changes in response to neuronal activity (Morrow et al. 2008). However, 
it is unclear how dysfunction in such general synaptic function could lead to autism 
and yet leave so many cognitive processes unaffected. Interestingly, it is known that 
early stages of neurodevelopment, such as neuronal production, axonal growth, and 
initial connectivity, are largely independent of synaptic functioning (Sur and 
Rubenstein 2005). Instead, the refinement of synapses, which occurs at a later 
developmental stage, relies on neuronal activity and eventually leads to synaptic 
plasticity and learning (Hong et al. 2005). 
 
Other biological processes proposed to be affected in ASDs include glutamatergic 
and serotonergic neurotransmission (Bear et al. 2004, Chugani 2004), and abnormal 
calcium signalling (Krey and Dolmetsch 2007). However, the genetic evidence for 
synaptic dysfunction and impaired synaptic cell adhesion coupled with the structural 
and functional evidence of cortical underconnectivity has lead to the prevailing 
hypothesis that autism is a neuronal disconnection syndrome (Frith 2004, 
Courchesne and Pierce 2005, Geschwind and Levitt 2007, Hughes 2007, Wang et al. 
2009b). 
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2.2.5 Linkage studies 
After the heritability and the genetic basis of ASDs was established, the next step 
was to locate the regions of the genome where the predisposing genes and genetic 
factors would reside. Microsatellite-based genome-wide linkage analysis together 
with regional candidate gene studies was the method-of-choice in autism genetics, as 
well as in other complex disease phenotypes, for many years until genome-wide 
SNP approaches emerged. The objective of a linkage analysis is to find a locus in 
the genome that is inherited together with the trait in question more often than it 
should by chance. Numerous studies have been performed in different populations, 
but overall, most identified loci have reached only suggestive levels of significance 
and replication has been marginal, as in many other complex diseases (Altmuller et 
al. 2001). Study samples have been small, especially in the early days, but it has also 
been shown that increasing the study sample does not necessarily result in 
comparably more significant linkage signals (Yonan et al. 2003). The lack of 
genome-wide significant linkage and replication probably reflects the underlying 
heterogeneity of the used study samples. Especially in large collaborative studies, 
samples are often from all over the world, increasing both genetic and diagnostic 
heterogeneity. To decrease heterogeneity, efforts have been made to subgroup study 
samples based on various selected phenotypic features, such as sex or age at first 
word. This approach has improved signals and even revealed a few loci reaching 
genome-wide significance, once again highlighting the challenges heterogeneity 
poses on all genetic research. Most of the linkage studies performed in ASDs have 
been extensively reviewed recently (Freitag 2007, Yang and Gill 2007, Abrahams 
and Geschwind 2008), and a summary of the most consistent findings is presented in 
Table 3. In this review, I will only focus on some of the most important findings, 
and findings from the Finnish population. 
 
Linkage signals for ASDs have been reported in almost all chromosomes, and no 
single locus can really be picked out as more significant than others, which is typical 
for complex neuropsychiatric disorders. Chromosome seven is probably the most 
studied chromosome in ASDs, and the only locus which was supported by two meta-
analyses (Badner and Gershon 2002b, Trikalinos et al. 2006). Linkage has been 
observed at two distinct loci, 7q22-q31 and 7q34-q36 (IMGSAC 1998, Ashley-Koch 
et al. 1999, Barrett et al. 1999, IMGSAC 2001a, b, Liu et al. 2001, Shao et al. 2002, 
Lamb et al. 2005), which both harbour some of the most rigorously studied 
candidate genes in ASDs, such as CNTNAP2, RELN, and MET (see Section 2.2.9). 
Chromosome 7q34-q36 has also been implicated by QTL-based linkage studies 
using endophenotypes instead of the end-state diagnosis. In studies by Alarcon and 
colleagues (Alarcon et al. 2002, Alarcon et al. 2005), three quantitative measures 
from the ADI-R screening questionnaire were considered, and evidence of linkage 
was found for language delay (age at first word) at this locus. 
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However, in the two largest linkage studies in ASDs to date (Yonan et al. 2003, 
Szatmari et al. 2007), support for linkage at chromosome seven was not observed. In 
the study by Yonan and colleagues, 345 multiplex families were analyzed, each with 
at least two siblings affected with ASDs. The most significant findings were on 
17q11 (maximum LOD score [MLS] = 2.83, p =0.00029) and on 5p13 (MLS=2.54, 
p =0.00059). The chromosome 17q locus is near the serotonin transporter (5-HTT) 
gene SLC6A4, and linkage evidence for this locus has been observed in at least five 
other studies (IMGSAC 2001b, Bartlett et al. 2005, Cantor et al. 2005, McCauley et 
al. 2005, Trikalinos et al. 2006). What makes this locus especially interesting is that 
three studies found considerable evidence of sex-specific effects at this locus. All of 
these studies divided their study samples to male-only versus female-only containing 
sibships, and in all cases, significant linkage was observed at 17q11 with the male-
only families (Stone et al. 2004, Cantor et al. 2005, Sutcliffe et al. 2005). However, 
in a follow-up study, no single SNP or haplotype was sufficient to account for the 
linkage signal (Stone et al. 2007). 
 
In the study by Szatmari and colleagues (2007), which reported the results of the 
Autism Genome Project Consortium (AGP), 11p12-p13 was the single major locus 
identified. Altogether 1181 families were analyzed for linkage and DNA copy 
number variation. Based on the CNV analyses, further subsetting of the families was 
performed to decrease heterogeneity, and suggestive linkage evidence was observed 
also for 15q23–25.3, in addition to 11p12–p13. This still did not change the fact that 
even with the largest reported ASD study sample thus far, almost no overlap was 
observed with previously published studies. 
 
The first genome-wide linkage scan for ASDs in the Finnish population was 
published in 2002 (Auranen et al. 2002). The authors analyzed 38 multiplex families 
with 87 affected individuals. The most significant LOD scores were observed at 
chromosome 3q25-27 (Zmax=4.31, MLS 4.81). Two other loci at 1q21-23 and 7q 
also showed some evidence of linkage (lod scores > 2). A follow-up study was 
conducted where these three loci were finemapped, but overall, it did not add much 
to the significance of the original study (Auranen et al. 2003). 
 
Another independent genome-wide linkage scan in Finland was performed in 
Asperger syndrome (Ylisaukko-oja et al. 2004). This study is still the only linkage 
study specifically for AS. Seventeen large pedigrees with 82 AS cases (and no 
autism cases) in multiple subsequent generations were analyzed. Strongest linkage 
was observed at chromosomes 1q21-23 (Zmax=3.58), 3p13-24 (Zmax=2.50), and 
13q31-33 (Zmax=1.59), and the linkage to the 3p locus was later replicated in an 
independent set of 12 Finnish AS families (Rehnström et al. 2006). Linkage to 
1q21-23 and 13q31-33 has been observed also in multiple linkage studies for 
schizophrenia (Blouin et al. 1998, Brzustowicz et al. 1999, Brzustowicz et al. 2000, 
Gurling et al. 2001, Badner and Gershon 2002a). 
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Table 3. Summary of ASD linkage peaks with support from multiple studies. Listed 
are loci, which obtained a logarithm of odds (LOD) score > 3 in at least one study, and 
a LOD > 2 in at least one additional study. The studies indicated with a star (*) 
performed also an analysis with families with affected males only. "Age at first word" is 
a measure taken from the ADI-R diagnostic interview, whereas the SRS screening tool 
measures the severity of social impairment associated with ASDs, and is completed by 
parents and/or teachers. Table adapted from Abrahams and Geschwind (2008). 
 
Locus Phenotype Cohort Reference 
1q21-q23 AS FIN Ylisaukko-oja et al. (2004) 
ASD FIN Auranen et al. (2002) 
2q23-q31 ASD IMGSAC IMGSAC (2001b) 
ASD US Buxbaum et al. (2001) 
3q25-q27 ASD FIN Auranen et al. (2002) 
ASD Utah Coon et al. (2005) 
5p13-p14 ASD AGP Szatmari et al. (2007) 
ASD AGRE Liu et al. (2001) 
ASD AGRE Yonan et al. (2003) 
7q22-q31 ASD IMGSAC IMGSAC (2001b) 
ASD IMGSAC IMGSAC (1998) 
7q34-q36 Age at first word AGRE Alarcon et al. (2002) 
Age at first word AGRE Alarcon et al. (2005) 
9q33-q34 Age at first word CPEA Schellenberg et al. (2006) 
ASD AGP Szatmari et al. (2007)* 
11p12-p13 ASD AGP Szatmari et al. (2007) 
SRS score AGRE Duvall et al. (2007) 
17q11-q21 ASD AGRE Stone et al. (2004)* 
ASD AGRE Cantor et al. (2005)* 
ASD AGRE Yonan et al. (2003) 
ABBREVIATIONS: AS=Asperger syndrome, ASD=autism spectrum disorder, FIN=Finland, 
IMGSAC=International Molecular Genetic Study of Autism Consortium, AGRE=Autism Genetic 
Resource Exchange, CPEA=Collaborative Programs of Excellence in Autism Network at the 
National Institute of Health, AGP=Autism Genome Project, SRS=Social Responsiveness Scale 
 
 
In summary, no consistent linkage evidence for any chromosomal region has been 
found in ASDs. Even when loci are relatively well replicated in multiple smaller 
studies, they have not been detected by the larger ones at all, further emphasizing the 
heterogeneity of the disorder and the need for even larger study samples. Also, since 
many of the published linkage studies have used overlapping or even same family 
material, their evidence of linkage cannot be considered independent. However, in 
the light of what is currently known about the genetic background of autism, there is 
a good chance that many of the identified linkage loci are real and that they harbor 
either multiple rare variants, possibly specific for a subset of samples, or common 
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variants with very small effects which escape consistent detection due to insufficient 
sample size. 
2.2.6 Genome-wide association studies 
To date (August 2010), three genome-wide association studies (GWAS) in autism 
have been published. The study by Wang and colleagues (2009b), reported the first 
and largest-to-date autism GWAS, with multiple large ASD cohorts. They started by 
analyzing 780 families from the Autism Genetic Resource Exchange (AGRE) with 
1299 affected individuals. No genome-wide significant signals were detected so they 
analyzed the Autism Case-Control (ACC) Cohort with 1204 additional cases (2503 
cases in total), and performed a meta-analysis with the AGRE data. This analysis 
yielded one genome-wide significant hit at chromosome 5p14.1 (rs4307059, 
p=3.4x10-8). To replicate this finding, two additional cohorts with 540 and 108 cases 
were analyzed. In both replication cohorts, the most significant association signals 
from the discovery cohorts were replicated with the same direction of association. 
The most significant SNPs all tagged the same haplotype block between two 
cadherin genes, CDH9 and CDH10, both of which mediate calcium dependent cell-
cell adhesion. A pathway-based association analysis further supported the role of 
neuronal cell adhesion molecules in autism susceptibility, which is in line with 
previous genetic findings. It should be noted that a separate GWAS paper has been 
published where one of the replication cohorts was analyzed independently, and the 
AGRE samples used as a replication cohort (Ma et al. 2009). With far less 
convincing evidence, the authors report common variants at the same 5p14.1 locus, 
which is not surprising, given that the study sample is completely overlapping with 
the Wang et al. study. 
 
The second study, by Weiss and colleagues (2009), performed a family-based study 
of genome-wide linkage and association in 1031 multiplex autism families with 
altogether 1553 affected individuals. All families had at least one affected individual 
meeting the ADI-R criteria for autism, and possible family members affected with 
an ASD were included. Families were obtained from the AGRE and US National 
Institute for Mental Health (NIMH) repositories. The study identified two regions of 
either suggestive or significant linkage at 6q27 and 20p13, respectively. As with the 
Wang et al. study, no genome-wide significant associations were identified with the 
initial study sample, but after the authors proceeded to genotype the most significant 
SNPs in additional autism families, one SNP at 5p15 reached genome-wide 
significance (p=2x10-7) in the combined analysis. The SNP was located between two 
genes, SEMA5A and TAS2R1, and due to previous evidence of SEMA5A in ASDs, 
the authors continued to demonstrate that the expression of SEMA5A was reduced in 
cortical samples of individuals with autism, thus confirming a previously reported 
finding from LCLs (Melin et al. 2006). 
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The third study reported results from the Autism Genome Project (AGP) 
Consortium GWAS with 1369 ASD families (1385 affected individuals) (Anney et 
al. 2010). One SNP, rs4141463 at chromosome 20p12.1, exceeded genome-wide 
significance (p=2.1x10-8). The authors proceeded to analyze a smaller replication 
study sample (595 families with 1086 affected individuals), again from the AGRE, 
but this did not add to the significance of the results, and in the combined analysis of 
both datasets, rs4141463 barely reached genome-wide significance (p=4.7x10-8). 
The SNP is located in MACROD2 gene, which is largely unknown. Additional 
exploratory analyses with phenotype subgroups were also performed, but no 
significant association results were obtained from these, considering the burden of 
multiple testing. 
 
Importantly, all three GWA studies use a partially overlapping set of samples, 
namely, the AGRE samples. Still, all of the reported associations are at distinct loci, 
even the two that are located on the same chromosome 5p region, and evidence for 
the reciprocal best loci could not be detected.  Since the availability of ASD samples 
in the field is limited, the publicly available AGRE sample collection is in wide use, 
introducing challenges to the interpretation of results in a wide variety of genetic 
studies which use partially (or completely) overlapping study samples. Yet, despite 
the questions that arise from the lack of overlap in the results of these studies, they 
nevertheless demonstrate that effect sizes for common variants in ASDs are very 
low (odds ratios for the best SNPs in all three studies range from 0.53 to 1.19) and 
massive study samples are required to identify these variants reliably. Taken 
together, these studies strongly suggest that common variants explain only a small 
fraction of the genetic background of ASDs, and alternative methods and larger 
study samples are required to address the role of rare genetic events. However, given 
the heterogeneity of the disorder, it is likely that most of the predisposing factors 
turn out to be family or subgroup specific and cannot be found simply by increasing 
sample size. 
2.2.7 Structural variation 
Before CNV analysis was made possible by high-throughput SNP arrays and the 
study of chromosomal abnormalities relied on traditional cytogenetic methods, it 
was estimated that cytogenetic abnormalities occured in ASDs with a frequency of 
3-5% (Ritvo et al. 1990, Chakrabarti and Fombonne 2001, Wassink et al. 2001a, 
Wassink et al. 2001b, Reddy 2005). Based on the information obtained from recent 
CNV studies, the current frequency estimate is 6-7% (Marshall et al. 2008) and this 
number is likely to increase as resolution in CNV detection improves. Also, 
including individuals with dysmorphic features and intellectual disability increases 
the estimate.  
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Like linkage, cytogenetic abnormalities in ASDs have been described in almost all 
chromosomes. The most frequent finding is to chromosome 15q11-q13 (Gillberg 
1998), where especially inherited duplications are common and account for 1-2% of 
all aberrations in ASDs (Freitag 2007, Abrahams and Geschwind 2008). Deletions at 
this locus are known to cause two cytogenetic imprinting disorders, Angelman 
syndrome (MIM#105830) and Prader-Willi (MIM#176270) syndrome, depending 
on whether the deleted region is of maternal or paternal origin. In ASDs, the 
duplications are usually of maternal origin. Yet, autistic features appear to be present 
in both Angelman syndrome and PWS. 
 
The first systematic genome-wide search for DNA copy number variation (CNVs) in 
autism was published in 2007 (Sebat et al. 2007). The study focused on idiopathic 
autism and identified an excess of de novo CNVs, i.e. CNVs not present in the 
respective parents, in individuals with autism compared with controls using 
comparative genomic hybridization (CGH). Validated de novo CNVs were 
identified in 12 out of 118 (10%) of patients with sporadic autism, in 2 out of 77 
(3%) of patients with an affected first-degree relative, and in 2 out of 196 (1%) of 
controls. In addition to identifying individually interesting CNVs and thereby 
providing clues of the possible pathology, this study reinforced the idea that there is 
a difference in the frequency of de novo CNVs between sporadic and familial autism 
cases, suggesting distinct mechanisms in each. This idea was later supported by a 
similar study (Marshall et al. 2008).  
 
In conjunction with the GWA studies performed in ASDs, many of the large cohorts 
have now also been analyzed for CNVs. In a study by Glessner and colleagues 
(2009), CNVs were analyzed in the ACC cohort (859 cases and 1409 controls), the 
AGRE cohort (1336 cases), and additional controls (n=1110). Numerous candidate 
loci with an enrichment of CNVs were identified in ASD cases compared with 
controls, and the CNVs were found to target genes involved in neuronal cell 
adhesion and ubiquitin degradation. In the Autim Genome Project (AGP) study 
(Pinto et al. 2010), rare (<1%) CNVs were analyzed in 996 ASD cases and 1287 
matched controls. Cases were found to carry a 1.19 fold higher global burden of rare 
CNVs, both de novo and inherited, especially at loci previously implicated in ASDs 
or intellectual disability. They also reported that the de novo CNV rate was roughly 
equal in simplex and multiplex families, which contrasts the previous studies. An 
interesting related observation is that the average age of fathers of affected children 
has increased (Reichenberg et al. 2006), which might partially explain the elevated 
de novo CNV rates and ASDs. 
 
A few individual CNV findings have recently gained attention in particular. For 
example, a recurrent de novo deletion on chromosome 16p11 was identified by three 
independent autism studies (Kumar et al. 2008, Marshall et al. 2008, Weiss et al. 
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2008). The deletion spans ~500 kb, overlaps ~30 genes, and seems to be present in 
~1% of autism cases in different cohorts. Occasionally, also the reciprocal 
duplication was observed in ASD cases. In one of the studies (Weiss et al. 2008), the 
deletion was found only from 2 out of 18 834 unscreened controls, which highlights 
the significant enrichment in individuals with autism. However, in the study by 
Glessner et al. (2009), CNVs at the 16p11 locus did not segregate to all cases within 
families and it was transmitted also to unaffected siblings, suggesting that the locus 
is not sufficient by itself to cause ASDs in these individuals. Overall, many of the 
identified CNVs overlap with previously implicated autism candidate genes, in 
particular genes encoding for synaptic cell adhesion molecules which further 
supports the role of synaptic dysfunction in ASDs (see Section 2.2.9). 
 
To conclude, although the identification of rare CNVs in ASDs has generated a lot 
of excitement, it should be remembered that de novo CNVs are found also in the 
general population. Thus, distinguishing pathogenic CNVs from benign ones 
remains a challenge. Also, it is difficult to evaluate, whether a single CNV in a 
single affected individual is sufficient to cause the phenotype, or whether CNVs 
mediate their pathogenicity in conjunction with other CNVs or predisposing 
mutations or polymorphisms. To facilitate this task, resources such as the Autism 
Chromosome Rearrangement Database (http://projects.tcag.ca/autism), are finally 
emerging to tackle the increasing numbers of findings. Additional resources, such as 
the Decipher database (Firth et al. 2009) and the EUCARUCA database (European 
Cytogeneticists Association Register of Unbalanced Chromosome Aberrations) 
provide phenotypic information of various microdeletion and duplication 
syndromes. 
2.2.8 Gene expression studies 
Genome-wide gene expression profiling in ASDs has greatly been hindered by the 
availability of samples, and only a handful of studies have been reported to date. 
Yet, despite being small, these studies have established that expression profiling, 
most commonly from lymphoblastoid cell lines (LCLs), can distinguish between 
affected individuals and their healthy siblings, as well as between different 
syndromic forms of autism (Baron et al. 2006a, Nishimura et al. 2007, Hu et al. 
2009b), once again highlighting the importance of accurate phenotypic subgrouping 
in genetic studies. Overall, on the level of individual genes, less than 1% of the 
genes that have been identified as differentially expressed in ASD studies overlap 
between studies (Abrahams and Geschwind 2008). This is not surprising because 
autism is known to be heterogeneous, but also because the study samples are small, 
and gene expression levels are easily affected by various technical and 
environmental artifacts. However, among the overlapping genes are multiple genes 
from the imprinted region on chromosome 15q11-q13, including UBE3A (ubiquitin 
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protein ligase E3A), NIPA2 (non imprinted in Prader-Willi/Angelman syndrome 2), 
and CYFIP1 (cytoplasmic FMR1 interacting protein 1) (Abrahams and Geschwind 
2008), possibly reflecting the common occurrence of cytogenetic abnormalities in 
ASDs at this locus (see Section 2.2.7). 
 
To date (August 2010), altogether seven studies have performed genome-wide 
expression profiling of ASD cases and controls from LCLs, and one from brain-
tissue (summarized in Table 4). A number of other studies have measured 
expression changes of individual, or a small number of, genes. Two of the genome-
wide studies profiled syndromic forms of autism, i.e. autistic individuals with a 
known chromosomal aberration (Baron et al. 2006a, Nishimura et al. 2007). 
Expression profiling has also been performed in closely related phenotypes, such as 
Fragile X syndrome (Bittel et al. 2007) and chromosome 15q duplication cases 
(Baron et al. 2006b). The largest of these studies analyzed gene expression in LCLs 
from 116 cases and 29 controls obtained from the AGRE (Hu et al. 2009b). Using 
various ADI-R diagnostic scores, the authors applied multiple clustering algorithms 
on ~2000 individuals with autism (Hu and Steinberg 2009), and identified subgroups 
of autistic probands (116 in total) with different severity scores which were then 
used in global gene expression analysis. Fifteen genes regulating circadian rhythm 
were differentially expressed in the subgroup with most severely affected 
individuals, whereas 20 genes associated with androgen sensitivity were 
differentially expressed in all of the cases compared with controls. The authors 
suggest that this might underlie the 4:1 prevalence bias in affected males and 
females. Relatedly, it has been suggested that higher levels of testosterone in the 
developing fetus could produce behaviors relevant to those seen in autism. This 
theory is part of the "extreme male brain" theory of autism (Baron-Cohen 2002, 
Baron-Cohen et al. 2005, Knickmeyer and Baron-Cohen 2006) which has remained 
controversial. 
 
Three studies have analyzed the genome-wide expression of micro-RNAs in ASDs, 
two in LCLs (Talebizadeh et al. 2008, Sarachana et al. 2010) and one in post-
mortem cerebellum (Abu-Elneel et al. 2008). All three studies reported some 
putatively interesting differentially expressed miRNAs (ranging from nine to 43) 
and target genes for these miRNAs, which seem to relate to autism-relevant 
biological processes. However, the number of affected individuals in these studies is 
extremely small, ranging from five to thirteen. Two miRNA, hsa-miR-23a and 106b, 
were differentially expressed in two of these studies (Abu-Elneel et al. 2008, 
Sarachana et al. 2010), but the statistical methods of the other was proved invalid 
(Buyske 2009), thereby questioning the results. No studies specific to ASDs have 
addressed the role of specific miRNAs. However, there are few examples from 
related disorders, such as Rett (Nomura et al. 2008) and Tourette syndromes 
(Abelson et al. 2005). 
 
2 Review of the Literature 
THL – Research 46|2010 50 Genetic Mechanisms Underlying 
Autism Spectrum Disorders 
In summary, gene expression studies in ASDs suffer from small sample sizes and 
limited statistical power. The number of studies will undoubtedly increase when 
more samples become available. While these studies have identified some putatively 
interesting differentially expressed genes and biological processes affected in ASDs, 
their biggest value has been in showing that gene expression profiles from LCLs can 
be used to distinguish different phenotypic subgroups in neuropsychiatric disorders.
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Table 4. Summary of gene expression studies published to date (August 2010). Only genome-wide studies are included. Studies 
focusing only on Fragile X syndrome or related disorders are not included. 
 
Reference Phenotype Samples Tissue 
Purcell et al. (2001) Autism 10 cases, 23 controls postmortem brain  
(mainly cerebellum) 
Baron et al. (2006a) Autism with dup(15q) 10 cases, 9 controls LCL 
Hu et al. (2006) Autism, ASD 5 discordant MZ twin pairs and  
two non-autistic siblings,  
one control MZ twin pair 
LCL 
Melin et al. (2006) Autism 6 cases, 6 controls LCL 
Nishimura et al. (2007) Autism with FMR1-FM, 
autism with dup(15q) 
15 cases  (8 with FMR1-FM, 7 with dup15q), 
15 controls 
LCL 
Gregg et al. (2008) Autism, ASD 49 cases  (35 AUT, 14 ASDs), 
12 controls 
Whole blood 
Hu et al. (2009a) Autism with severe  
language impairment 
21 discordant sib-pairs  
(one affected, one non-autistic) 
LCL 
Hu et al. (2009b) Idiopathic autism with three 
subgroups based on ADI-R 
severity scores 
116 cases, 29 controls LCL 
ABBREVIATIONS: AUT=autism, ASD=autism spectrum disorder, LCL=lymphoblastoid cell line, MZ=monozygotic, FMR1-FM=Fragile X 
mutation, dup(15q)=chromosome 15q11-q13 duplication 
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2.2.9 Candidate gene studies 
As with linkage studies, the number of candidate gene studies in ASDs is beyond the 
scope of this review. Therefore, only some of the key findings will be presented. 
Since Study I of this thesis focuses entirely on the DISC1 gene, it will be separately 
reviewed in the following section.  
 
Most of the positional candidate genes studied in ASDs fall between chromosome 
7q22 and 7q36 regions, due to frequent linkage findings (Section 2.2.5). These genes 
include the met proto-oncogene (MET), reelin (RELN), contactin associated protein-
like 2 (CNTNAP2), and Engrailed 2 (EN2), amongst others. Of these, RELN is 
probably the most studied. Association of a 5’ untranslated region (UTR) 
trinucleotide repeat polymorphism to ASDs has been reported by multiple genetic 
studies (Persico et al. 2001, Skaar et al. 2005, Serajee et al. 2006), and on the 
biological side, defects in reelin signalling in post-mortem cortices and reduced 
plasma levels of reelin have been detected in individuals with autism (Fatemi 2002, 
2004). 
 
Of the other genes at 7q, strong association and functional evidence was obtained for 
a common functional variant in the promoter of the MET gene, which disrupts MET 
transcription and cortical MET signalling in ASDs (Campbell et al. 2006, Campbell 
et al. 2007). The EN2 gene has been linked to cerebellar abnormalities in mutant 
mice (Bauman and Kemper 2005), and association to autism has been detected in a 
few studies (Gharani et al. 2004, Benayed et al. 2005). However, one of the most 
convincing positional candidate genes in autism altogether is CNTNAP2. It is 
located in a linkage peak for a language-related QTL (Alarcon et al. 2002, Alarcon 
et al. 2005), and fine-mapping of the region revealed an association between a SNP 
in CNTNAP2 and a language-related autism endophenotype. Subsequent studies 
have found evidence that both common and rare genetic variants, as well as 
cytogenetic and gene expression-related abnormalities in CNTNAP2 increase the 
risk of ASDs (Alarcon et al. 2008, Arking et al. 2008, Bakkaloglu et al. 2008). 
 
The imprinted locus on chromsome 15q11-q13 has been frequently studied due to 
the chromosomal abnormalities observed at this locus (see Section 2.2.7). The 
GABAA receptor subunit gene cluster, with gamma-aminobutyric acid A receptor, 
beta 3 (GABRB3) gene in particular, has received most of the attention, after GABA 
receptor density was found to be decreased in the hippocampus of individuals with 
autism (Blatt et al. 2001). Two other genes, ATPase class V type 10C (ATP10C) and 
the ubiquitin-protein ligase E3A (UBE3A) located in the maternal expression 
domain, are involved with the phenotypically similar Angelman syndrome. 
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However, mutations have not been identified at 15q and the overall association 
evidence remains inconclusive (Gupta and State 2007). 
 
S y n a p t i c  c e l l - a d h e s i o n  g e n e s  
The last few years have been exciting times in autism research, and the 
understanding of the molecular pathology in ASDs has taken a huge leap forward 
compared with what was known before. The identification of rare, high-penetrance 
mutations in genes encoding for various synaptic cell-adhesion molecules has 
directed the attention of researchers to the synapse, and, for the first time, a specific 
molecular mechanism explaining a piece of the puzzle is emerging. Although the 
identified mutations are rare and account only for a small fraction of all autism 
cases, related evidence is accumulating, and the hypothesis of synaptic dysfunction 
underlying ASDs has gained widespread acceptance (Garber 2007). 
 
The first piece of evidence emerged, when eight females were reported to have de 
novo deletions of the short arm of the X chromosome (Xp22). Three of these 
females had autism (Thomas et al. 1999). Later, in an attempt to pinpoint the 
causative factors at the deleted region, mutations in two neuroligin genes (NLGN3 
and NLGN4) were identified and found to be associated with ASDs (Jamain et al. 
2003, Laumonnier et al. 2004). Both mutations, a frameshift and an amino-acid 
changing substitution, were identified in two brothers with no other features of a 
genetic syndrome, and they arose de novo in the unaffected mothers. Both genes 
have subsequently been screened for mutations in several ASD cohorts, but so far, 
only rare events have been seen (Yan et al. 2005). Other members of the NLGN 
gene family have been less well characterized. 
 
Neuroligins are cell-adhesion molecules that connect the pre- and postsynaptic 
membranes of glutamatergic and GABAergic synapses, and function in 
synaptogenesis during brain development (Song et al. 1999, Varoqueaux et al. 
2004). Neuroligins bind another group of proteins at the synaptic junction, called 
neurexins, and together they are crucial proteins for trans-synaptic cell adhesion, and 
for aligning and activating synapses (Boucard et al. 2005). When mutations and 
deletions in neurexin 1 (NRXN1) in individuals with autism were identified (Feng et 
al. 2006, Szatmari et al. 2007), substantial excitement was generated and the 
synaptic dysfunction hypothesis was fully adopted. 
 
SHANK3 gene (SH3 and multiple ankyrin repeat domains 3), located at 22q13, was 
linked to ASDs and defects in synaptogenesis in a similar fashion. Different genetic 
lesions in SHANK3 were identified in probands of three ASD families, including 
two deletions and a frameshift mutation. A later study screened ~400 individuals 
with ASDs and identified rare de novo variants in SHANK3 in almost 1% of these 
cases (Moessner et al. 2007). SHANK3 is a synaptic scaffolding protein which binds 
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both neuroligins and neurexins (Meyer et al. 2004). Recently, also SHANK2 was 
implicated in ASDs and intellectual disability (ID). De novo CNVs were detected in 
the gene in two unrelated individuals with ASDs and ID, after which sequencing of 
~600 affected individuals and controls revealed additional mutations in the gene 
(Berkel et al. 2010). Interestingly, also CNTNAP2 belongs to the neurexin 
superfamily (Poliak et al. 1999). 
 
Together with the recent evidence from autism GWA studies, which identified 
common variants in two cadherin genes, another group of cell-adhesion molecules 
(Wang et al. 2009b) (see Section 2.2.6), the recent large CNV scans in ASDs have 
further strengthened the role of the aforementioned genes by identifying rare CNVs 
which overlap with NRXN1, NLGN1,  SHANK2, and SHANK3 (Szatmari et al. 2007, 
Bucan et al. 2009, Glessner et al. 2009, Pinto et al. 2010). In summary, as evidence 
of synaptic dysfunction in autism continues to accumulate, this specific group of 
genes is by far the most interesting target for future genetic research in autism, and 
has the potential to contribute significantly to our understanding of the disorder. Yet, 
many of the other candidate genes studied in ASDs remain interesting as well, and 
warrant further studies. It is possible that when the biological processes affected in 
ASDs begin to unravel, unexpected connections between many of these genes are 
discovered. 
2.2.10 Disrupted-in-Schizophrenia-1 (DISC1) 
G e n e t i c  f i n d i n g s  
DISC1 gene was originally identified in large Scottish pedigree, where a balanced 
translocation between chromosomes 1q42.1 and 11q14.3 was found to co-segregate 
with schizophrenia (SCZ) and related psychiatric conditions. The pedigree contains 
individuals with major depression, bipolar disorder (BPD), adolescent conduct 
disorder, anxiety, and minor depression (St Clair et al. 1990), suggesting that the 
translocation was not specific for SCZ but instead predisposes to an unspecific 
neuropsychiatric outcome. It was noticed that all translocation carriers, even the 
ones without a psychiatric diagnosis, had abnormal amplitudes of the P300 event-
related potential, which is used as a measure for underlying cognitive defect 
(Blackwood et al. 2001). However, the protein coding gene disrupted by the 
translocation was named Disrupted-in-Schizophrenia-1 and has been extensively 
studied as a candidate gene for schizophrenia since. However, it is now known that 
the neurobiological effects of DISC1 are very wide-ranged, and the gene has been 
linked to many aspects of neurodevelopment and neuropsychiatric phenotypes. 
 
The initial translocation finding was supported by genetic linkage observed at the 
DISC1 locus at chromosome 1q42 in Finnish schizophrenia families (Ekelund et al. 
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2001, Ekelund et al. 2004). Later, specific SNP-haplotypes within DISC1 were 
shown to be associated with SCZ and impaired visual working memory functions in 
SCZ (Hennah et al. 2003, Hennah et al. 2005). The most significant allelic 
haplotype was named "HEP3", and later studies have found association with either 
the same haplotype or SNPs in its vicinity in SCZ, BPD, schizoaffective disorder 
(Hodgkinson et al. 2004, Sachs et al. 2005, Thomson et al. 2005b, Maeda et al. 
2006, Zhang et al. 2006, for e.g. DeRosse et al. 2007, Palo et al. 2007), and major 
depression (Hashimoto et al. 2006), as well as various endophenotypes defined 
using neurocognitive (Burdick et al. 2005, Thomson et al. 2005a, Liu et al. 2006) or 
imaging measurements (Callicott et al. 2005, Cannon et al. 2005). In some of these 
studies, the observed effects have been sex-specific, with most of the association 
signal originating from affected males. The role of DISC1 in psychiatric illness has 
been extensively reviewed for example by Chubb and colleagues (2008). 
 
The DISC1 locus at 1q42 harbors two other genes as well. DISC2 (Disrupted-in-
Schizophrenia-2), located antisense to DISC1 and disrupted by the original 
translocation as well, is not known to encode a protein product. However, evidence 
exists that it might regulate DISC1 expression through its non-coding RNA product 
(Millar et al. 2000b, Blackwood et al. 2001, Millar et al. 2001). TSNAX (translin-
associated factor X) is located downstream of DISC1 and remains less well 
characterized. Four intergenic exons are located between DISC1 and TSNAX (see 
Section 4.3), and TSNAX has been observed to form fusion transcripts with DISC1 
through intergenic splicing involving these exons (Millar et al. 2000a). 
 
B i o l o g y  o f  D I S C 1  
Based on current knowledge, DISC1 is considered a "hub" protein with extensive 
protein-protein interactions and a role in several pathways (Camargo et al. 2007). 
Disruption of these "DISC1 pathways", instead of DISC1 only, has been proposed to 
mediate the risk for mental illness (Millar et al. 2003, Hennah et al. 2006), and 
association of the DISC1-interacting genes with schizophrenia and other related 
phenotypes has been observed (for e.g. Yamada et al. 2004, Burdick et al. 2008, 
Numata et al. 2009, Tomppo et al. 2009).  
 
There is an increasing number of studies attempting to model DISC1 disease biology 
and function in model organisms such as mouse, Drosophila, and zebrafish. Despite 
the obvious challenges related to phenotypic assessment of psychiatric disorders in 
other organisms, several disease-related traits and behavioural features can be 
studied, along with neuroanatomical and physiological features. Overall, numerous 
Disc1 knockout and transgenic mice have been studied to date, most of which show 
behavioural and anatomical deficits that can be linked to psychiatric disease 
(Brandon et al. 2009). For example, mice of the 129S9 SvEv strain carry a deletion 
polymorphism in Disc1 exon 6, which introduces a premature stop codon in exon 7 
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(Koike et al. 2006). These mice display deficits in working memory, as reported also 
in schizophrenia (see previous section).   
 
The information obtained from these studies, along with cellular studies suggest that 
the main functions of DISC1 relate to neurite outgrowth, neuronal migration, 
synaptogenesis, glutamatergic neurotransmission, microtubule network formation, 
and cAMP signalling (Chubb et al. 2008). Recently, DISC1 was shown to regulate 
neural progenitor proliferation by modulating canonical Wnt signalling via 
inhibition of GSKβ/β-catenin signaling (Mao et al. 2009). Most of the information 
of DISC1 function has come from the study of its binding partners (Figure 4). 
 
For example, one of these binding partners, phosphodiesterase 4B (PDE4B), was 
shown to carry a balanced translocation in a subject diagnosed with schizophrenia 
and a relative with chronic psychiatric illness (Millar et al. 2005). PDE4B and 
DISC1 were suggested to be interacting genetic factors in schizophrenia and to 
participate in the regulation of cAMP signaling. Interestingly, the same study also 
showed that DISC1 and PDE4B expression level in patient lymphoblastoid cell lines 
carrying the original DISC1 translocation t(1;11) or the PDE4B translocation 
t(1;16), respectively, was reduced with ~50%, suggesting that haploinsufficiency is 
the likely mechanism for SCZ susceptibility in these individuals.  
 
Other well-known binding-partners of DISC1 include for example FEZ1 
(Fasciculation and elongation protein ζ-1) and NDEL1 (nuclear distribution gene E 
homologue-like 1). DISC1 and FEZ1 co-localize to the growth cones of cultured 
neurons (Miyoshi et al. 2003) and reduced FEZ1 expression in rat hippocampal 
neurons was shown to result in neuronal defects affecting neuronal polarity, axon 
growth, and intracellular transport (Ikuta et al. 2007). Studies on the interaction of 
NDEL1 and DISC1 have elucidated the role of DISC1 in the microtubule / 
centrosome cascade affecting neurite outgrowth (Ozeki et al. 2003). NDEL1 
localizes to the centrosome along with other DISC1 binding proteins, and its 
knockdown has been shown to block neurite production, possibly due to deficient 
microtubule-based transport to the growing neurite tip (Kamiya et al. 2006). 
 
In mouse, DISC1 expression is highest at embryonic and postnatal stages which 
coincide with active neurogenesis and the onset of puberty (Schurov et al. 2004). It 
is expressed both in neurons and glia cells, predominantly in mitochondria with 
additional nuclear, cytoplasmic, and actin-associated locations evident (James et al. 
2004). During embryonic development, DISC1 is known to regulate neuronal 
migration and structural plasticity, and it has been shown that either the depletion of 
endogenous DISC1 or the expression of mutated DISC1 can impair neurite 
outgrowth and the proper development of the cerebral cortex in vivo  (Kamiya et al. 
2005). Thus, it seems that during cortical neurogenesis, DISC1 acts to facilitate 
neuronal maturation. However, another study demonstrated that DISC1 negatively 
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regulates neuronal maturation in the adult hippocampus (Duan et al. 2007), thereby 
suggesting a completely opposite role for DISC1 in adult neurogenesis. Yet, defects 
in early cortical development are considered more important for example in 
schizophrenia (Ross et al. 2006), since neurogenesis is much more prevalent at that 
time compared with adulthood. 
 
 
Figure 4. DISC1 interacting proteins and their functional role. A selection of DISC1 
binding and/or interacting proteins (left box) and related biological processes and 
cellular functions (right box) are displayed. Figure based on information from Chubb et 
al. (2008) and Brandon et al.(2009). 
 
It should be noted that DISC1 has multiple isoforms which vary significantly in 
length, exon composition, and in the sequence of their 3’UTR sequences. The 
Uniprot database (www.uniprot.org) currently (August 2010) recognizes four 
different DISC1 protein isoforms produced by alternative splicing. These are named 
"long" (L), "long variant" (Lv), "short" (S), and "extra short" (Es), of which L has 
been chosen as the canonical sequence. However, for example the Ensembl database 
(www.ensembl.org) currently reports 11 alternative transcripts, of which ten produce 
a protein product, and RefSeq (http://www.ncbi.nlm.nih.gov/refseq) lists 23 
alternative transcripts, including the four in Uniprot. Most of these variants lack 
multiple 3’ exons and instead have alternate 3’ segments compared with variant L. 
Further, other studies have demonstrated that the variability of DISC1 splicing is 
extremely complex, especially in the brain, where more than 50 alternative 
transcripts were recently identified (Nakata et al. 2009). Thus, it is a huge challenge 
to relate the genetic and biological information available to the different isoforms, 
which are likely to reflect the subtle tissue-specificity and regulation of DISC1-
mediated processes. 
 
In conclusion, the genetic evidence for DISC1 is consistent with the idea that 
multiple mechanisms, affected by several independent mutations, link pathways 
involving DISC1 and its binding partners to clinical neuropsychiatric phenotypes. It 
has been suggested that such mutations can either i) cause reduced expression of all 
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DISC1 isoforms, ii) alter the spectrum of isoforms present, iii) alter the stability of 
DISC1, or iv) alter the ability of DISC1 to bind its interactors (Mackie et al. 2007). 
Current knowledge implies that aberrations in DISC1 function underlie a wide range 
of phenotypes, from severe psychiatric disorders such as schizophrenia to milder 
neuropsychiatric manifestations, such as Asperger syndrome. It remains to be seen 
whether also other members of the DISC1 pathway are involved in these 
phenotypes, and whether the wide-range molecular effects of DISC1 turn out to be 
true also for other genes implicated in psychiatric illnesses. 
 
 
 
3 Aims of the Study 
 
THL – Research 46|2010 59 Genetic Mechanisms Underlying 
Autism Spectrum Disorders 
3 AIMS OF THE STUDY 
In this study we have taken two different approaches to study the genetic basis of 
autism spectrum disorders. The first is a candidate gene approach, in which we have 
focused on a single gene, DISC1 (Disrupted-in-schizophrenia-1), and performed 
targeted experiments to address a highly specific question. The second is a 
hypothesis-generating genome-wide approach, in which we have used different 
levels of genomic data to gain information of the genetic basis of autism spectrum 
disorders in a group of genealogically connected individuals from a population sub-
isolate, and started to explore the underlying biological processes in these 
individuals. 
 
More specifically we have aimed to: 
 
I. Study whether genetic polymorphisms in DISC1 predispose to autism 
spectrum disorders (Study I) 
 
II. Investigate in vitro whether genetic polymorphisms in DISC1 affect the 
regulation of its expression by specific micro-RNAs in an allele-specific 
manner (Study I, unpublished data) 
 
III. Comprehensively characterize the genetic architecture of autism spectrum 
disorders in genealogically connected individuals from Central Finland in 
order to identify the predisposing genetic variants, shared haplotypes, and 
biological pathways (Studies II and III). 
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4 MATERIALS AND METHODS 
All of the methods used in this study are described in detail in the original 
publications. An overview of the methods is given below, with an emphasis on the 
methods used with the unpublished data. 
4.1 Study sample 
The Finnish families used in this study were recruited by the National Institute for 
Health and Welfare (previously called the National Public Health Institute) in 
Helsinki through university and central hospitals in collaboration with the University 
of Helsinki. All autism spectrum disorder diagnoses were assessed according to 
detailed structured interviews based on the diagnostic criteria in the International 
Classification of Diseases, 10th Revision (ICD-10) (World Health Organization 
1993) and the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV) (American Psychiatric Association 1994). Supplementing diagnostic 
information was collected with instruments such as the Childhood Autism Rating 
Scale (CARS), Asperger Syndrome Screening Questionnaire (ASSQ) (Gillberg and 
Gillberg 1989, Ehlers and Gillberg 1993, Ehlers et al. 1999), Asperger Syndrome 
Diagnostic Interview (ASDI) (Gillberg et al. 2001) and criteria proposed by Gillberg 
and co-workers (Gillberg and Gillberg 1989, Ehlers and Gillberg 1993). All of the 
study subjects underwent throrough medical and clinical examinations, including 
neurological examinations and psychological and neuropsychological evaluations. 
Diagnoses were ascertained by multidisciplinary teams with extensive experience 
and common training, using the same set of diagnostic instruments. The autism 
diagnoses have later been validated using the Autism Diagnostic Interview - Revised 
(ADI-R) questionnaire (Lord et al. 1994), the gold standard of the field, which 
resulted in 96% consistency with the original diagnoses (Lampi et al. 2010). This 
study has been approved by relevant ethical committees, and informed written 
consent was received from all of the participating families. The different study 
samples are presented below, and exact numbers of families, individual cases, and 
controls analyzed in Studies I-III are listed in Table 5. 
4.1.1 Autism families 
The autism study sample consists of 97 Finnish families with altogether 138 affected 
individuals (105 males, 33 females) diagnosed with childhood autism (AD; autistic 
disorder), Asperger syndrome (AS) or pervasive developmental disorder not 
otherwise specified (PDD-NOS). Only families with at least one child with autism 
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are included. Families with associated medical conditions such as Fragile X 
syndrome or profound intellectual disability were excluded. Individuals with AS and 
PDD-NOS were included in this study sample because approximately one-third of 
the probands with autism had a first-degree relative with these conditions. The 
affected individuals are divided into three liability classes based on their diagnosis. 
Individuals with strictly defined autism comprise the first liability class (LC1), 
whilst LC2 includes also individuals with AS, and LC3 all affected individuals 
(autism, AS, PDD-NOS). 
4.1.2 Asperger syndrome families 
The Asperger syndrome (AS) study sample consists of 29 large Finnish pedigrees 
with only individuals with AS in multiple subsequent generations. The sample does 
not overlap with the autism study sample. The total number of affected individuals is 
143 (85 males, 58 females) of which 119 completely fulfill the ICD-10 criteria for 
AS and comprise the liability class 1 (LC1). Additional 24 have AS-like features but 
do not completely meet all of the diagnostic criteria (LC2). Only individuals with 
normal cognitive development before the age of three were included. 
4.1.3 Extended ASD pedigrees originating from Central Finland 
A central part of this thesis is formed by the analysis of a large, extended ASD 
pedigree from Central Finland (CF). This pedigree (subsequently referred to as 
Pedigree 1) consists of 18 Finnish families (20 nuclear families), which have been 
genealogically traced back to the 17th century and found to originate from common 
ancestors (Figure 5). Altogether, the pedigree has 34 affected individuals (25 males, 
9 females), of which 17 are diagnosed with autism (including a monozygotic twin 
pair, of which only one used in analyses), 14 with AS, and three with PDD-NOS. Of 
the families in the pedigree, 14 are included in the autism sample, one in both autism 
and AS sample, and three in neither. The pedigree was first described by Auranen 
and colleagues (2003) after which six new families have been added and more 
detailed genealogical links established, as presented in Study II. 
 
In Study III, we also analyzed a second, smaller extended autism pedigree 
originating from the same CF region (Pedigree 2) (Figure 6). This pedigree consists 
of eight families with 11 affected individuals (seven males, four females), of which 
nine are diagnosed with autism, one with AS, and one with PDD-NOS. The affected 
individuals from Pedigree 1 and 2 were combined to form the CF-GWAS case-
control dataset, which, in addition to the 27 cases from the two pedigrees (one 
affected individual per nuclear family), contained 24 individuals with at least two 
4 Materials and Methods 
THL – Research 46|2010 62 Genetic Mechanisms Underlying 
Autism Spectrum Disorders 
grandparents born in the same Central Finland region, but with no genealogical links 
to the pedigrees.  
 
All genealogical studies were carried out using local church and civil registers (for 
information post year 1850) and the Finnish National Archives for the earlier 
periods, in accordance with published criteria (Varilo 1999). 
 
 
 
 
Figure 5. Pedigree 1 originating from Central Finland. The core pedigree and links to 
the common ancestors are marked in blue. Abbreviations: PDD-NOS=pervasive 
developmental disorder not otherwise specified. 
 
 
Figure 6. Pedigree 2 originating from Central Finland. The schizophrenia family was 
not used in this study. Abbreviations: Fam=family, SCZ=schizophrenia, PDD-
NOS=pervasive developmental disorder not otherwise specified. 
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4.1.4 Control samples 
In Studies I and II, all analyses involving Pedigree 1 were performed using 
independent regional controls (n=93) in order to properly control for the diversity of 
background alleles in different regional study samples. The controls were collected 
from the same geographical area where the families in the extended pedigree 
originate. In Study I, randomly selected trios representative of the Finnish 
population (n=60) were additionally used as population controls to enable allele-
frequency comparisons with the other DISC1 association studies performed in 
Finnish study samples. 
 
In Study III, controls samples for the CF-GWAS dataset (n=181) were matched 
from a large available pool of Finnish controls with GWAS data available using 
complete linkage agglomerative clustering based on pairwise identity-by-state (IBS) 
distance. In Study III, we additionally used three publicly available datasets as 
controls in the pathway analysis. The autism GWAS dataset consists of 1001 
families with 1529 individuals with autism from the US population (Wang et al. 
2009b), and was obtained from the Autism Genetic Resource Exchange (AGRE; 
http://www.agre.org) (Geschwind et al. 2001). The autism gene expression dataset 
(Hu et al. 2009b) was obtained from the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/, dataset ID: GSE15402). It consists of 87 males 
with idiopathic autism and 29 non-autistic, roughly age-matched controls, also from 
the AGRE. In order to reduce genetic heterogeneity and to increase comparability 
between the publicly available autism datasets, we re-analyzed the AGRE-GWAS 
dataset after excluding all siblings with milder ASD phenotypes. The third dataset is 
a Crohn’s disease (CD) GWAS dataset from the Wellcome Trust Case Control 
Consortium (WTCCC) (2007), consisting of 1748 cases and 2938 controls. The two 
autism datasets are amongst the largest autism studies published to date, whilst the 
Crohn’s disease dataset represents a phenotype with a relatively well established 
biology for which certain pathways can be expected to be found. 
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Table 5. Description of samples analyzed in each study. The total number of individuals denotes the number of individuals, for 
which a DNA sample was available in each study. 
 
Study sample Families Individuals Affected individuals Study 
Total Males Females LC1 LC2 LC3 
Autism families 97 356 138 105 33 118 8 12 I, II 
AS families 29 210 143 85 58 119 24 x I, II 
Autism+AS families combined 126 566 218 190 91 237 32 12 I 
CF Pedigree 1 18(20) 34 33* 24 9 16(17) 14 3 I, II, III 
CF Pedigree 2 8 11 11 8 3 9 1 1 III 
CF-GWAS (includes Pedigrees 1 and 2) x 51 51 39 12 45 4 2 III 
CF regional controls 1 x 93 x NA NA x x x I, II 
CF regional controls 2a x 181 x 115 66 x x x III 
CF-EXPR cases x 10 10 10 x 9 x 1 III 
CF-EXPR controls x 10 x 10 x x x x III 
Finnish control trios 60 180 x 106 74 x x x I 
AGRE-GWASb 1001 2460 1500 1203 297 1500 x x III 
AGRE-EXPR cases x 87 87 87 x 87 x x III 
AGRE-EXPR controls x 29 x 29 x x x x III 
CD-GWAS x 1748 1748 682 1066 NA NA NA III 
CD-GWAS controls x 2938 2938 1440 1458 x x x III 
ABBREVIATIONS: AS=Asperger syndrome, CF=Central Finland, EXPR=global gene expression study, GWAS=genome-wide association 
study, LC=liability class, CD=Crohn’s disease, AGRE=Autism Genetic Resource Exchange, NA=not applicable 
a Dataset overlaps partially with CF regional controls 1. 
b Dataset pruned to include only families with at least one LC1 autism case. Additional siblings with LC2 or LC3 phenotype were also excluded. 
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4.2 Genotyping 
Genomic DNA was extracted from EDTA-treated peripheral blood samples using 
the Puregene DNA purification system (Qiagen) according to manufacturer’s 
instructions, or by using a phenol-chloroform protocol modified from the original 
protocol by Vandenplas and colleagues (1984). Most of the DNA samples were 
extracted and processed by the DNA Extraction Unit of the National Institute for 
Health and Welfare (Helsinki). 
 
Genotyping of single-nucleotide polymorphisms (SNPs) in Studies I and II (n=11 
and n=152, respectively) was primarily done using the homogenous MassEXTEND 
(hME) and iPLEX technologies of the Sequenom MassARRAY platform 
(Sequenom Inc.), as specified by manufacturer’s instructions. In Study II, some of 
the SNPs were additionally genotyped using fluorogenic 5‘ nuclease allelic 
discrimination chemistry (TaqMan) with the ABI Prism 7900 Sequence Detection 
System (Applied Biosystems). 
 
Genotyping of the microsatellite markers in Study I (n=2) was done using the ABI 
3730 DNA sequencer (Applied Biosystems). In Study II, microsatellites of the initial 
genome-wide scan (n=1109) were genotyped by deCODE Genetics Inc. (Reykjavik, 
Iceland), whereas the follow-up microsatellites (n=44) were genotyped as in Study I. 
The average intermarker distance in the genome-wide scan of Study II was 3.43 cM. 
 
In Studies I and II, all genotypes were checked for correct Mendelian transmission 
using PEDCHECK v.1.1 software (O'Connell and Weeks 1998) and monitored for 
Hardy-Weinberg equilibrium (HWE) and duplicate sample accuracy. All markers 
accepted for analysis displayed a minimum genotyping success rate of 90%, with the 
majority of markers having a success rate of over 95%. The borderline for the minor 
allele frequency (MAF) of SNP markers was 5%, with most of the SNPs having a 
MAF over 10%. 
 
In Study III, the genome-wide SNP data for the CF-GWAS study sample was 
produced at the Broad Institute (Boston, USA) using the Illumina HumanHap 300 
Beadchip, which includes over 317 000 tag SNPs derived from the Phase I of the 
International HapMap project (2005). The regional controls were genotyped with the 
Illumina HumanHap 370 and 550 Beadchips at the Broad Institute and at the 
Wellcome Trust Sanger Institute (Cambridge, UK), which include over 317 000 and 
550 000 tag SNPs from HapMap Phase I+II, respectively. The publicly available 
AGRE-GWAS dataset has been genotyped with Illumina HumanHap 550 Beadchip, 
and the CD-GWAS with Affymetrix GeneChip 500K arrays, both of which include 
over half a million of SNPs. 
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All quality checks of the genome-wide SNP data were performed using PLINK 
software (Purcell et al. 2007). Genotypes were checked for correct Mendelian 
transmission when family information was available. To exclude sample swaps and 
contamination, gender checks were performed, and the samples monitored for 
identical-by-descent (IBD) sharing and mean heterozygosity. For GWA analysis, we 
only used SNPs genotyped in both case and control datasets. The following basic 
quality control criteria were applied: genotyping calling rate per SNP and per sample 
> 90%, MAF > 5%, HWE > 0.0001. 
4.3 Study of DISC1 as a candidate gene for ASDs (Study I and 
unpublished data) 
In Study I, we carried out a targeted replication of a previous DISC1 association 
study performed in Finnish families ascertained for schizophrenia (Hennah et al. 
2003) to investigate the role of DISC1 in ASDs. We analyzed the previously 
reported markers and haplotypes both separately and jointly in 97 Finnish autism 
families and 29 AS families, as well as in Pedigree 1 originating from Central 
Finland. Further, the observed association (see Section 5.1.1) led us to search for 
explanations to the wide-ranging neurobiological effects observed with DISC1. 
Consequently, we identified polymorphic miRNA target sites in the gene and 
decided to study them further with the hypothesis that altered miRNA regulation of 
DISC1 would provide a plausible explanation for the wide-range of disease 
associations and neurobiological effects observed with the gene. 
4.3.1 Association and haplotype analysis 
We analyzed altogether 11 SNPs and two microsatellite markers spanning a ~600 kb 
region on chromosome 1q42 with DISC1, DISC2, and TSNAX genes (see Section 
5.1). Since the aim of this study was to replicate previous findings for DISC1 rather 
than fully analyze the genetic variation in the gene, markers were chosen based on 
previous DISC1 studies in schizophrenia and bipolar disorder. The two 
microsatellite markers were chosen according to previous linkage studies in the 
Finnish population (Ekelund et al. 2001, Ekelund et al. 2004) and the SNPs 
according to the original Finnish DISC1 association study (Hennah et al. 2003) and 
a later study by Thomson and colleagues (2005b). 
 
All analyses were performed separately for the autism and AS study samples, as 
well as CF Pedigree 1. In addition, autism and AS families were analyzed jointly as 
a broad ASD phenotype (Table 5). Due to previous evidence of sex-dependent 
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effects with DISC1 and the overall higher prevalence of ASDs in males, we 
performed statistical analyses also with affected males only (autism sample n=105, 
AS sample n=85), using the genotypes of females only for phase determination. In 
all statistical analyses of this thesis, the ASD phenotype was analyzed as a binary 
trait, that is, all individuals were treated either as affected or unknown, which is 
common practice especially in most complex disease studies where it is often 
challenging to assign individuals as healthy. 
 
Both single marker and haplotype association analyses were performed using FBAT 
1.5.5 (Horvath et al. 2001) and TRANSMIT 2.5.4 (Clayton 1999) software. Both are 
family-based transmission disequilibrium tests (TDT) for alleles and haplotypes, and 
are able to test for transmission even with incomplete parental genotype data and 
unknown phase. In all analyses, we accounted for possible effects of linkage on the 
results by using the empirical variance option of FBAT and performing 100 000 
bootstrap replicates in TRANSMIT.  
 
Haplotype analysis was restricted to four specific haplotypes (named "HEP1-4") 
associated with SCZ in Finnish families (Hennah et al. 2003) in order to reduce the 
multiple testing burden. We tested the exact same haplotypes as in the original 
study, except in the case of HEP2 where rs1630250 and rs1655285 were used as 
surrogates for the haplotype information provided by the original haplotype 
consisting of rs1615344, rs1615409 and rs766288 (see Section 5.1). 
 
Pseudomarker vs. 0.9.7 beta program (Göring and Terwilliger 2000) was used as the 
sole method of analysis with Pedigree 1, due to its capability to handle complex 
pedigree structures. Since Pedigree 1 has only a small number of informative 
transmissions available, FBAT and TRANSMIT were not applicable. With 
Pseudomarker, single marker association and linkage in different kinds of pedigree 
structures can be analyzed both separately and jointly. It is also capable of 
incorporating data from independent controls to a family-based analysis to improve 
the estimation of allele frequencies, thus enabling us to use the regional controls in 
the same analysis with Pedigree 1. Haplotype association analysis was not 
performed in Pedigree 1. Pseudomarker was also used to monitor for two-point 
linkage in all study samples. 
4.3.2 Polymorphic miRNA target site prediction 
We used two available databases to search for polymorphic miRNA target sites in 
DISC1, Patrocles (http://www.patrocles.org) (Hiard et al. 2010) and PolymiRTS 
(http://compbio.utmem.edu/miRSNP/home.php) (Bao et al. 2007). Since the aim 
was to look specifically for polymorphic miRNA target sites, we did not address the 
multitude of non-polymorphic miRNA target sites predicted for DISC1. 
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To predict the target sites, PolymiRTS uses same criteria as TargetScan, one of the 
most commonly used miRNA target prediction algorithms (Lewis et al. 2005, 
Grimson et al. 2007, Friedman et al. 2009).  Perfect Watson-Crick base-pair match 
is required for the target seed nucleotides 2-7. Additionally, either a perfect match 
for seed nucleotide 8 or an "anchor" adenosine immediately downstream of the 2-7 
seed in the target is required. PolymiRTS looks only for SNPs located in the 3’UTR 
regions of genes and requires the predicted target site to be present in at least two 
other vertebrate genomes. It is also capable of categorizing the identified target sites 
based on "wobble" pairing, which refers to situations where A/G alleles in the target 
mRNA are able to form G:U wobble base pairs with the miRNA, leading to a 
possibly less deleterious effect. 
 
Patrocles also restricts its search to SNPs in the 3’UTR, and requires the target site 
to be present in at least one other primate genome. It uses two separate sets of target 
motifs. The so called "X-motifs" are a group of 540 octamers identified on the basis 
of unusually high motif conservation scores in the 3’UTR (Xie et al. 2005). "L-
motifs" meet the TargetScan criteria, as described above. 
 
In the beginning of this study, only the four most well-known isoforms of DISC1 
were properly annotated and known (see Section 2.2.10). Therefore, all the 
polymorphic target predictions take into account only these transcripts (L, Lv, S, 
Es). For the purpose of this study, we limited our search only to the two longest 
isoforms, L and Lv. 
4.3.3 DISC1 expression constructs 
In order to functionally validate the identified polymorphic miRNA target sites, we 
created expression constructs of DISC1. A full length EST clone of DISC1 Lv (long 
variant isoform) including full 3’UTR and 5’UTR sequences was obtained from the 
IMAGE consortium (Lennon et al. 1996) (clone ID: IMAGE:9007180). An 
overexpression construct was created by cloning the full length gene (6856 bp) into 
a pcDNA3.1(+)/Hygro vector (Invitrogen) by creating suitable artificial restriction 
enzyme (RE) sites using short oligoduplexes harbouring the desired site (Figure 7, 
Table 6). The presence and correct orientation of the insert was verified by 
restriction analysis and direct sequencing. Expression constructs harbouring the 
alternative SNP alleles were created using the QuikChange Lightning Site-Directed 
Mutagenesis Kit according to manufacturer’s instructions (Stratagene). Mutagenic 
primers were designed using QuikChange Primer Design Program 
(http://www.stratagene.com/ qcprimerdesign) and are provided in Table 7. 
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Table 6. Properties of the synthetic oligoduplex used in DISC1 Lv cloning. The core structure denotes the restriction enzyme 
sites that were introduced into the plasmid. 
 
Core structure Sequence Length 
(bp) 
Tm Overhang 
5’-NheI-X-SalI-X-BssH II-X-KpnI-3’ 5'-CTAGCAGTCGACATTAGCGCGCAGGTAC-3' 28 66°C NheI, KpnI 
3’-X-SalI-X-BssH II-X-5’ 3'-GTCAGCTGTAATCGCGCGTC-5' 20 61°C none 
ABBREVIATIONS: Tm=melting temperature, bp=base pair 
 
Table 7. Mutagenic primers used in site-directed mutagenesis. Primers designed with QuikChange Primer Design Program 
(Stratagene). 
 
#rs wt 
allele 
Mutant 
allele 
Primer sequence (5’ to 3’) Length 
(bp) 
Tm 
rs11122396 A G gtcatgttttaaccacaagccgtaactcatctgttgtctttgc 
gcaaagacaacagatgagttacggcttgtggttaaaacatgac 
43 
43 
79.7°C 
79.7°C 
rs980989 G T ttgccatgctaagccctttacattcatatcctataatccc 
gggattataggatatgaatgtaaagggcttagcatggcaa 
40 
40 
78.5°C 
78.5°C 
rs9308481 G A tctaaggcacagagctggtaaaatatgaagtaatagtgaacc 
ggttcactattacttcatattttaccagctctgtgccttaga 
42 
42 
78.7°C 
78.7°C 
rs11803088 C T atgccttcttgtatatgtaattcaatacttttatttttaatatcctcaccttatctaat 
attagataaggtgaggatattaaaaataaaagtattgaattacatatacaagaaggcat 
59 
59 
78.1°C 
78.1°C 
ABBREVIATIONS: wt=wild type, bp=base pair, Tm=melting temperature 
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Figure 7. DISC1 Lv overexpression construct. The cloning sites for the synthetic 
oligoduplex and the DISC1 Lv insert are shown. Vector map provided by Invitrogen. 
4.3.4 Cell culture and transfections 
In order to study, whether the miRNAs predicted by Patrocles and PolymiRTS 
would have an allele-specific effect on DISC1 expression in HEK293FT cells, we 
designed a set of different transfection experiments. The overall experimental setup 
is summarized in Figure 8. 
 
The experiment was divided into three parts. First, we measured effects of the 
selected miRNAs on endogenous DISC1 expression in 293FT cells. Second, we 
measured the effects of the same miRNAs in 293FT cells transiently overexpressing 
the wild type DISC1 Lv construct. Thirdly, we repeated the overexpression 
experiment using constructs with the alternative SNP alleles with the best miRNAs 
from the first two rounds. We used Pre-miR miRNA precursor molecules (Ambion) 
to mimic and enhance the effect of the endogenous miRNA. In addition to the 
miRNAs tested, each transfection experiment contained untransfected cells, one or 
two siRNAs against DISC1 (Sigma MISSION® siRNA), and a Pre-miR precursor 
negative control miRNA (Ambion) to monitor for unspecific technical artefacts. The 
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negative control miRNA was used as the baseline for monitoring miRNA-induced 
changes in expression. Each transfection experiment contained three to four 
biological replicates, of which three with the most consistent RNA yield were 
selected for qPCR. Each experiment was independently replicated three times. 
 
293FT cells (Invitrogen) were cultured in Dulbecco’s Modified Eagle Medium (D-
MEM) (Gibco) with L-glutamine, 4500 mg/L D-Glucose, and 110 mg/L sodium 
pyruvate. The medium was supplied with 10% FBS, 1% penicillin, and 1% 
streptomycin, and cultured in +37°C and 5% CO2.  
 
Transfections were performed in 96-well format using 6000 cells per well, miRNA 
and siRNA concentration of 30 nM per reaction, and in co-transfections 100ng of 
plasmid DNA per reaction, as recommended by the manufacturer. We performed 
transfections using the siPORT NeoFX reverse transfection protocol (Ambion). In 
this protocol, the transfection complexes are pipetted to the plate and overlaid with 
the desired number of cells in a fixed volume. Briefly, cells were counted and 
diluted suitably to seed 6000 cells per well in 80 µl volume. The transfection 
reagent, Pre-miR miRNA precursor molecules, siRNA molecules, and plasmid DNA 
(in the overexpression experiments) were diluted in plain D-MEM, and the 
transfection complexes prepared according to manufacturer’s instructions. 
Transfection complexes (20 µl) were dispensed to the 96-well plates and overlaid 
with the cell suspension (80 µl). Cells were assayed after 48 h. 
Figure 8. Overview of the experimental setup. 
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4.3.5 RNA extraction and quantitative PCR 
Total RNA from transfected cells was extracted using TRI Reagent (Molecular 
Research Center, Inc.). Cells were lysed with 120 µl of TRI Reagent and total RNA 
extracted according to manufacturer’s instructions. We supplemented the protocol 
with manual Phase Lock Gel tubes (5Prime) to facilitate the separation of the 
organic and aqueous phases during extraction. RNA was treated with DNaseI 
enzyme (Fermentas) to remove any residual genomic DNA, and converted to cDNA 
using High Capacity RNA-to-cDNA Master Mix (Applied Biosystems) according to 
manufacturers’ instructions. Quantitative Real-Time PCR was performed with 
7900HT instrument using SYBR Green PCR Master Mix (Applied Biosystems) and 
the absolute quantification method. A five-point standard curve for each primer pair 
was included in each run, and absolute expression values for each sample were 
extracted based on the standard curves. Human GAPDH gene was used as the 
reference gene. DISC1 expression was monitored with one pair of primers, picked 
from a test of eight primer pairs, designed to the boundary of exons 7 and 8 of 
DISC1 with Primer Express 2.0 (Applied Biosystems) to avoid signal from residual 
genomic DNA (primer sequences provided in Table 8). Since exons 7 and 8 are only 
present in the longer DISC1 isoforms (L and Lv), the qPCR signal should capture 
only the expression of these isoforms. Raw qPCR data was analyzed using the SDS 
2.3 software (Applied Biosystems). 
 
More specifically, qPCR was performed in 10 µl reaction volume in 384-well 
format. Each reaction contained a total of 10 ng of cDNA template, 5 µl of SYBR-
mix, and 0.7 pmol of each primer. The standard curve samples had a known amount 
of 0.2, 2, 10, 20, and 50 ng per reaction. Each qPCR experiment (done on 384-well 
plates) contained samples from one transfection experiment in three technical 
replicates. Since each transfection experiment contained three biological replicates, 
and was additionally repeated three times, we had in total nine replicates of each 
test. 
Table 8. Quantitative PCR primers sequences for human DISC1 and GAPDH. 
Primer Sequence Length 
(bp) 
Tm GC 
GAPDH p1 AACAGCGACACCCATCCTC 19 60 58 
GAPDH p2 CATACCAGGAAATGAGCTTGACAA 24 62 46 
DISC1 p1 AAAATCCCTCAACTTGTCACTTAAAGAA 28 60 32 
DISC1 p2 CTCAGGGTGCTGCAGAATTTC 21 59 52 
ABBREVIATIONS: Tm=melting temperature, GC=GC content of the sequence, bp=base pair, 
p1=forward primer, p2=reverse primer 
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4.3.6 Statistical analysis of qPCR data 
Careful quality control was carried out to the qPCR data in order to ensure high data 
quality and avoid sources of bias. For each sample, we required the Ct values of all 
three technical replicates to fall within one Ct value. PCR efficiency was estimated 
from the slope of the standard curve, and the correlation coefficient of the curve 
monitored for overall standard quality. A melting curve analysis was performed at 
the end of each reaction to verify specific PCR amplification. Relative expression 
values of DISC1 for all samples and replicates independently were obtained by 
dividing the absolute expression value of DISC1 with that of GAPDH. A mean 
relative quantity was calculated to represent each biological replicate from the three 
technical replicate values. This value was then used in the subsequent statistical 
analyses. 
 
The statistical significance of the effects of the miRNAs (and siRNAs) was assessed 
using a linear regression model with DISC1 expression level as the dependent 
(linear) variable. Linear regression was calculated between the mean relative 
quantity of DISC1 and the outcome, separately for each miRNA or siRNA and the 
negative control (altogether nine measurements from three different experiments). 
The negative control miRNA was used as the baseline in all comparisons. To correct 
for possible plate effects we included different qPCR runs as covariates in the 
model. Given the initial small number of cells in each well, we wanted to be sure 
that random differences in RNA extraction efficiency or RNA yield were not 
influencing the expression values. Thus, we also included the original RNA 
concentration of samples as a covariate in the model. However, the RNA 
concentration did not have an impact on the results (data not shown) so it was 
eventually removed from the model. All statistical analyses were performed using 
functions in the R Stats packages in R-2.10.0 (http://www.r-project.org) 
4.4 Genetic analyses in the Central Finland extended pedigrees 
(Studies II and III) 
In Studies II and III we analyzed different types of genetic data from the two CF 
extended pedigrees and some additional individuals from the same region (CF-
GWAS study sample). We analyzed Pedigree 1 for linkage and linkage 
disequilibrium using microsatellite markers and finemapped the most significant 
regions of linkage with SNP markers. The findings from Study II were followed up 
in Study III with a denser set of genome-wide SNP markers and additional gene 
expression and pathway analyses. 
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4.4.1 Genome-wide linkage and LD analyses in Pedigree 1 (II) 
In the initial genome-wide scan, we analyzed altogether 1109 microsatellite markers 
using the decode Genetic Map (Kong et al. 2002). The fundamental hypothesis of 
the study was that the observed genealogical links in Pedigree 1 reflect identical-by-
decent (IBD) sharing of the same ancestral susceptibility variant(s). Therefore, we 
wanted to maximally extract information of allele sharing both within and across the 
families in our analysis. Our primary approach was the joint analysis of LD and 
Linkage of single markers genome-wide implemented in the Pseudomarker vs 0.9.7 
beta analysis program (Göring and Terwilliger 2000). Both dominant and recessive 
Pseudomarker analyses were conducted, although the structure of the pedigree and 
the obtained results support inheritance in a recessive-like fashion. The "dominant 
Pseudomarker analysis" is analogous to affected relative pair methods in large 
families, and it weights the sharing between parents affected with ASDs and their 
affected children more strongly than that between unaffected parents and affected 
children. In the "recessive Pseudomarker analysis" contributions of both parents are 
weighted equally. Genotypes from 22 regionally matched controls were included in 
the analyses to improve power in LD analyses as well as to better estimate allele 
frequencies in the linkage analysis. 
 
To monitor for allele sharing within families, we additionally analyzed multipoint 
linkage in the pedigree using the non-parametric multipoint linkage (NPL) analysis 
of Simwalk2 v.2.91 software (Sobel and Lange 1996), which is especially suitable 
for complex pedigrees. Simwalk2 produces five NPL statistics, of which we chose to 
focus on two that have been shown to be best suitable for the analysis of dominant 
and recessive traits (Lange and Lange 2004). These are the "BLOCKS" and "MAX-
TREE" statistics, which are referred to as "NPL_recessive" and "NPL_dominant" in 
this study, respectively. 
 
Pedigree 1 includes one nuclear family which has altogether 13 individuals affected 
with an ASD (one MZ twin pair with autism and 11 individuals with AS). To avoid 
the dominance of this single family in the analyses, we ran all analyses with and 
without the 11 AS cases (designated as Set 2 and Set 1 analyses, respectively). One 
of the monozygotic twins was included in both sets. This strategy was employed 
throughout Study II. 
4.4.2 Follow-up and candidate gene analysis in Pedigree 1 (II) 
Based on the initial genome-wide scan with Pseudomarker and Simwalk2, we chose 
ten most significant loci for follow-up. We increased the density of markers at these 
loci by genotyping 44 additional microsatellites. Based on the follow-up results and 
previous evidence for involvement in ASDs for two of the loci, we chose three for 
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fine-mapping (1q23, 15q12, and 19p13). Regional candidate genes were chosen 
from these loci based on biological relevance to autism (see Section 5.2.2), and 
analyzed with SNP markers using Pseudomarker. The SNPs were chosen using the 
Tagger algorithm in Haploview program (http://www.broadinstitute.org/haploview) 
to maximize the capture of common variation in the investigated genes (Barrett et al. 
2005, de Bakker et al. 2005). As in the initial scan, we included genotype data from 
regional controls in the analysis, and increased the number of controls to 93, in order 
to further increase the accuracy of allele frequency estimation in the analysis. Due to 
prior evidence in autism, two of these loci, 1q23 and 15q12, were analyzed also in 
the nationwide autism and AS study samples, in addition to Pedigree 1 to assess 
their possible significance outside the isolate. 
4.4.3 Genome-wide SNP analyses (III) 
After the microsatellite-based genome-wide study of Pedigree 1 was published 
(Kilpinen et al. 2009), a number of studies have shown that genetic heterogeneity in 
autism is substantial, and that rare, family specific variants and mutations are likely 
to explain the majority of autism cases (see Section 2.2.9). Thus, we wanted to make 
an effort to thoroughly dissect the genetic architecture of ASDs in Pedigree 1. We 
therefore increased the marker density by using genome-wide SNP data, and 
extended our original study sample of 18 families (Pedigree 1) with 33 additional 
families (including Pedigree 2) from the same CF subisolate (CF-GWAS) to follow 
up the original scan. 
 
The two extended pedigrees were analyzed for shared regions of homozygosity 
(ROHs) to monitor for possible recessive susceptibility variants. ROHs exceeding 
100 kb were identified and assessed for overlap among individuals. A minimum 
overlap of 50 kb was used as a cutoff and only ROHs shared between more than half 
of the affected individuals in each pedigree and homozygous for the same haplotype 
were included. Liberal cutoffs for both segment length and frequency were used so 
that no regions of interest would be missed.  
 
To identify shared, enriched risk variants inherited in a dominant-like fashion, 
shared segment analysis was performed as described previously (Purcell et al. 
2007). Since we assumed inheritance from a common ancestor, we required IBD 
sharing among more than half of the cases in each pedigree, and that the same alleles 
would be shared between all pairs of affected individuals in the region. Only non-
correlated SNPs in linkage equilibrium were used (approximately 56000 SNPs), as 
regions with high LD result in false positive calls of IBD sharing. We primarily 
looked for extended segments shared IBD between pairs of individuals exceeding 
1000 kb. To evaluate whether the obtained results were specific to the pedigrees, we 
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assessed all regions of interest from the homozygosity and shared segment analyses 
also in the 181 regionally matched controls. 
 
Traditional genome-wide association analysis (allelic chi-square test with one 
degree of freedom) was performed with tools implemented in PLINK (Purcell et al. 
2007). Since a case-control association study requires the analyzed cases and 
controls to be independent, i.e. not related, we only included one affected individual 
per nuclear family into the GWAS. Since the included cases nevertheless were 
distantly related, we performed IBD analyses to evaluate the degree of their 
relatedness. Since the cases were no more related to each other than to the controls, 
no corrections for relatedness were applied in the analysis. Aware of the insufficient 
statistical power of the dataset, GWAS was initially performed for the purpose of 
pathway analysis. 
4.4.4 Analysis of differential gene expression in ASD cases and controls 
(III) 
Genome-wide gene expression profiles in Study III were obtained from ten 
individuals with ASDs (nine with autism, one PDD-NOS) and ten controls matched 
for age (5-17 years) and sex (CF-EXPR). Profiles were produced from mononuclear 
lymphocytes isolated from peripheral blood samples using BD Vacutainer CTP cell 
collection tubes (BD). Total RNA was extracted using TRIzol (Invitrogen), purified 
with RNeasy Mini Kit (Qiagen), and hybridized to human Affymetrix U133 Plus 2.0 
arrays (Affymetrix) according to manufacturer’s instructions. RNA concentration 
was measured with a ND-1000 spectrophotometer (ThermoScientific) and the 
sample quality analyzed using the RNA Nano assay of the 2100 Bioanalyzer 
platform (Agilent Technologies) prior to cDNA synthesis. Two micrograms of total 
RNA was treated according to the eukaryotic RNA labeling protocol (Affymetrix). 
15 micrograms of biotin labeled cRNA was fragmented according to the Affymetrix 
eukaryotic sample protocol. Hybridization, staining and washing of the chips was 
performed under standard conditions. The arrays were scanned with GeneChip 
Scanner 3000 7G (Affymetrix) at the Biomedicum Genomics core facility (Helsinki, 
Finland). 
 
All gene expression data analysis and handling was performed using Bioconductor 
2.3 (http://www.bioconductor.org) (Gentleman et al. 2004) implemented in R 2.8.0 
software (http://www.r-project.org). Sequence-based re-annotation of the 
Affymetrix probes was performed according to the latest release of the Entrez gene 
database (build 36.3) (Dai et al. 2005). Re-annotation was performed, because it is 
widely known that the original selection of probes by Affymetrix relied on early, 
incomplete genome and transcriptome annotation. Thus, a probeset that is supposed 
to measure the expression level of a single gene might contain a significant 
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proportion of individual probes which map to multiple, or completely wrong 
transcripts, biasing the overall signal (Zhang et al. 2005). The original Affymetrix 
U133Plus2.0 chip set contains 54120 probe sets, whereas after re-annotation they 
were grouped in 17788 probesets, representing 17726 unique Entrez gene identifiers 
and 62 quality control probesets. The re-annotation packages for Bioconductor were 
obtained from the NuGO R-server (http://nugo-r.bioinformatics.nl/NuGO_R.html) 
and Brainarray server (http://brainarray.mbni.med.umich.edu/Brainarray/ 
default.asp). Package versions 11.0.2 (database) and 11.0.1 (cdf and probe) were 
used. Extensive quality control (QC) of the raw data was carried out, in order to 
ensure a good array-array correlation. Basic QC was performed using the 
AffyQCReport package and the degree of RNA degradation was addressed using the 
AffyRNAdeg function of the Affy package implemented in Bioconductor. 
 
Preprocessing of the data and calculation of the expression values was performed 
using the robust multiarray average (RMA) algorithm (Irizarry et al. 2003) 
implemented in the Affy package (Gautier et al. 2004) in Bioconductor. The RMA 
algorithm fits a linear model for all probesets across all arrays. Selection of the 
differentially expressed genes was performed with statistical methods implemented 
in the Limma package (Smyth 2004). Empirical Bayes method was used to moderate 
standard errors for the estimated log-transformed fold changes. This results in more 
stable inference and improved power, especially for experiments with small 
numbers of arrays (Smyth 2004). The basic statistic used to analyze the significance 
of differential expression is a moderated t-statistic, which is computed for each 
probeset and each contrast (in this study: only one contrast, cases versus controls). It 
is interpreted as ordinary t-statistic except that the standard errors have been 
moderated across genes using a Bayesian model. Also, the degrees of freedom are 
increased, reflecting the greater reliability associated with the smoothened standard 
errors (Smyth 2004). P-values were adjusted for multiple testing using the 
Benjamini and Hochberg’s (BH) method (Benjamini and Hochberg 1995). 
Additionally, a B-statistic, i.e. the log-odds that a gene is differentially expressed, is 
produced. A B-statistic of zero corresponds to a 50-50 chance that the gene is 
differentially expressed, and it is automatically adjusted for multiple testing by 
assuming that 1% of the genes are expected to be differentially expressed. 
 
The publicly available gene expression dataset used in Study III (referred to as 
AGRE-EXPR) was analyzed using TIGR 40K human arrays and obtained as 
normalized data which we further re-annotated and analyzed in the same way as the 
CF-EXPR data. Probe information was provided as Genbank IDs (total number of 
probesets=41472). However, in agreement with the original publication of the 
GSE15402 dataset (Hu et al. 2009b) we applied a 30% filter to the data, removing 
all probes with missing values in > 30% of the samples (n=35/116). We removed in 
total 16078 of 41472 probesets, leaving 25394 probesets for analysis. After 
removing probes with no matching Genbank ID, we were left with a probe list 
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corresponding to 15 920 Entrez gene IDs. Unlike in the original publication, where 
the individuals with autism were divided into three phenotypic subgroups based on 
ADI-R scores, we assigned all samples as cases or controls only (87 cases and 29 
controls). 
4.4.5 Pathway analysis 
Pathway analysis was performed with a non-parametric in-house developed 
algorithm (named GWANA), which can be applied to both GWAS and gene 
expression datasets, as described before (Pietilainen et al. 2008, Aulchenko et al. 
2009). The method uses the ranking of genes or transcripts in a dataset together with 
their biological pathway annotations to list pathways that are enriched among the 
most highly associated or differentially expressed genes. A cumulative score is 
calculated based on how extreme the observed combination of associated (i.e. high 
ranking) genes in a given pathway is. This score is compared to all associated or 
differentially expressed genes and their pathways. The more genes a pathway has 
among all top-ranked genes or transcripts, the better the cumulative score. The 
significance of this enrichment is inferred from the distribution of 10000 
permutation cycles. All detailed description of the GWANA method is provided in 
the Supplementary Note of Study III. 
 
The pathway analysis was based on the Gene Ontology (GO) classification of genes, 
with all three ontologies (biological process, molecular function, cellular 
component) included in the same analysis. The topology of the GO-tree was fully 
utilized by enumerating all available routes towards the root of the GO tree and 
adding all encountered vertexes as GO annotations for the given gene. The 
maximum size for a reported pathway was set to 200, an arbitrary cut-off aimed to 
limit the analysis to biologically more meaningful pathways. We required at least 
two genes to be associated or differentially expressed per pathway, in order to 
prevent small categories appearing to be significantly overrepresented on the basis 
of a single, possibly chance hit. Closest genes for SNPs and GO annotations for 
genes were queried from the Ensembl database (release 53, hg36). 
 
GWAS datasets were analyzed by ranking all SNPs according to their original 
GWAS p-value. SNPs were mapped to genes by setting the maximum allowed 
distance of a SNP from its representative gene to 10kb from the 5’ and 3’ ends of a 
gene. When multiple SNPs mapped to a single gene, the SNP with the highest rank 
was retained, whereas SNPs that did not map to genes with the applied criteria were 
excluded. The permutation step was applied to the initial marker ranks, meaning that 
the SNP association p-values were randomized and the analysis repeated 10 000 
times. In addition to evaluating the significance of the pathway enrichment, the 
permutation step also accounts for any gene length and uneven SNP distribution 
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related bias in the analysis. To find out how much the size of the input SNP list 
affects the results, we ran the pathway analysis with different p-value thresholds for 
individual SNPs (p<0.05/0.01/0.005/0.001). This was also done in order to avoid 
limiting the analysis on the most significant variants (or transcripts) only, since this 
approach would be likely to ignore numerous false negative hits, especially in a 
phenotype like autism, where effect sizes of common genetic variants are small. 
 
Gene expression datasets were analyzed by ranking all transcripts based on i) p-
value for differential expression and (ii) absolute fold change to allow for both up 
and downregulated genes in the same pathway. As with SNP data, initial transcript 
ranks were permuted 10 000 times, and if duplicate genes were present, the highest 
ranking of that gene was used. No p-value thresholds were applied, allowing the use 
of the whole input list in the analysis.  
 
In order to further evaluate the performance of the GWANA pathway method we 
also applied it to GWAS and expression data from the AGRE study sample, as well 
as GWAS data from Crohn’s disease (CD), for which the underlying biology is 
better established and certain pathways can be expected to be found. 
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5 RESULTS AND DISCUSSION 
5.1 Role of DISC1 in ASDs (Study I and unpublished data) 
Since the initial report of the balanced translocation disrupting DISC1 and co-
segregating with schizophrenia and other major mental illnesses in a Scottish 
pedigree (St Clair et al. 1990), the gene has been extensively analyzed in many 
neuropsychiatric phenotypes. Following these, a wide range of functional studies has 
emerged (see Section 2.2.10), and DISC1 has become one of the most studied 
candidate genes in psychiatric genetics. Due to (i) the established biological 
functions of the DISC1 protein in early neurodevelopment, (ii) the versatility of 
neuropsychiatric phenotypes associated or otherwise related to DISC1, and (iii) 
shared neurocognitive defects between schizophrenia and ASDs such as impaired 
executive function and social functioning (Baron-Cohen and Belmonte 2005, Happe 
et al. 2006), it seems possible that abnormal DISC1 functioning would underlie also 
early-onset neuropsychiatric disorders, such as autism and AS. This is supported by 
the sex-dependent association findings reported for DISC1, which is of interest 
regarding the overall higher prevalence of all ASDs in males. In this study, we set 
out to investigate the possible role of genetic variants in DISC1 in autism spectrum 
disorders, with the hypothesis that DISC1 might be involved in fairly general 
neurodevelopmental processes, which, if disturbed, could lead to several slightly 
differing and even overlapping phenotypes such as ASDs and schizophrenia. Since 
one of the early association findings of DISC1 and SCZ was reported in Finnish 
families (Hennah et al. 2003), we hypothesized that the probability of finding a 
common genetic variant for ASDs and SCZ might be higher in the isolated Finnish 
population compared to study samples with mixed backgrounds. 
5.1.1 Association analysis 
We tested in total 11 SNPs and two microsatellite markers on chromosome 1q42, 
spanning a ~600 kb region with DISC1, DISC2, and TSNAX genes. Family-based 
association of single markers was detected in the autism study sample only with 
D1S2709, a microsatellite marker intragenic to DISC1 (TRANSMIT global 
p=0.022; FBAT p=0.010). This association was stronger when only affected males 
were included in the analysis (TRANSMIT global p=0.019; FBAT p=0.004). In the 
AS sample, no evidence of single marker association was seen. However, when only 
affected AS males were considered, SNP rs1322784 displayed association with both 
TRANSMIT (global p=0.0058) and FBAT (p=0.0195) (Table 9). This particular 
SNP is located ~101 kb apart from D1S2709, and appeared noteworthy also when 
comparing allele frequencies across study samples. The major allele frequency in the 
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AS sample was 0.83 compared to 0.78 in the regional controls and 0.72 in the 
Finnish population controls. In the combined study sample of both autism and AS 
families, modest association was seen with rs1411771 with FBAT (p=0.042; 
p=0.029 affected males only), but this could not be detected with TRANSMIT.  
 
When analyzing Pedigree 1 separately, evidence of association was found for 
rs1322784, the best SNP in the AS families. For this SNP, the most significant 
association was observed when calculating LD under the assumption of linkage (LD 
| Linkage), with a p-value of 0.0007. The joint analysis of LD and linkage (LD + 
Linkage) yielded p=0.002. Modest evidence of association was detected also for 
D1S2709, the best marker in the autism families (p=0.0376, LD + Linkage; 
p=0.0260 LD | Linkage). Interestingly, when marker allele frequencies in Pedigree 1 
(naffected=33) were compared with other study samples, we noticed, that the major 
allele frequency in cases for the best SNP, rs1322784, was 0.98 compared with the 
frequency in the regional controls of 0.78 and the Finnish population average of 
0.72. In fact, all except one of the affected individuals were AA homozygotes for 
rs1322784. This deviation between cases and both regional and Finnish population 
controls appeared highly significant using Fisher’s exact test (p=9.3x10-5 and 
p=9.89x10-7, respectively). 
 
Since linkage to 1q42 has been observed in Finnish SCZ families, we also analyzed 
our samples for two-point linkage. No significant evidence of linkage was observed 
in any of the study samples. However, again, some modest evidence emerged, when 
only AS males were considered (best LOD score 1.23, rs1000731, dominant model). 
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Table 9. Association analysis results of DISC1 in the autism and AS families. P-values < 0.05 are marked in bold. The SNP 
alleles are given in column two, with the major allele listed first. 
 
Marker Alleles Autism families Asperger syndrome families 
FBAT all Males 
only 
TRANSMIT 
all 
Males 
only 
FBAT 
all 
Males 
only 
TRANSMIT 
all 
Males 
only 
rs1630250 G/C 0.823 0.444 0.649 0.289 0.138 0.220 0.147 0.303 
rs1655285 G/C 0.847 0.549 0.456 0.272 1.000 0.739 0.912 0.506 
D1S251  0.897 0.609 0.849 0.691 0.205 0.196 0.268 0.107 
rs751229 T/C 0.553 0.972 0.796 0.737 0.889 0.402 0.766 0.282 
rs3738401 G/A 0.426 0.197 0.788 0.522 0.423 0.170 0.324 0.237 
rs1322784 A/G 0.279 0.542 0.250 0.408 0.086 0.0195 0.160 0.0058 
rs967244 A/G 0.453 0.705 0.405 0.821 0.346 0.718 0.295 0.415 
rs6675281 C/T 0.724 0.945 0.867 0.986 0.175 0.564 0.226 0.455 
rs1000731 C/T 0.643 0.536 0.583 0.446 0.285 0.385 0.284 0.272 
D1S2709  0.010 0.004 0.022 0.019 0.351 0.972 0.579 0.979 
rs821616 A/T 0.783 0.592 0.568 0.271 0.701 0.403 0.469 0.038 
rs1411771 T/C 0.106 0.050 0.076 0.077 0.299 0.290 0.471 0.591 
rs980989 G/T 0.267 0.210 0.208 0.282 0.541 0.403 0.609 0.415 
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5.1.2 Haplotype association analysis 
Haplotype association analysis was performed only to four specific haplotypes 
(named HEP1-4) which have previously shown association in Finnish families 
ascertained for schizophrenia. We tested the same haplotypes as in the original 
study, except in the case of HEP2 where rs1630250 and rs1655285 were used as 
surrogates for the haplotype information provided by the original haplotype (Figure 
9). 
 
In the autism sample and in the combined sample, none of the tested haplotypes 
showed evidence of association (best p-values 0.135 and 0.107, respectively). 
Suggestive association was detected only in the AS study sample with the HEP3 
haplotype (rs751229 and rs3738401); no evidence of association was observed with 
HEP1, 2 or 4. In the whole AS sample, a global p-value of 0.030 was obtained for 
HEP3 with TRANSMIT (best allele combination TA; 17.6 observed transmissions, 
12.7 expected transmissions). The same alleles were associated also when only 
affected AS males were used in the analysis (TRANSMIT global p=0.015; 13.5 
observed transmissions, 9.0 expected transmissions). However, HBAT did not show 
any association with the exact same haplotype (Table 10). 
 
In order to further define the extent of the potentially associating haplotype, we 
combined the HEP3 SNPs with neighboring SNPs in both directions. In the whole 
AS sample, none of the combinations (rs1655285 + HEP3 / HEP3 + rs1322784) 
appeared significant. However, again, when only AS males were considered, the 
combination of HEP3 plus the additional rs1322784 in the telomeric direction 
(HEP3+1) gave a global p-value of 0.0013 (TRANSMIT; best allele combination 
TAA; 13.4 observed transmissions, 9.0 expected transmissions). The HBAT analysis 
displayed a p=0.024 with two of these three SNPs, rs3738401 and rs1322784. 
 
The most significant association signal originates from a ~150 kb region delimited 
by rs751229 and rs1322784. Similar association results at this region have been 
observed in many earlier studies, although not with the exact same HEP3+1 
combination of SNPs. To name a few, Zhang and colleagues reported a haplotype 
association to schizophrenia involving the HEP3 SNPs and a third SNP preceding 
rs1322784 (Zhang et al. 2006), whereas another study reported an association of 
rs1322784 to schizophrenia and HEP3 to schizoaffective disorder (Hodgkinson et al. 
2004). Two other studies reported associations of haplotypes involving various 
combinations of the HEP3 SNPs and rs1322784 with schizophrenia, bipolar 
disorder, and psychotic disorder (Thomson et al. 2005b, Palo et al. 2007). Overall, 
most association findings seem to localize to two distinct regions of DISC1, the 3’ 
and 5’end of the gene, probably implying that the actual risk allele(s) remain to be 
identified or that multiple distinct genetic mechanism are operating on the region. 
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Since our sample size is relatively small, these results warrant replication in an 
independent ASD study sample. However, the fact that our finding co-localizes with 
the HEP3 region of the gene, which has been replicated several times to date, makes 
it highly interesting. Also, the associating alleles are the same that showed 
association in Finnish SCZ and BPD study samples. Especially interesting is the 
observation that in Pedigree 1, all but one of the affected individuals are 
homozygous for the best SNP in this study (rs1322784), possibly indicating 
enrichment of risk alleles in individuals with common genealogical origin. 
 
 
 
 
 
Figure 9. Schematic figure showing the exonic structure of the DISC1 region at 1q42. 
DISC1 and DISC2 exons are marked in black, TSNAX exons in gray, and intergenic 
exons in white. Most significant single marker and haplotype associations in the autism 
study sample (blue) and AS study sample (red) are denoted. Non-synonymous SNPs are 
indicated with a star. The location of the original HEP2 haplotype (Hennah et al. 2003) 
is indicated with dotted lines. 
 
The association signal in this study seems to arise from a broad diagnostic category 
of ASDs, and from affected males in particular (although it should be noted that 
most of the affected individuals in all of the study samples are males, given the 
overall higher prevalence of ASDs in males). We have made an effort to carefully 
harmonize the diagnostic criteria across all families, and firmly establish the 
diagnosis, not only for autism but also for AS. To date, evidence of DISC1 
association and linkage has been observed in multiple neuropsychiatric phenotypes, 
in addition to schizophrenia (see Section 2.2.10). This is in line with the original 
DISC1 translocation finding, which was not associated with schizophrenia only. The 
accumulating evidence strongly suggests a role for DISC1 in a broad range of 
neurobiological and developmental processes, which are capable of causing 
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multiple, sometimes overlapping psychiatric conditions when disrupted. 
Interestingly, after the results of Study I were published, another study reported a 
deletion at 1q42 involving DISC1, DISC2, and TSNAX in an individual affected with 
developmental delay and autistic behaviours (Williams et al. 2009), providing 
further support for the involvement of DISC1 in ASDs. 
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Table 10. Results of the DISC1 haplotype association analysis. Haplotypes are presented in the genomic order. HEP3-1 and 
HEP3+1 were not tested in the autism study sample (x) because no evidence of association was seen in the initial analysis of 
HEP1-4. P-values < 0.05 are marked in bold. 
 
Haplotype SNPs Autism families Asperger syndrome families 
HBAT 
all 
Males
only 
TRANSMI
T all 
Males
only 
HBAT 
all 
Males 
only 
TRANSMIT 
all 
Males 
only 
HEP2 rs1630250 
rs1655285 
0.912 0.519 0.492 0.242 0.244 0.463 0.173 0.143 
HEP3-1 rs1655285 
rs751229 
rs3738401 
x x x x 0.578 0.212 0.308 0.143 
HEP3 rs751229 
rs3738401 
0.707 0.592 0.954 0.704 0.288 0.115 0.030a 0.015a 
HEP3+1 rs751229 
rs3738401 
rs1322784 
x x x x 0.197 0.670 0.110 0.0013b 
HEP1 rs6675281 
rs1000731 
0.805 0.668 0.796 0.851 0.299 0.573 0.229 0.416 
HEP4 rs1411771 
rs980989 
0.263 0.135 0.242 0.159 0.553 0.571 0.819 0.449 
a Alleles TA 
b Alleles TAA 
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5.1.3 Polymorphic miRNA target prediction 
To search for biological explanations for the wide-ranged effects of the DISC1 gene, 
we focused on SNPs located in a miRNA binding site, i.e. the seed region, since 
such SNPs can affect the binding and the regulatory relationship between a miRNA 
and its target gene in an allele-specific manner, and thus associate to the resulting 
phenotype. Abelson and colleagues (2005) were the first to show that a SNP in the 
3’ UTR of SLITRK1 affected the interaction between the gene and human miRNA 
hsa-miR-189, and associated with Tourette’s syndrome (see also Section 2.1.5). 
Likewise, Clop et al (2006) identified a G to A substitution in the 3’ UTR of the 
sheep GDF8 gene that created an illegitimate target site for two miRNAs, causing 
translational inhibition of the mutant transcripts. 
 
SNP alleles can affect miRNA binding in two ways. They can either disrupt an 
existing target site leading to the loss of normal repression control of the target gene, 
or create a novel target site leading to abnormal target gene repression. The 
significance of the effect depends for example on the degree of conservation of the 
target site and redundancy effects. Since population genetic data supports strong 
purifying selection against SNPs that destroy conserved target sites and create novel, 
illegitimate targets (Hiard et al. 2010), the polymorphic miRNA target sites that do 
exist are likely to have true biological effects.  
 
Since the available full length DISC1 clone (IMAGE:900180) corresponds to the 
DISC1 Long variant (Lv) isoform, we limited our search of polymorphic target sites 
to the two longest known DISC1 isoforms, L and Lv. Both Patrocles and 
PolymiRTS identified three SNPs with potential effect on a predicted miRNA 
binding site (rs11122396, rs9308481, and rs11803088). However, the predicted 
miRNAs differed slightly between the two programs. In addition, PolymiRTS 
identified a fourth SNP, rs980989, with a possible effect on a miRNA binding site. 
We included all of these four SNPs and all of the nine targeting miRNAs to further 
functional analysis. In total, seven miRNAs were predicted to target the wild-type 
DISC1 Lv construct. Two additional miRNAs were predicted to target the 
alternative SNP alleles (Table 11). 
 
Of the four SNPs, rs980989 did not show association to ASDs in Study I (see Table 
9). The other three SNPs were not included in the original study, but were 
subsequently genotyped in the same set of samples and tested for association. None 
of them showed evidence of association with either autism or AS (p>0.05, data not 
shown). However, there is association evidence for these SNPs in other 
neuropsychiatric phenotypes, such as schizophrenia and various cognitive traits 
(Hennah et al. 2003, Palo et al. 2007). 
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With two of these SNPs, rs11122396 and rs980989, the ancestral SNP allele, 
determined by human versus chimpanzee genome alignment, is not predicted to 
affect miRNA binding. Instead, in both cases, the derived allele is predicted to create 
a novel, illegitimate binding site and cause abnormal gene repression. With 
rs9308481, the ancestral allele G is part of a non-conservative binding site for four 
mature miRNAs, whereas the derived allele is predicted to disrupt this site. 
However, the SNP that is most likely to have a true effect is rs11803088, whose 
ancestral allele C is part of a conserved miRNA target site for hsa-miR-559. The 
derived allele T is predicted to disrupt this conserved site. If this were to be true, 
expression of DISC1 in individuals TT homozygous for this SNP would be higher 
than in CC homozygotes, due to loss of normal repression control of hsa-miR-559. 
However, the situation is further complicated by the fact that the derived T allele is 
simultaneously predicted to disrupt a non-conservative binding site for hsa-miR-
548c. 
 
All predictions for miRNA binding and effect are blind to redundancy effects. A 
gene is typically targeted by multiple miRNAs, so the loss of the regulatory effects 
of just one might not have an effect at all, or it might be too small to be detected, 
given that the silencing effects of miRNAs are typically less than 50% (Bartel 2009). 
Also, the overall effect on target gene expression might be quite different in 
heterozygote versus homozygote individuals, who lack the binding site completely. 
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Table 11. Summary of DISC1 polymorphic miRNA target prediction results. Predictions are combined from Patrocles and 
PolymiRTS. The SNP alleles of the wild type DISC1 Lv construct are indicated with an asterisk (*). miRNAs and SNPs predicted by 
both programs are underlined. The effect of the SNP on the target site is denoted as follows: C=derived allele creates a novel 
miRNA binding site, N=derived allele disrupts a non-conservative miRNA binding site, D=disrupts a conservative miRNA binding 
site. 
 
#rs Positiona MAF 
CEU 
Octamer ("seed")b Effect SNP allele Targeting 
miRNA  
(stem loop) 
Stem 
loop 
location 
Mature miRNA 
rs11122396 230241891 0.042 caAGCC[A]Taactc C 
C 
C 
A*  
 
 
G (ancestral) 
miR-135a-1 
miR-135a-2 
miR-135b    
none 
3p21 
12q23.1 
1q32 
 
hsa-miR-135a 
 
hsa-miR-135b 
rs980989 230242818 0.217 tttACA[T]TCAtat C T 
G* (ancestral) 
miR-409 
none 
13q32.3 
 
hsa-miR-409-3p 
rs9308481 230242929 0.225 taaAAT[G]TGAagt 
aaaAT[G]TGAAgt  
 
AAT[G]TGAA 
N 
N 
N 
N 
G* (ancestral) 
 
 
 
A 
miR-323 
miR-23a 
miR-23b 
miR-130a 
none 
14q32 
19p13 
9q22.3 
11q12 
 
hsa-miR-323-3p 
hsa-miR-23a 
hsa-miR-23b 
hsa-miR-130a* 
rs11803088 230243392 0.069 cttTTA[C]TTTtaa 
cttttA[T]TTTTAa 
N 
D 
C* (ancestral) 
T 
miR-559 
miR-548c 
2p21 
12q14.2 
hsa-miR-559 
hsa-miR-548c-3p 
ABBREVIATIONS: MAF=minor allele frequency, CEU=HapMap CEPH population 
a RefSeq build 36.3 
b Genomic sequence 5’ to 3’ 
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5.1.4 Effect of miRNAs on DISC1 expression 
We tested the effects of altogether seven miRNAs on endogenous DISC1 expression 
in 293FT cells and on the overexpression of DISC1 Lv, hsa-miR-135a, 135b, 323-
3p, 23a, 23b, 130a*, and 559. We started with these seven because they target the 
wild type alleles of rs11122396, rs980989, rs9308481, and rs11803088 of the DISC1 
Lv construct (Table 11). In qPCR, for all samples, the standard deviation of the Ct 
values of the technical replicates was < 0.5, with most samples having a standard 
deviation of < 0.3, indicating good technical quality. Variation among biological 
replicates was more substantial, especially in the overexpression experiments. 
 
In the endogenous experiment, based on the linear regression analysis, two miRNAs 
(hsa-miR-135b and hsa-miR-559) significantly reduced the level of endogenous 
DISC1 expression compared with the negative control miRNA (p-values 0.015 and 
p=0.0045, respectively). The two siRNAs (positive controls) also displayed 
significant downregulation of endogenous DISC1 (p-values 0.016 and 0.023), as 
expected (Table 12). 
 
In the overexpression experiment, significantly more variation and "noise" was seen 
among the biological replicates. Based on the regression analysis, no miRNA 
induced a statistically significant effect on DISC1 expression, and of the positive 
controls, only one produced a significant reduction in DISC1 expression (p=0.032). 
However, miR-559 and miR-135b still showed the same direction of effect as in the 
endogenous experiment in most of the biological replicates (Table 12). Since the 
overexpression assay allows the testing for possible allele specific effects, we 
repeated the experiment for these two miRNAs with the mutated DISC1 Lv 
constructs harboring the alternative alleles for the two SNPs these miRNAs target. 
Very interestingly, as predicted, with miR-559 the expression level of DISC1 
increased notably when using a construct with the derived SNP allele for 
rs11803088, compared with the ancestral allele. This would suggest that the normal 
repression control mediated by miR-559 is lost with the derived allele. With miR-
135b, the allele-specific effects were not as clear, and additional replicates are 
required to clarify the effect. 
 
It should be noted, that endogenous DISC1 expression includes the total expression 
of all DISC1 isoforms targeted by the primer, whereas the overexpression 
experiments primarily measure effects on the Lv isoform, since the overexpression 
from the used construct is driven by a strong promoter compared with endogenous 
DISC1 levels. Since the multitude of DISC1 transcript variants remain poorly 
characterized, it is possible that the introduced miRNAs have effects also on the 
other isoforms. Most of the DISC1 isoforms differ with regard to their 3’UTR 
sequence, meaning that they are likely to be regulated by different sets of miRNAs. 
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However, it is not possible to address isoform specificity (other than Lv) in this 
study setting. 
 
There are numerous factors affecting our experiment which need to be tested before 
any final conclusions can be made. For example, to verify the robustness of the 
silencing effect, the experiments need to be repeated with different numbers of cells 
and different miRNA concentrations, and the level of endogenous miRNA 
expression in 293FT cells needs to be determined for the studied miRNAs. Also, it 
should be investigated, whether the observed effects can be reversed by knocking 
down the miRNA mediating the effect. Even if a significant reduction in DISC1 
expression is seen when a specific miRNA is introduced, it is hard to prove that the 
effect is in fact mediated by the miRNA silencing pathway of the cell. It is possible 
that the miRNA actually binds somewhere else, and the silencing effect is caused as 
a secondary, downstream effect. Thus, knocking down the endogenous miRNA, and 
possibly also the miRNA overexpression, to reverse the effect would provide an 
additional level of confidence. Further, since it is well-recognized that miRNA 
silencing effects are not always consistent on the RNA and protein levels, the effects 
on DISC1 expression should be measure also on protein level. Thus, the next step in 
our study will be to perform the same set of transfection experiments using 
luciferase assays, which is a quick, antibody-independent way of monitoring 
changes at the protein level. 
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Table 12. Summary of the qPCR results. Results are presented for the two best miRNAs and two positive controls in three 
independent experiments. Additionally, the results for the alternative allele in the overexpression experiment are presented in two 
independent experiments. Fold change values and the percent difference are calculated relative to the negative control miRNA. 
The reported values represent the mean of three biological replicates. 
 
miRNA Experiment 1 Experiment 2 Experiment 3 Experiment 4 Experiment 5 
FC %diff FC %diff FC %diff FC %diff FC %diff 
Endogenous experiment 
miR-135b -1.245 -24.5 -1.217 -21.7 -1.044 -4.4 NA NA NA NA 
miR-559 -1.204 -20.4 -1.330 -33.0 -1.199 -19.9 NA NA NA NA 
siRNA-A -1.190 -19.0 -1.227 -22.7 -1.229 -22.9 NA NA NA NA 
siRNA-B -1.251 -25.1 -1.295 -29.5 -1.197 -19.7 NA NA NA NA 
Overexpression experiment, wild type allele Alternative allele 
miR-135b -1.045 -4.5 -1.195 -19.5 -1.403 -40.3 1.091 9.1 -1.253 -25.3 
miR-559 -1.255 -25.5 1.042 4.2 -1.463 -46.3 1.141 14.1 1.527 52.7 
siRNA-A -1.453 -45.3 -1.255 -25.5 -1.687 -68.7 -1.407 -40.7 -1.228 -22.8 
siRNA-B -1.214 -21.4 -1.350 -35.0 -1.183 -18.3 x x x x 
ABBREVIATIONS: FC=fold change, %diff=percent difference, NA=not applicable, X=not tested 
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5.1.5 Conclusions 
Identifying the first reported association between DISC1 and ASDs in a widely 
replicated genomic region is highly interesting, and clearly demonstrates that 
phenotypic borders in psychiatric genetics are loose. Considering the well-
recognized challenges in diagnostics of mental disorders, it is likely that there are 
genes such as DISC1, which are involved in widespread neurobiological processes, 
which can be disturbed by various mechanisms leading to slightly differing, and 
even overlapping phenotypes. The existence of a common "DISC1 pathway", 
involving DISC1-interacting genes, has already been suggested, providing a possible 
biological link between such phenotypes. DISC1 can also be connected to ASDs via 
one of its interacting proteins, microtubule-associated protein 1A (MAP1A) (Morris 
et al. 2003). MAP1A physically interacts with discs, large homolog 4 (Drosophila) 
(DLG4) (Brenman et al. 1998) that is known to interact with neuroligin genes (Irie 
et al. 1997). Neuroligins are neuronal cell-adhesion molecules and well-known 
susceptibility genes for ASDs, proving further evidence of the molecular 
interconnectivity in neuropsychiatric disorders. 
 
In this study, we have followed up our association finding and started to explore the 
possible molecular mechanisms through which DISC1 might exert its widespread 
effects. We identified polymorphic miRNA target sites in the 3’UTR of DISC1 and 
identified a specific miRNA, hsa-miR-559, which seems to have an allele-specific 
effect on DISC1 expression in vitro. The study is still ongoing and further 
experiments are being conducted to obtain more information about the possible 
allele-specific regulatory relationship between DISC1, hsa-miR-559, and hsa-miR-
135b. Although it is not possible to make final conclusions yet, altered miRNA 
regulation would offer a tempting explanation for some of the wide-ranged effects of 
DISC1. 
5.2 Genome-wide linkage and LD in Pedigree 1 (Study II) 
In this study, we described an extended ASD pedigree originating from Central 
Finland (referred to as Pedigree 1) (Figure 5), and analyzed it for ASD susceptibility 
loci. The pedigree consists of 20 families, scattered all over Finland, which have 
been genealogically traced back to the 17th century and found to originate from 
common ancestors. Since the genetic heterogeneity of ASDs has greatly hampered 
the identification of genetic risk loci and variants, we wanted to take advantage of 
the substantially higher degree of LD observed in population isolates such as 
Finland (Service et al. 2006) (see Section 2.1.4), and of the reduced genetic 
heterogeneity in genealogically connected individuals. Thus, we performed a 
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traditional genome-wide scan for linkage and LD in Pedigree 1 with microsatellites. 
We hypothesized that if the observed genealogical links of Pedigree 1 reflect 
identical-by-descent (IBD) sharing, a few causative variants (or even a single 
variant) could be expected to be enriched to this pedigree. 
 
The pedigree was discovered when the genealogy of all of the families in the 
nationwide Finnish ASD study sample was systematically examined. First, ten 
families whose ancestors originated from a single small farm in Central Finland ~5-
10 generations ago were identified. When the ancestral trees were followed back up 
to 12 generations, we were able to distinguish nine ancestors connecting these 10 
families, which, most interestingly, were born on the same small farm 215-350 years 
ago (Auranen et al. 2003). Ten additional nuclear families with ASDs were later 
linked to this core pedigree. We were also able to reveal further genealogical links 
among the 20 families.  
5.2.1 Linkage and LD scan 
In the initial genome-wide scan, we analyzed 1109 microsatellite markers across the 
genome. Altogether nine loci were identified in the recessive LD+Linkage analysis 
of Pseudomarker (Table 13). These nine loci exceeded the threshold of –log(p)=2.5 
which was chosen as the cut-off for the selection of a reasonable number of follow-
up loci based on the overall distribution of the results (Figure 2 of Study II). To 
demonstrate that some of the signals were obtained from haplotype sharing among 
affected individuals instead of linkage only, we also monitored the LD|Linkage test 
of Pseudomarker for these nine loci, which allows for linkage but does not assume 
it. The most significant LD+Linkage results were obtained with D1S2707 on 
chromosome 1q23.2 and D15S156 on 15q12 (p=0.00082 and p=0.00081, Set1, 
respectively). With both markers, the evidence was almost entirely attributable to 
sharing across families (LD|Linkage, p=0.00079 and p=0.0009, respectively). In the 
dominant Pseudomarker analysis, only one locus exceeded the chosen threshold.  
 
Additionally, one significant locus was identified in the multipoint linkage analysis 
with Simwalk2 (NPL_dominant, –log(p)=3.57, D19S591) at chromosome 19p13.3 
(Figure 10). The second most significant locus in the Simwalk2 analysis was 
observed at chromosome 6 (NPL_dominant, D6S958, -log(p)=2.15, whilst results 
for all other loci were below –log(p)=1.5 with both dominant and recessive statistics 
(data not shown). 
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Table 13. Results of the initial genome-wide Pseudomarker analysis in Pedigree 1. All 
markers exceeding –log(p)=2.5 in a Set1 analysis are listed. 
Ranking Marker Chra Genetic  
locationb 
(cM) 
LD+Linkage 
[-log(p)] 
LD|Linkage  
[-log(p)] 
Recessive Pseudomarker 
1 D15S156 15q12 15.1 3.09 3.05 
2 D1S2707 1q23 156.1 3.09 3.10 
3 D13S232 13q12 8.7 3.01 2.85 
4 D14S283 14q11 14.7 2.96 2.52 
5 D8S1132 8q23 ~113.1 2.68 2.84 
6 D6S1279 6p24 ~30 2.66 1.59 
7 D5S2090 5q32 150.0 2.62 2.81 
8 D5S2006 5q35 205.7 2.56 2.74 
9 D6S422 6p22 42.8 2.51 2.58 
Dominant Pseudomarker 
1 D14S1071 14q12 28.2 2.76 2.93 
a UCSC Human Genome Browser, May 2004 assembly (hg17) 
b From ptel based on deCODE Genetic map (Kong et al. 2002) 
5.2.2 Follow-up and candidate gene analysis 
We chose altogether ten loci from the initial genome-wide scan for follow-up, 
including the nine most significant loci from the recessive Pseudomarker analysis 
and the one significant locus from the multipoint linkage analysis. Additional 44 
microsatellites were genotyped and analyzed at these ten loci (full marker 
information and results are presented in Supplementary Table S1 and S2 of Study 
II). Based on the information from the follow-up results and previous evidence in 
ASDs for two of the loci, we chose three loci to take further to finemapping (1q23, 
15q13, and 19p13). Chromosome 1q23 has been implicated by two previous 
genome-wide screens for ASDs in Finnish families (Auranen et al. 2002, Ylisaukko-
oja et al. 2004), whereas prior evidence for 15q11-q13 arises from cytogenetic 
studies (Gillberg 1998, Wassink et al. 2001a, Veenstra-VanderWeele and Cook 
2004). Regional candidate genes at these loci were chosen based on biological 
relevance to ASDs and previous research results, and analyzed using a total of 152 
SNP markers (Table 14). Due to prior evidence in ASDs, SNPs on chromosome 1 
and 15 were analyzed also in the nationwide ASD family sample, whereas SNPs on 
chromosome 19 were primarily analyzed in Pedigree 1, except for the most 
significant SNPs. The results of the candidate gene analysis are presented in full in 
Supplementary Table S2 of Study II. 
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Figure 10. Multipoint linkage analysis results on chromosome 19 in Pedigree 1. The 
upper figure shows the results of the initial genome-wide scan with the two best markers 
displayed, whereas the lower figure presents the signal after the inclusion of seven 
follow-up microsatellites. The follow-up region is indicated with dotted lines. 
Set1=analysis with only one affected individual from Family 2, Set2=analysis with all 13 
affected individuals from Family 2. Results produced by Simwalk2. Abbreviations: 
Rec=recessive, Dom=dominant. 
 
On chromosome 1q, the finemapping covered 31 SNPs from six genes over a region 
of ~3 Mb. Most significant evidence was detected in Pedigree 1 at ATP1A2 gene 
with rs1016732 (p=0.00048, Set2, LD+Linkage, recessive Pseudomarker), which is 
located just 14.7 kb away from the best microsatellite of the initial scan. As with the 
microsatellite, the association evidence was primarily attributable to sharing across 
the families (p=0.00058, LD|Linkage). Encouragingly, also the four consecutive 
SNPs were modestly associated (from p=0.03 to p=0.006, LD+Linkage). However, 
only marginal evidence of association was observed with any of these SNPs in the 
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nationwide collection of ASD families (best p-values ~0.01). ATP1A2 is part of a 
syntenic rodent epilepsy locus, centered around D1S2707, together with ATP1A4, 
KCNJ10, and KCNJ9 (Buono et al. 2004, Ferraro et al. 2004). Association between 
seizure susceptibility, idiopathic generalized epilepsy and KCNJ10 has also been 
detected in humans (Lenzen et al. 2005), which is of interest, since up to 30% of 
individuals with autism suffer from epilepsy (Gillberg and Billstedt 2000). 
 
On 15q, we analyzed 41 SNPs from four genes over a region of ~2.3 Mb. Modest 
association was detected with six SNPs from a GABAA receptor subunit gene cluster 
(from p=0.02 to p=0.0023, LD+Linkage, Set2, recessive Pseudomarker), with the 
most significant results originating from four consecutive SNPs within GABRB3 
(from p=0.04 to p=0.00084, LD|Linkage, best SNP rs7173713). As with the SNPs 
on chromosome 1q, only marginal evidence was seen outside Pedigree 1 in the 
nationwide samples. 
 
Candidate genes on chromosome 19p were mainly analyzed in Pedigree 1 in the 
absence of previous evidence for this locus. Since the most significant multipoint 
linkage signal for this locus was obtained in a Set 2 analysis (Figure 10), with all 13 
affected individuals from Family 2 included, we focused on the Set 1 analysis in the 
finemap, to identify association signals independent of Family 2 (see Section 4.1.3). 
We analyzed 80 SNPs from 13 genes over a region of almost 6 Mb. The most 
significant association in the whole study was observed within a cluster of three 
genes, TLE2, TLE6, and AES (also known as TLE5), located just 12.8 kb away from 
the best microsatellite at this locus, D19S591. Altogether eight consecutive SNPs 
yielded LD+Linkage p-values < 0.04 in the same analysis (Set1, dominant 
Pseudomarker), consistently with the original linkage. Of these SNPs, best results 
were obtained with rs4806893 and rs216283 (both p=0.000078), and rs216276 
(p=0.00063). Evidence of sharing across families was observed with five of these 
SNPs (from 0.05 to p=0.00019, LD|Linkage). The eight SNPs cover a region of 16.5 
kb and are located within TLE2 and the 3’UTR/intergenic region of TLE6 (the genes 
are transcribed in reversed directions). To further assess the role of these SNPs, we 
analyzed them further in the nationwide ASD family sample, but again, no 
comparable evidence of association was seen outside Pedigree 1. Based on 
haplotype analysis of the eight most significant SNPs, no single haplotype could be 
expected to account for the entire association signal (Supplementary Table S3 of 
Study II). 
 
The three genes belong to the human TLE (transducin-like enhancer of split) family 
of proteins homologous to the Drosophila Groucho protein, which is involved in 
neurogenesis during embryonic development as part of the Notch signaling pathway 
(Stifani et al. 1992, Miyasaka et al. 1993). All of the human TLE-genes share a 
conserved TLE_N protein domain (Pfam ID PF03920) and act as transcriptional co-
repressors. Similar to their Drosophila counterparts, human TLEs are thought to 
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negatively regulate neuronal development and differentiation (Chen and Courey 
2000). Interestingly, loss-of-function of Groucho and other components of the Notch 
pathway result in the overproduction of neurons (Heitzler et al. 1996), which is of 
relevance given that macrocephaly and increased brain volume are frequent 
observations in individuals with autism (Fombonne et al. 1999, Cody et al. 2002). 
Interestingly, TLE2, together with forkhead box G1 (FoxG1), was recently shown to 
be crucial in the formation of the ventral telencephalon (Roth et al. 2010). 
5.2.3 Conclusions 
Focusing on rare forms of common diseases has proved to be of high importance in 
unraveling genes and underlying disease mechanisms (for e.g. Vionnet et al. 1992). 
Also, the syndromic forms of autism spectrum disorders such as autism caused by 
the Fragile X mutation or a chromosome 15q11-q13 duplication, have received 
considerable attention, and increased our understanding of the underlying genetic 
and biological mechanisms. In addition, the autism field has recently seen many 
studies, where a single, high-penetrance mutation has been identified as the 
causative mutation in individual families (see Section 2.2.9). Since LD-based 
mapping has been successfully used to identify disease genes in monogenic diseases 
in the Finnish population (for e.g. Varilo et al. 1996), this study had an ideal setting 
for genetic mapping based on linkage and haplotype sharing, and the enrichment of 
a few causative variants in the affected individuals of Pedigree 1 was considered 
likely. 
 
Unexpectedly, this was not what we found. The results of the genome-wide scan and 
the following candidate gene and haplotype analysis clearly showed that there are 
multiple genomic loci affecting the phenotype in the pedigree. Our results provide 
additional support to two previously established ASD risk loci, at 1q23 and 15q11-
13, and highlight a third interesting locus at 19p13. Suggestive linkage at 19p13 has 
been reported in previous genome-wide linkage scans in ASDs, but the reported 
LOD-scores have been small. Thus, the multipoint linkage signal obtained in this 
study with just 20 families is promising. In fact, haplotype analysis at the linked 
regions revealed that at this locus, all of the families of Pedigree 1 show complete 
segregation with the trait (i.e. linkage), implying that this locus is likely to contribute 
to the phenotype in the pedigree. However, the locus appears specific to Pedigree 1, 
since none of the candidate gene association results replicate outside of the pedigree 
in the nationwide ASD study sample. Also, none of the candidate gene association 
signals were significant enough to completely explain the linkage signal, suggesting 
that additional variation is contributing to the signal at each locus. Given that this 
study was mostly performed with microsatellite resolution with an average 
intermarker distance of 3.43 cM, it cannot be ruled out that the affected individuals 
would share shorter regions of their genome in common. Study III was initiated to 
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address this question and follow-up the results of this study. However, if a shared 
rare variant would be present in the pedigree, it would have been found already by 
linkage. 
Table 14. Candidate genes on 1q23, 15q12, and 19p13 chosen for finemapping. 
Gene Gene namea Chr Size 
(kb) 
Genotyped 
SNPs 
KCNJ10 potassium inwardly-rectifying channel, 
subfamily J, member 10 
1q23 32.0 6 
KCNJ9 potassium inwardly-rectifying channel, 
subfamily J, member 9 
1q23 7.9 2 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 
polypeptide 
1q23 27.8 5 
ATP1A4 ATPase, Na+/K+ transporting, alpha 4 
polypeptide 
1q23 35.4 7 
NOS1AP nitric oxide synthase 1 (neuronal) adaptor 
protein 
1q23 298.6 6 
RGS4 regulator of G-protein signaling 4 1q23 7.2 5 
UBE3A ubiquitin protein ligase E3A 15q12 68.3 10 
GABRB3 gamma-aminobutyric acid (GABA) A receptor, 
beta 3 
15q12 227.5 19 
GABRA5 gamma-aminobutyric acid (GABA) A receptor, 
alpha 5 
15q12 113.6 6 
GABRG3 gamma-aminobutyric acid (GABA) A receptor, 
gamma 3 
15q12 652.5 6 
PALM paralemmin 19p13 39.3 9 
GRIN3B glutamate receptor, ionotropic, N-methyl-D-
aspartate 3B 
19p13 9.3 2 
EFNA2 ephrin-A2 19p13 13.8 2 
MBD3 methyl-CpG binding domain protein 3 19p13 16.0 4 
GNG7 guanine nucleotide binding protein (G protein), 
gamma 7 
19p13 191.4 21 
TLE6 transducin-like enhancer of split 6  
(E(sp1) homolog, Drosophila) 
19p13 17.6 7 
TLE2 transducin-like enhancer of split 2  
(E(sp1) homolog, Drosophila) 
19p13 31.4 11 
AES amino-terminal enhancer of split 19p13 9.5 8b 
GNA15 guanine nucleotide binding protein (G protein), 
alpha 15 (Gq class) 
19p13 27.5 8 
SH3GL1 SH3-domain GRB2-like 1 19p13 40.1 4 
SEMA6B sema domain, transmembrane domain (TM),  
and cytoplasmic domain, (semaphorin) 6B 
19p13 15.9 2 
NRTN neurturin 19p13 4.5 1 
PSPN persephin 19p13 0.6 1 
ABBREVIATIONS: Chr=chromosome, bp=base pair 
a According to HUGO Gene Nomenclature Committee (HGNC) 
b Includes one intergenic SNP 
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5.3 The genetic architecture of ASDs in genealogically connected 
individuals (Study III) 
In Study III, we used three complementary approaches to follow up the results 
obtained in Study II. First, we extended our study sample (Pedigree 1, 18 families) 
with 33 additional families originating from the same geographical region (including 
Pedigree 2) (referred to as CF-GWAS). Second, we increased our marker density 
from microsatellites to genome-wide high-density SNP data. This enabled us to 
investigate whether the affected individuals in Pedigree 1 and Pedigree 2 would 
share shorter genomic regions than visible with microsatellite resolution. Third, we 
performed pathway analysis using information from both GWAS and global gene 
expression analysis from the same study sample. With these approaches we aimed to 
thoroughly dissect the genetic background of ASDs in this population sub-isolate, 
and begin to explore the biological processes and mechanisms underlying ASDs in 
these individuals. 
5.3.1 Genome-wide association analysis 
Isolated populations have traditionally been useful in mapping of monogenic 
disorders, and recently, their usefulness also in complex disease genetics has been 
demonstrated. For example, a study in multiple sclerosis showed that if there are 
common risk factors affecting the phenotype enriched in individuals from an isolate, 
these can be identified using a very small number of distantly related individuals and 
carefully matched population controls (Jakkula et al. 2010). This study setting is 
analogous to the one here, which initially motivated us to perform a traditional case-
control GWA analysis in our study sample, which in more admixed populations 
would be much too small to have enough statistical power to reliably identify 
common variation. 
 
In the GWA analysis of the CF-GWAS study sample and matched controls (51 
cases, 181 controls), we detected seven SNPs from seven different loci, with p-
values < 1 x 10-5. One of the SNPs, rs9309326 on chromosome 2p16.1, reached 
genome-wide significance with p=6.88x10-9. None of these SNPs overlapped with 
previously reported autism GWAS results, even though two were located on 
chromosome 5p, a region implicated by two previous studies (Wang et al. 2009b, 
Weiss et al. 2009). None of the identified loci overlapped with the linkage regions 
from Study II either, but this is not unexpected since a GWA analysis is specifically 
designed to target common genetic variants, unlike linkage analysis. To rule out 
possible sources of bias regarding this SNP, we took a careful look at the quality 
control measures. However, no genomic inflation was observed in the genome-wide 
distribution of p-values (λ=1.05), which rules out possible population stratification 
effects. The success rate for the SNP was 99.6%, HWE p-value p=0.0001, and the 
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three genotype categories were clearly separated into clusters, indicating good 
overall genotyping quality for this SNP. The odds ratios (OR) of rs9309326 and the 
six other significant SNPs are very large compared with previously reported results 
from autism (ORs from 3.13 to 7.08), but it is not unexpected to observe larger 
effects in isolated populations. Alternatively, the effect sizes might be overestimated 
due to small sample size. 
 
The minor allele frequency (MAF) for the most significant SNP was 0.28 in the CF 
cases versus 0.07 in the controls. To assess the validity of the allele frequency in the 
relatively small set of controls used, we checked the MAF also in a set of 7740 
samples from the general Finnish population. The MAF was 0.11, compared with 
0.14 in the HapMap CEU population, suggesting good comparability. The 
association signal was not traceable back to a single pedigree, as the minor allele 
was carried by 50% of the cases in Pedigree 1 (n=9), one case in Pedigree 2, and 14 
of the other CF cases. To further assess the role of the most significant GWAS 
findings, all SNPs with p<1 x 10-4 in the CF-GWAS (36 in total) were genotyped in 
all available family members of the CF-GWAS cases, as well as in the nationwide 
collection of Finnish autism families (n=126). A family-based analysis in these 
individuals did not replicate the signals from the original case-control results, 
suggesting that they are specific to the CF isolate. 
5.3.2 Haplotype analysis 
The genome-wide significant SNP rs9309326 is located between two recombination 
hotspots, based on recombination rates estimated from HapMap data (Figure 1 of 
Study III). To further characterize the region surrounding this SNP, we performed 
haplotype association analysis with ten-SNP sliding windows at this locus. As 
expected, the most significant association was seen with a haplotype which includes 
rs9309326 (p=9.96 x 10-7), but we also observed three other haplotypes with 
significant associations (p<3.90 x 10-5), suggesting that the association signal at this 
locus is not driven entirely by rs9309326. Also, the association signal started to 
decrease as soon as SNPs exceeding the recombination hotspots were included in the 
haplotypes. 
 
The lack of association with other SNPs at the region can in part be explained by the 
low correlation (i.e. degree of LD) among the SNPs (0.01 < r2 < 0.13), as expected 
with 317k SNP chip data. SNPs on this platform have specifically been chosen to 
tag single haplotype blocks only, thereby being mostly uncorrelated. However, 
modest LD could still be seen with rs9309326 and the haplotypes not including the 
SNP. For all haplotypes, the global association signal could be attributed to 
haplotypes enriched to cases (frequency from 0.08 to 0.22) and almost absent from 
controls (frequency from 0.003 to 0.05). 
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The closest gene to the most significant SNP is B-cell CLL/lymphoma 11A isoform 
(BCL11A), located ~53 kb upstream. All but two of the associated haplotypes 
overlap with the 3’ end of the gene, suggesting that both the SNP and the haplotypes 
tag an ASD risk allele at this locus. BCL11A has been strongly associated with 
regulation of fetal haemoglobin levels (Menzel et al. 2007, Sankaran et al. 2008, 
Uda et al. 2008). It is a TF specifically expressed in hematopoietic tissue and the 
brain (Leid et al. 2004). Interestingly, BCL11A was recently shown to alter the 
distribution of nuclear actin and downregulate axon branching in hippocampal 
neurons (Kuo et al. 2009). It has also been reported to interact with 
Calcium/calmodulin-dependent serine kinase (CASK), a causative gene for X-linked 
mental retardation and brain malformalities (Najm et al. 2008, Tarpey et al. 2009). 
CASK was shown to regulate axonogenesis through interaction with BCL11A (Kuo 
et al. 2010). 
5.3.3 Shared segment analysis and homozygosity mapping 
Genome-wide homozygosity and shared segment analyses were performed in 
Pedigree 1 and Pedigree 2, both of which have genealogical roots in Central Finland. 
Homozygosity mapping was used to test for possible recessive susceptibility 
variants whereas the shared segment analysis can identify shared, enriched risk 
variants inherited in a dominant-like fashion. The loci identified in these two 
analyses are summarized in Table 15. No regions shared by all of the affected 
individuals were identified in either pedigree, an observation made already with 
microsatellites in Study II with Pedigree 1. However, this study confirmed that even 
with a substantially denser resolution, no single genomic region is shared by all of 
the cases, despite distant relatedness. Instead, we identified small subsets of cases 
which shared regions in common. The most interesting regions of homozygosity 
(ROH) were identified on chromosomes 4p15.1 and 18q22 in Pedigree 1 and 
Pedigree 2, respectively. At these loci, all but one of the affected individuals per 
pedigree were homozygous for a small region (< 100 kb). The ROH on 4p15.1 does 
not overlap with any genes, whereas the region on 18q22 overlaps with a single gene 
coiled-coil domain containing 102B (CCDC102B) with a largely unknown function. 
 
Similar results were obtained in the shared segment analysis. No regions were 
shared by more than four pairs of affected individuals (Study III, Supplementary 
Note). Altogether five regions of interest were identified, three in Pedigree 1 and 
two in Pedigree 2, but in all of these regions, there were typically only two pairs of 
cases (and no more than three), which shared the exact same allelic combination 
IBD. To find out whether the identified shared segments and ROHs were specific to 
the two pedigrees, we assessed the regions also in the matched controls. All of the 
regions were common in controls as well, suggesting that they represent ancestral 
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haplotypes and any possible mutations would have been introduced more recently 
onto this background. These results support the idea that risk factors for ASDs are 
family specific, although in theory, the small ROHs shared by almost all affected 
individuals in both pedigrees might still reveal a shared risk variant if sequenced. 
 
Table 15. Regions of interest identified in the homozygosity and shared segment 
analyses in Pedigree 1 and Pedigree 2. 
Chromosome PED Start (kb)a End (kb)a Size (kb) SNPs Type 
2q14.3 PED1 124193 129108 4915 74 Shared seg 
4p15.1 PED1 33720 34094 373 23 ROH 
4q34.1 PED1 173091 175514 2423 53 Shared seg 
6p22 PED2 28629 28738 109 6 ROH 
7q31.31 PED2 117503 117943 440 48 ROH 
8q11.22 PED2 51513 52109 596 38 ROH 
9q12-q21 PED2 68191 72418 4227 68 Shared seg 
10p15.3 PED1 1433 2080 646 34 Shared seg 
11p11.2 PED1 48105 48573 467 29 ROH 
15q23-q24.1 PED1 69899 70794 894 57 ROH 
15q23-q24.1 PED2 69889 70501 611 47 ROH 
16q22.3 PED2 71027 71875 848 21 Shared seg 
18q22.1- 
q22.2 PED2 64802 64929 126 37 ROH 
ABBREVIATIONS: PED=pedigree, kb=kilobase, ROH=region of homozygosity, seg=segment 
a According to the hg18 genome build. 
 
In summary, using genome-wide SNP markers, we did not identify any shared 
genomic regions in the two CF pedigrees. Thus, it seems that even within a set of 
distantly related families, genetic heterogeneity is significant, and rare genetic 
variants specific to subsets of, or individual, families comprise the majority of risk 
factors for ASDs. None of the identified regions overlap with the linkage regions 
identified in Study II, which suggests that the putative rare variants harboured by the 
linkage regions in Pedigree 1 are distinct from the ones highlighted by the SNP-
based shared segements and regions of homozygosity. Since many of the ROHs and 
shared segments contain genes that have been previously implicated in ASDs, such 
as CNTNAP5 (Pagnamenta et al. 2010) and ankyrin-repeat domain genes (Marshall 
et al. 2008, Willemsen et al. 2010), the next obvious step is to sequence these 
regions to identify the underlying mutations. We additionally identified one 
genome-wide significant common SNP in the GWA analysis of the CF-GWAS 
dataset, which seems to confer risk to ASDs in these individuals. 
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5.3.4 Global gene expression analysis 
Gene expression studies in autism have been greatly hindered by the availability of 
samples, and only a handful of studies have been reported. Yet, despite being small, 
these studies have established that expression profiling, most commonly from 
lymphoblastoid cell lines (LCLs), can distinguish between affected individuals and 
their healthy siblings, as well as between different syndromic forms of autism 
(Baron et al. 2006a, Nishimura et al. 2007, Hu et al. 2009b), thus again highlighting 
the importance of accurate phenotypic subgrouping in genetic studies. 
 
Using mononuclear lymphocytes, altogether 325 differentially expressed genes were 
observed between ten ASD cases and ten controls (CF-EXPR dataset) at p=0.01 
significance level (non-adjusted t-test p-value < 0.01). Of these, we defined 17 genes 
upregulated (FC > +1.5) and 55 downregulated (FC < -1.5) in individuals with 
ASDs compared to controls. The fold change range of these genes was -2.24 to 
+4.14. Ten most significantly up and downregulated genes are listed in Table 16. At 
p=0.05 significance level, 1286 genes were differentially expressed. Given the small 
size of the dataset, the data was primarily used as a whole for the purpose of 
pathway analysis. After correcting for multiple testing, none of the p-values for the 
identified genes remained significant. 
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Table 16. Most significantly up and downregulated genes in the CF-EXPR dataset. Genes are ranked based on moderated t-test 
non-adjusted p-values. P-values were adjusted using the Benjamini and Hochberg's (BH) method. 
Gene 
symbol 
Entrez  
gene ID 
Fold 
change 
p-value Adjusted 
p-valuea 
Gene nameb Locus 
Upregulated      
MEX3B 84206 1.26 4.25E-05 0.2130 mex-3 homolog B (C. elegans) 15q25.2 
DNMT3B 1789 1.33 6.16E-05 0.2130 DNA (cytosine-5-)-methyltransferase 3 beta  20q11.2 
TNF 7124 2.32 9.49E-05 0.2130 tumor necrosis factor  6p21.3 
IFNG 3458 2.87 9.77E-05 0.2130 interferon, gamma  12q14 
KIAA0495 57212 1.25 0.000197 0.3055 KIAA0495 1p36.32 
IER5 51278 1.79 0.000260 0.3055 immediate early response 5 1q25.3 
IGHV4-34 28395 1.41 0.000417 0.3530 immunoglobulin heavy variable 4-34 14q32.33 
MYL4 4635 1.47 0.000887 0.4625 myosin, light chain 4, alkali; atrial, embryonic 17q21-qter 
WDR62 284403 1.23 0.000973 0.4625 WD repeat domain 62 19q13.12 
BGLAP 632 1.33 0.00148 0.4687 bone gamma-carboxyglutamate (gla) protein  1q25-q31 
Downregulated      
GNPDA2 132789 -1.92 3.57E-06 0.0635 glucosamine-6-phosphate deaminase 2  4p13 
WDR43 23160 -1.74 1.73E-05 0.1534 WD repeat domain 43  2p23.2 
MRPL13 28998 -1.93 5.63E-05 0.2130 mitochondrial ribosomal protein L13  8q22.1-q22.3 
DDX1 1653 -1.41 7.65E-05 0.2130 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1  2p24 
TP53RK 112858 -1.53 0.000108 0.2130 TP53 regulating kinase  20q13.2 
C18orf19 125228 -1.38 0.000126 0.2240 chromosome 18 open reading frame 19 18p11.21 
FAM175B 23172 -1.63 0.000226 0.3055 family with sequence similarity 175, member B 10q26.13 
PPP1R8 5511 -1.61 0.000240 0.3055 protein phosphatase 1, regulatory (inhibitor) subunit 8 1p35 
COMMD2 51122 -1.62 0.000279 0.3055 COMM domain containing 2 3q25.1 
FBXO30 84085 -2.04 0.000280 0.3055 F-box protein 30  6q24 
a Adjusted using the Benjamini and Hochberg's (BH) method. 
b According to HUGO Gene Nomenclature Committee (HGNC).
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5.3.5 Pathway analysis 
GWAS datasets have only recently been used for other purposes than case-control 
association or CNV analysis. There is an increasing number of  reports of pathway 
analysis using GWAS data (for e.g. Lesnick et al. 2007, Baranzini et al. 2009, 
Holmans et al. 2009, Wang et al. 2009b, O'Dushlaine et al. 2010), but the combined 
use of gene expression data and SNP data for the purpose of pathway analysis has 
mostly been limited to eQTL-based (expression quantitative trait locus) approaches 
(Zhong et al. 2010). Also, the pathway methodology has mainly focused on the 
analysis of the most significant association hits, which is likely to ignore a 
significant number of false negative hits, especially in phenotypes such as autism, 
where large effect size common variants cannot be expected. 
 
In this study, we wanted to use pathway analysis to better address the role of 
common genetic variation in the CF-GWAS dataset. Since the dataset is small and 
has limited power to identify common variants on a genome-wide significant level, 
we wanted to include also the "grey zone" SNP results in the pathway analysis and 
try to partially overcome the problem of ignoring false negative results. We also 
wanted to extend the pathway analysis to global gene expression data from the same 
individuals to investigate whether changes observed at different levels of genomic 
data would reflect disturbances in same biological processes, thus providing an 
additional layer of confidence regarding the results. The key observations from the 
pathway analysis can be summarized as follows: i) apparent pathway level overlap 
was observed only between the two isolate datasets, CF-EXPR and CF-GWAS, 
which implicated vasculature development and axon guidance molecules in the 
pathogenesis of ASDs ii) overlap between the CF and the AGRE datasets was 
marginal, and iii) different p-value thresholds applied to the GWAS data did not 
markedly affect the pathway results. The ten most significant pathways from each 
dataset are presented in Tables 17-20. 
 
A .  C e n t r a l  F i n l a n d  d a t a s e t s  
In both CF-GWAS and CF-EXPR datasets, multiple GO-categories related to 
vasculature development were identified among the 15 most significant pathways. 
These included processes such as angiogenesis, blood vessel development, and EGF 
signalling in the GWAS data, and vascular endothelial growth factor (VEGF) 
production-related categories in the expression data (Tables 17 and 18). 
Interestingly, angiogenesis and axon guidance are known to be partially regulated by 
same molecules (Adams and Eichmann 2010). All of these categories included 
genes, such as semaphorin 5A (SEMA5A) and neuropilin 2 (NRP2), which are 
known to function in axon guidance (Adams and Eichmann 2010). Hypoxia 
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inducible factor 1, alpha subunit (HIF1A) was the only overlapping gene in the 
vasculature-related pathways identified in the GWAS and gene expression datasets. 
 
Other pathways which showed overlap between the two datasets were related to the 
actin cytoskeleton. CF-GWAS implicated "actin filament organization" whereas in 
CF-EXPR "actin cytoskeleton reorganization" was seen. Interestingly, actin 
cytoskeleton reorganization is closely associated with axon guidance through the 
axon growth cone.  Other interesting categories were for example "protein 
polyubiquitination" in the CF-GWAS, a biological process implicated by a recent 
large CNV study in autism (Glessner et al. 2009), and two methyltransferase 
categories containing DISC1, which has been associated with ASDs in the same 
isolate (see Study I). 
 
B .  A G R E  d a t a s e t s  
The most significant pathways observed in the CF datasets overlapped only 
occasionally with the pathways obtained from the AGRE datasets. Namely, helicase 
activity and protein ubiquitination were identified in both GWAS datasets, the latter 
of which has previously been linked to autism (Glessner et al. 2009). Further, the 
AGRE-GWAS implicated "positive regulation of neurogenesis" category with genes 
such as roundabout, axon guidance receptor, homolog 1 and 2 [Drosophila] (ROBO1 
and ROBO2), which link directly to vascular patterning and axon guidance, as 
identified in the CF data.  
 
No apparently overlapping pathways between the AGRE-GWAS and the AGRE-
EXPR datasets were seen (Tables 19 and 20). However, AGRE-GWAS had two 
categories related to nitric oxide metabolism and AGRE-EXPR yielded "regulation 
of glutamate signalling" and "postsynaptic density". Interestingly, nitric oxide is a 
known neurotransmitter in the brain, which is known to reinforce glutamatergic 
signalling as part of long-term potentiation (Haley et al. 1992). 
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Table 17. Summary of the pathway analysis results, Central Finland gene expression dataset (CF-EXPR). Closely related 
pathways are counted as a single category. A minimum of two differentially expressed genes per pathway were required. 
 
Rank GO ID Pathway Optimal 
p-value 
Permuted
p-value 
Genes in
pathway 
Regulated 
genes 
1 GO:0051640 organelle localization 6.78E-05 0.0006 35 19 
2 GO:0000242 pericentriolar material 0.00016467 0.0007 3 2 
3 
GO:0004715 
non-membrane spanning protein tyrosine kinase 
activity 6.26E-05 0.0008 20 8 
4 GO:0031532 actin cytoskeleton reorganization 0.00017129 0.0011 8 4 
5 GO:0001515 opioid peptide activity 0.00047084 0.0012 3 2 
6 GO:0010573 vascular endothelial growth factor production 0.00033389 0.0021 6 5 
7 GO:0043550 regulation of lipid kinase activity 0.00104429 0.0021 3 3 
8 GO:0008156 negative regulation of DNA replication 0.00032367 0.0022 9 9 
6 
GO:0010574 
regulation of vascular endothelial growth factor 
production 0.00033390 0.0022 6 5 
9 GO:0034464 BBSome 0.00053425 0.0024 5 3 
10 GO:0051640 regulation of hormone metabolic process 0.00051435 0.0026 8 7 
ABBREVIATIONS: GO=Gene Ontology, BBS=Bardet-Biedl syndrome 
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Table 18. Summary of the pathway analysis results, Central Finland genome-wide association dataset (CF-GWAS). Closely 
related pathways are counted as a single category. P-value threshold for individual marker significance in GWAS p=0.01. A 
minimum of two suggestively associated genes per pathway were required. 
 
Rank GO ID Pathway Optimal 
p-value 
Permuted
p-value 
Genes in
pathway 
Regulated 
genes 
1 GO:0016528   sarcoplasm 1.69E-07 0.0001 26 6 
2 GO:0032583   regulation of gene-specific transcription 0.00013053 0.0002 48 6 
1 GO:0016529   sarcoplasmic reticulum 4.06E-06 0.0003 25 5 
2 GO:0043193   positive regulation of gene-specific transcription 5.24E-05 0.0003 33 5 
3 GO:0004700   atypical protein kinase C activity 0.00016893 0.0004 3 3 
4 GO:0000775   chromosome, centromeric region 0.00338175 0.0007 77 3 
4 GO:0000793   condensed chromosome 0.00390092 0.0015 81 3 
5 GO:0001755   neural crest cell migration 0.00141258 0.0025 18 3 
6 GO:0051124   synaptic growth at neuromuscular junction 0.00343003 0.0027 6 3 
7 GO:0006110   regulation of glycolysis 0.00066297 0.003 11 3 
8 GO:0001525   angiogenesis 1.92E-05 0.0031 145 10 
8 GO:0001568   blood vessel development 5.77E-05 0.0031 199 11 
9 GO:0008168   methyltransferase activity 0.0023585 0.0034 162 5 
10 GO:0000209   protein polyubiquitination 0.03253891 0.0034 13 3 
ABBREVIATIONS: GO=Gene Ontology 
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Table 19. Summary of the pathway analysis results, AGRE gene expression dataset (AGRE-EXPR). Closely related pathways 
are counted as a single category. A minimum of two differentially expressed genes per pathway were required. 
 
Rank GO ID Pathway Optimal 
p-value 
Permuted
p-value 
Genes in
pathway 
Regulated 
genes 
1 GO:0014069 postsynaptic density 0.00011479 0.0005 11 5 
2 GO:0001539 ciliary or flagellar motility 0.00013554 0.0014 20 12 
3 GO:0032297 negative regulation of DNA replication initiation 0.00095414 0.0022 3 2 
4 GO:0005930 axoneme 0.00038024 0.0023 9 7 
5 GO:0044447 axoneme part 0.00041054 0.0023 7 7 
3 GO:0000076 DNA replication checkpoint 0.00095414 0.0023 3 2 
5 GO:0005858 axonemal dynein complex 0.00041054 0.0026 7 7 
3 GO:0030174 regulation of DNA replication initiation 0.00095414 0.0028 3 2 
6 GO:0030159 receptor signaling complex scaffold activity 0.00073845 0.0029 4 4 
7 GO:0006383 transcription from RNA polymerase III promoter 0.00066984 0.0031 8 7 
8 GO:0004459 L-lactate dehydrogenase activity 0.00233629 0.0044 3 2 
9 GO:0014048 regulation of glutamate secretion 0.00254639 0.0044 2 2 
10 GO:0016783 sulfurtransferase activity 0.00262402 0.0051 2 2 
ABBREVIATIONS: GO=Gene Ontology 
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Table 20. Summary of the pathway analysis results, AGRE genome-wide association dataset (AGRE-GWAS). Closely related 
pathways are counted as a single category. P-value threshold for individual marker significance in GWAS p=0.01. A minimum of 
two suggestively associated genes per pathway were required. 
Rank GO ID Pathway Optimal 
p-value 
Permuted 
p-value 
Genes in
pathway 
Regulated 
genes 
1 GO:0005882      intermediate filament 3.07E-05 0.0001 129 5 
1 GO:0045111      intermediate filament cytoskeleton 3.31E-05 0.0001 131 5 
2 GO:0033177      
proton-transporting two-sector ATPase complex, 
proton-transporting domain  0.00025466 0.0001 20 7 
2 GO:0033179      proton-transporting V-type ATPase, V0 domain       2.84E-05 0.0002 8 5 
1 GO:0045095      keratin filament  0.00047670 0.0002 63 3 
3 GO:0004003      ATP-dependent DNA helicase activity 0.00012113 0.0003 23 3 
3 GO:0003678      DNA helicase activity 0.00039583 0.0004 34 3 
4 GO:0001636      
corticotrophin-releasing factor gastric inhibitory 
peptide-like receptor activity 0.00139591 0.0008 5 3 
5 GO:0035014      phosphoinositide 3-kinase regulator activity 0.00019815 0.0014 9 5 
3 GO:0008026      ATP-dependent helicase activity 0.00078974 0.0015 98 4 
3 GO:0070035      purine NTP-dependent helicase activity 0.00078974 0.0015 98 4 
3 GO:0008094      DNA-dependent ATPase activity 0.00084989 0.0016 44 3 
6 GO:0006809      nitric oxide biosynthetic process 0.00113630 0.0016 27 7 
6 GO:0046209      nitric oxide metabolic process  0.00113630 0.0016 27 7 
7 GO:0050901      leukocyte tethering or rolling 0.0048216 0.0017 5 3 
2 GO:0033176      proton-transporting V-type ATPase complex 0.00085783 0.0018 21 6 
8 GO:0042594      response to starvation 0.00387370 0.0025 30 8 
3 GO:0004386      helicase activity 0.00162357 0.0039 138 5 
9 GO:0006740      NADPH regeneration 0.00532658 0.0045 10 3 
9 GO:0006098      pentose-phosphate shunt  0.00532658 0.0045 10 3 
10 GO:0046323      glucose import 0.00162506 0.0058 16 4 
ABBREVIATIONS: GO=Gene Ontology 
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C .  C r o h n ’ s  d i s e a s e  d a t a s e t  
In order to further evaluate the performance of the GWANA method we applied it to 
a Crohn’s disease (CD) GWAS dataset (1748 cases, 2938 controls) from the 
Wellcome Trust Case Control Consortium (WTCCC) (2007). Since the underlying 
biology of CD is better established than that of autism, certain biological processes 
could be expected to be found. Pathway analysis was performed using the same 
criteria and p-value thresholds as with the autism datasets. 
 
Briefly, we identified many biological processes which are known to play a role in 
CD. These include "phagocytosis", "cellular response to unfolded protein", "defense 
response to Gram-negative bacteria", and "JAK-STAT cascade". Most of these were 
identified with all p-value thresholds, but the "JAK-STAT cascade" could be seen 
only with the broadest threshold. Notably, genes or pathways related to the HLA 
genes were not seen. Very similar results have been observed in a previous study, 
which performed a protein interaction network-based pathway analysis using the 
same CD dataset (Baranzini et al. 2009). In summary, applying the pathway analysis 
algorithm to the CD dataset demonstrated that GWANA can identify biologically 
relevant pathways from GWAS data, and provided an additional layer of confidence 
regarding the pathway results obtained with the ASD datasets. 
 
D .  D i s c u s s i o n  o n  p a t h w a y  a n a l y s i s  
The genetic background of CD is known to be different than that of autism, which 
may cause the pathway analysis to perform differently in these datasets. GWA 
studies in CD have demonstrated that a small group of risk alleles with relatively 
strong effects are present whereas in autism the hits are more widely spread and of 
lower risk. Since the GWANA method is specifically designed to analyze the "gray 
zone", and it operates with the ranking of markers or transcripts relative to each 
other rather than their individual significance to assess regulated pathways, it is 
likely to perform better with data with a relatively even distribution of moderately 
significant p-values. Thus, in fact, it should perform better with autism data than 
with CD data, and may even fail to recognize known CD pathways comprised of 
few, extremely significant hits. For example, the two genes most robustly associated 
to CD, NOD2 and IL23 (Barrett et al. 2008), do not appear among the regulated 
genes in the pathway analysis, and HLA genes were absent. This can also be due to 
the lack of evidence of interaction between these genes and the rest of the most 
significantly regulated genes. However, overall, the pathway analysis was able to 
identify multiple relevant pathways for CD, providing further support to the results 
obtained from the ASD datasets. 
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Since the pathway analysis method is based on the ranking of SNPs and transcripts 
relative to each other, rather than their individual significance, it is not clear how the 
significance of the obtained pathways should be evaluated, i.e. which pathways are 
more significant than others, and how much noise is introduced by small pathways 
which appear significant, possibly because of chance hits. This is clearly 
demonstrated by the Crohn’s disease dataset, in which relevant processes were 
clearly identified, but which would be hard to separate from noise without prior 
knowledge of the biology. However, in the case of CD, all of the relevant pathways 
appeared to have a fairly large number of regulated genes, suggesting that filtering 
out the smallest categories might help to reduce false positives also in ASDs. 
 
An obvious limitation to our pathway analysis method is that effects of variable LD 
are not considered or accounted for when mapping SNPs to their representative 
genes. The method was originally developed to be used with the Illumina 
HumanHap 300 series data, in which the genotyped SNPs are supposed to tag a 
single haplotype block, thereby reducing the problem of interdependent SNPs in 
pathway analysis. Also, the method uses the single most significant SNP to represent 
each gene, which, even though not ideal, is the most frequent approach taken by 
other studies as well (Baranzini et al. 2009). Thus, the statistic does not capture 
information of multiple distinct variants in a gene contributing to the overall 
association signal. 
5.3.6 Conclusions 
In this study, we made an effort to thoroughly investigate both common and rare 
genetic variation as well as gene expression and biological pathways in two 
extended ASD pedigrees from a population isolate. Our initial hypothesis was that 
the genealogical links would reflect IBD sharing, and that one or a few genomic 
regions shared by the affected individuals could be identified and used to pinpoint 
the causal variants. Given the well-known heterogeneity in ASDs, we did not expect 
to find haplotypes shared by all of the cases, but instead thought that a few 
haplotypes shared by ~half of the affected individuals would be present. Instead, the 
results obtained in Study III demonstrated that genetic heterogeneity in ASDs is so 
substantial, that even in genealogically connected individuals from a population 
isolate rare, family-specific variants probably comprise the majority of the overall 
genetic risk. We identified one genomic region in each pedigee where the majority 
of the affected individuals shared a homozygous segment of < 100 kb. Although 
small genomic regions can be shared just by chance, these regions should still be 
followed up as it is possible that they carry a shared risk variant. 
 
We unexpectedly identified one genome-wide significant SNP at chromosome 
2p16.1 in the GWA analysis of the CF-GWAS case-control dataset, which, together 
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with haplotype association analysis at this locus, implicates that there is an ASD risk 
variant present at this locus, in or near BCL11A. The function of BCL11A, together 
with convergent pathway analysis findings from SNP and gene expression data from 
the CF individuals, highlights axon guidance molecules in the pathogenesis of 
ASDs. As the most significant SNP association did not replicate in the nationwide 
Finnish family sample, the risk factor seems specific to the CF isolate. 
 
Unless the increasing knowledge of the interplay of common and rare genetic 
variation reveals completely new and unexpected genetic mechanisms, it seems that 
the genetic background of autism is explained by rare, family specific genetic 
variants, and sequencing is the only method to tackle these. However, it is 
nevertheless possible that such scattered rare mutations, together with possible 
common variants, contribute to similar biological processes and pathways. In this 
study, we began exploring the biological processes behind ASDs using study 
samples from Central Finland and the AGRE. Pathway analysis of both GWAS and 
gene expression datasets from these study samples further supported family 
specificity, since the results obtained from the AGRE provided only little support for 
the pathways from the Finnish datasets. Clearly overlapping pathways related to 
vasculature development and reorganization of the actin cytoskeleton were observed 
in the CF-GWAS and CF-EXPR datasets. These identified pathways implicated 
multiple genes known to participate in axon guidance and are thus intriguing, given 
the obtained association finding to BCL11A. Also, synaptic cell-adhesion and 
cortical underconnectivity have recently been extensively discussed as potential 
biological causes for ASDs. Given the exploratory nature of the pathway analysis, 
the results should be considered suggestive only. Although isolate-specific results 
are generally challenging to replicate due to lack of independent, comparable 
datasets, validation of these pathways would provide valuable clues about the 
pathology underlying ASDs. However, if family-specific factors contribute to the 
disease susceptibility, replication might not be an appropriate method to validate 
initial findings. Parallel pathway analysis of SNP and gene expression data from the 
same study subjects might in part help to address this problem. To conclude, a 
comprehensive analysis of genealogically connected individuals with ASDs 
provided multiple lines of evidence for genes involved in axon guidance. We 
suggest that the genetic risk of ASDs in these individuals is likely to comprise of 
different combinations of rare genetic variants, and targeted resequencing of the 
identified regions of homozygosity, haplotypes, and linkage regions is essential to 
understand the underlying mutational spectrum. 
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Human genetics has come a long way since the completion of the Human Genome 
Project. At the time, it took more than ten years, billions of dollars, and the effort of 
hundreds of scientists to sequence the haploid genome of one individual, whereas 
today, ten years later, it is entirely plausible and affordable to study millions of 
genomic loci in thousands of individuals in a timeline of months. The moment is 
quickly approaching when the full genomes of many individuals can be sequenced 
and analyzed routinely –examples of this are already emerging in the form of large-
scale exome and whole genome sequencing initiatives, such as the 1000 Genomes 
project. Exciting years lie ahead for geneticists, when studying the entire genome at 
once – the very essence of genetics – will become routine.  
 
Even though numerous new susceptibility variants for many disease phenotypes and 
other traits have been successfully discovered and replicated in GWA studies, 
linking single genetic variants to specific, and often biologically artificial, 
phenotypes has only covered a fraction of the genetic variation in these traits. This 
suggests that in most cases there is additional, rarer genetic variation contributing to 
the end-state phenotype. Also, the functional role of the most significantly 
associated SNPs from GWA studies has not been adequately defined, highlighting 
the need to study the effects the genetic variants have on various intermediate 
phenotypes at the cellular level, such as gene expression. Understanding how gene 
expression is regulated will therefore be key, and, at least in humans, will be 
challenging due to the astonishing variety of subtle regulatory  mechanisms present, 
as discovered also in this project. 
 
The pace of development and progress in methodology has been breathtaking: the 
last few years have seen a quick leap from genome-wide association studies to CNV 
and eQTL analysis, sequence-based transcriptomics, and analyses of epigenetic 
modifications. The long years of inconclusive linkage and candidate gene 
association studies have been mostly forgotten, and while it seems that many large-
scale studies have essentially become hypothesis-free, the importance of targeted 
functional studies has become even more important. With genome-wide approaches 
providing detailed maps of where to look, there is still but a vague understanding of 
the mechanisms that mediate disease susceptibility conferred by a single variant. It 
has become evident that simply looking at the DNA sequence is not enough –
additional layers of genomic data need to be added in order to elucidate the 
connections among sequence variants, transcripts, and eventually, functional protein 
products. The field will undoubtedly see many new "omics" in the years to come. 
 
6 Concluding Remarks and Future Prospects 
THL – Research 46|2010 116 Genetic Mechanisms Underlying 
Autism Spectrum Disorders 
When this study was first started, knowledge of the genetic basis of autism spectrum 
disorders was on the same level as in most other psychiatric and neurological 
disorders. The era of GWA studies was yet to come, and it was generally accepted 
that these disorders have a complex genetic basis with multiple genetic factors, 
mostly common, increasing the risk of disease together with influence from 
environmental factors. The first large-scale GWA studies in ASDs published in 2009 
yielded few common risk factors, whereas intriguing examples of rare, high-
penetrance mutations in synaptic cell-adhesion genes started to emerge. It is now 
known that common variants do not play a significant role in ASDs, unless some 
previously unknown genetic mechanism masks their true effect from the current 
analysis methods available. Instead, evidence of family-specific rare genetic events 
such as mutations and de novo CNVs is accumulating, and it seems likely that a 
substantial proportion of ASD cases will be explained by these events, with or 
without interaction and influence with common polymorphisms. 
 
The nature of rare genetic variants makes sequencing the superior method to find 
them. As next-generation sequencing methods become more widely available, a 
wave of exome sequencing studies in ASDs is expected in the coming years. Later, 
the approach is likely to extend to full genomes, since a proportion of the variants 
are likely to be non-coding, regulatory changes. Sequencing will be the next step in 
this study as well, since the affected individuals from the Central Finland pedigrees 
will soon undergo exome sequencing. Hopefully this will lead to the identification 
of the causal variants in these pedigrees. 
 
It is often questioned whether the knowledge obtained from complex disease 
genetics studies will be of any use to the clinicians, early diagnosis, or the actual 
treatment of patients. Especially in the case of autism, where treatments currently 
seem to be light-years away, an earlier diagnosis might not be a significant 
improvement. Also, even if providing a molecular diagnosis is of great value to 
individual families, in terms of public health, identification of rare genetic causes for 
a disease is less exciting. Uniform applications, such as diagnostics, are hard to build 
on a scattered set of findings. However, even if "the autisms" present with multiple 
etiologies and painstaking heterogeneity, the strive to understand their origin is 
continuously teaching us novel things about the brain and neurobiology. 
Understanding autism would essentially mean understanding the brain, and this is, in 
fact, what should keep us going. 
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Patrocles www.patrocles.org 
PolymiRTS http://compbio.uthsc.edu/miRSNP/home.php 
miRBase www.mirbase.org 
TargetScan www.targetscan.org 
HapMap www.hapmap.org 
PFAM http://pfam.sanger.ac.uk 
UCSC http://genome.ucsc.edu 
Haploview www.broadinstitute.org/haploview/haploview 
HapMap www.hapmap.org 
Gene Ontology www.geneontology.org 
Ensembl www.ensembl.org 
OMIM http://www.ncbi.nlm.nih.gov/omim 
PLINK http://pngu.mgh.harvard.edu/~purcell/plink 
GEO http://www.ncbi.nlm.nih.gov/geo 
AGRE www.agre.org 
WTCCC www.wtccc.org.uk 
Autism Chromosome Rearrangement Database 
http://projects.tcag.ca/autism 
Decipher https://decipher.sanger.ac.uk 
EUCARUCA http://agserver01.azn.nl:8080/ecaruca/ecaruca.jsp 
Entrez www.ncbi.nlm.nih.gov/Entrez 
Brainarray http://brainarray.mbni.med.umich.edu/Brainarray 
NuGO R-server http://nugo-r.bioinformatics.nl 
R www.r-project.org 
Bioconductor www.bioconductor.org 
Flybase http://flybase.org 
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